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Abstract 
TET enzymes are relatively novel players in the epigenetic regulation of mammalian DNA 
methylation. They participate in DNA demethylation, but their precise roles in different 
developmental and disease scenarios are not fully understood. The aim of this work was to 
investigate the biological roles of TET enzymes in lineage-committed normal and cancer 
cells. To this end, murine primary cells with genetic deletion of TET enzymes and human 
cancer cells with recurrent mutations in the cofactor providing isocitrate dehydrogenases 
(IDH), provoking competitive inhibition of TET enzymes, were analyzed.  
By characterizing mouse embryonic fibroblasts adipogenic differentiation defects, 
inefficient activation of genes relevant to adipogenesis and widespread gene deregulation 
upon TET1/2-deficiency were discovered. Examination of the genome-wide DNA methylation 
landscape demonstrated the hypermethylation of DNA methylation canyons as a main 
characteristic of the TET1/2-deficient methylome. Canyons were associated with 
developmentally important genes and canyon collapse due to hypermethylation coincided 
with developmental gene deregulation, defective induction of adipogenic markers and the 
hypermethylation of their promoters. Together, these findings uncovered a novel epigenetic 
regulatory role in the maintenance of DNA methylation canyons for TET1 and TET2 that is 
essential for epigenetic programming during differentiation.  
In the second part of this thesis, published array-based DNA methylation profiles of a 
large acute myeloid leukemia (AML) patient cohort were used to examine mutant IDH- 
(mIDH) and TET-dependent DNA methylation changes. This confirmed the known association 
between mIDH and genome-wide hypermethylation. However, similar global methylation 
changes were not present in TET2 mutant patients and mIDH carrying patients lacked 
specific canyon hypermethylation. Intriguingly, neither overexpression of mIDH, nor treatment 
of a leukemia cell line with D-2-hydroxyglutarate, which is a putative TET inhibitor produced 
by mIDH, recapitulated the mIDH-associated hypermethylation. Instead, comparison with 
hematopoietic reference methylomes revealed high similarity between mIDH-associated and 
myeloid progenitor methylation profiles, suggesting the involvement of differentiation state 
rather than TET inhibition in the hypermethylation phenotype. These findings implicate a 
previously unnoted factor in the epigenomic changes of AML cells with mIDH, which may be 
critical to understand and therapeutically target mIDH-dependent pathogenesis. 
 
  

Zusammenfassung 
TET Enzyme sind relativ neue Akteure in der epigenetischen Regulation von DNA-
Methylierung in Säugern. Sie wirken an DNA-Demethylierung mit, jedoch sind ihre konkreten 
Rollen in verschiedenen Differenzierungs- und Krankheitsszenarien nicht vollständig 
aufgeklärt. In der vorliegenden Arbeit sollten die biologischen Funktionen von TET-Enzymen 
in determinierten normalen sowie Krebszellen erforscht werden. Dazu wurden primäre 
Mauszellen mit genetischer TET-Deletion und humane Krebszellen mit wiederkehrenden 
Mutationen in den Cofaktor-bereitstellenden Isocitrat-Dehydrogenasen (IDH), welche zu einer 
kompetitiven Enzymhemmung der TET Proteine führen, untersucht. 
Mittels Charakterisierung von embryonalen Mausfibroblasten wurden Defekte in der 
adipogenen Differenzierung, der Aktivierung von Adipogenese-relevanten Genen und der 
Genexpression bei TET1/2-Defizienz entdeckt. Die Untersuchung der genomweiten DNA-
Methylierung identifizierte die Hypermethylierung von sogenannten DNA-Methylierungs-
Canyons als wesentliches Merkmal des TET1/2-defizienten Methyloms. Canyons waren mit 
entwicklungsbiologisch relevanten Genen assoziiert und ihr Zusammenbruch durch 
Hypermethylierung war begleitet von Regulationsdefekten in Entwicklungsgenen, fehlerhafter 
Induktion von adipogenen Markern und Promoter-Hypermethylierung. Diese Ergebnisse 
schreiben TET1 und TET2 eine neuartige regulatorische Rolle in der Erhaltung von Canyons 
zu, die essentiell für die epigenetische Programmierung während der Differenzierung ist. 
Im zweiten Teil dieser Arbeit wurden publizierte Array-basierte DNA Methylierungsprofile 
einer großen akuten myeloischen Leukämie (AML) Patienten-Kohorte verwendet, um 
Methylierungsveränderungen durch mutante IDH (mIDH) und TET Enzyme zu analysieren. 
Dies bestätigte die bekannte Assoziation zwischen mIDH und genomweiter DNA 
Hypermethylierung. Allerdings waren ähnliche Veränderungen nicht in TET2 mutanten 
Patienten vorhanden und Patienten mit mIDH wiesen keine spezifische Canyon 
Hypermethylierung auf. Interessanterweise wurde die mIDH-assoziierte Hypermethylierung 
auch weder durch die Überexpression von mIDH, noch die Behandlung von Leukämiezellen 
mit D-2-Hydroxyglutarat, welches ein durch mIDH produzierter, mutmaßlicher TET Inhibitor 
ist, exakt nachgebildet. Stattdessen offenbarte der Vergleich mit hämatopoetischen 
Referenzmethylomen eine hohe Ähnlichkeit zwischen mIDH-assoziierten und myeloischen 
Progenitorzell-Methylierungsprofilen, was auf eine Beteiligung des Differenzierungsgrades 
anstelle der TET Inhibition an der Hypermethylierung hinweist. Diese Ergebnisse involvieren 
einen bisher unbeachteten Faktor in die epigenomischen Veränderungen von AML-Zellen mit 
mIDH, welcher entscheidend für das weitere Verständnis und die gezielte Therapie von 
mIDH-abhängiger Pathogenese sein könnte. 
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1 Introduction 
The genomic sequence of a living creature contains the entire information needed to build the 
organism. But how can the static genome translate into a variety of specialized cell types and 
functions as observed in complex beings? In 1942 Waddington described that “between 
genotype and phenotype […] there lies a whole complex of developmental processes” and 
termed this phenomenon “epigenetics” (Waddington, 1942). Nowadays, epigenetic research 
investigates (mitotically and/or meiotically heritable) molecular changes, modulating gene 
function and eventually the phenotype, independently of alterations in the DNA sequence 
(Russo, Martienssen and Riggs, 1996). Epigenetic processes establish stable gene 
expression patterns defining cellular identity, but at the same time are reversible and 
dynamic, allowing cellular plasticity and differentiation. Several components orchestrate the 
complex epigenetic interplay, among them covalent modifications of nucleic acids and 
histones, chromatin remodelers and non-coding RNAs. 
1.1 The mammalian DNA methylation machinery 
Presently, known covalent modifications of DNA bases include N6-methyladenine (6mA), 
N7-methylguanine, C5-methylcytosine (5mC) and its oxidized derivatives 
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5mC), 5-carboxylcytosine (5caC) as well 
as 5-hydroxymethyluracil (Achwal et al., 1983; Breiling and Lyko, 2015).  
DNA methylation at the carbon-5 position of cytosine was first described in 1948 
(Hotchkiss, 1948) and due to intensive studies is now the best characterized epigenetic 
modification. It is highly conserved and present in all three domains of life. In mammals, it is 
the most common modification termed the fifth base of the genome and has crucial roles in 
development, differentiation and disease (Li and Zhang, 2014; Smith and Meissner, 2013). 
The family of DNA methyltransferases (DNMTs) is responsible for the establishment and 
maintenance of this mark. 
1.1.1 DNA methyltransferases 
DNMTs catalyze the transfer of a methyl group from its donor S-adenosylmethionine (SAM) to 
position five of the cytosine carbon ring (Figure 1.3). While DNMT3A and B are de novo 
methyltransferases responsible for initial establishment of DNA methylation, DNMT1 is the 
maintenance transferase ensuring faithful propagation of the methylation mark during cell 
division (Figure 1.1A). Since replication is semi-conservative in mammals, palindromic 
hemimethylated CpG residues can be recognized by DNMT1 and copied to the daughter 
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DNA strand, resulting in symmetrically methylated CpGs (Figure 1.1C). This process has an 
error rate of ~1% per division and thus can ensure the gross maintenance of this mark (Reik, 
2007). DNMT1 is ubiquitously expressed in proliferating cells and most abundant during S 
phase (Kishikawa et al., 2003). Its targeting to DNA replication forks relies on the physical 
interaction with PCNA and UHRF1, which is capable of binding hemimethylated CpGs 
(Bostick et al., 2007; Chuang et al., 1997; Smith and Meissner, 2013). Homozygous deletion 
of DNMT1 in mESCs leads to a drastic reduction of global DNA methylation, disruption of 
imprinted gene regulation, complete X-inactivation and derepression of retrotransposons (Goll 
and Bestor, 2005). 
 
 
Figure 1.1: Mammalian DNA (de)methylation machinery.  
(A) Domain structure of DNA methyltransferases (adapted from Goll and Bestor, 2005). (B) Domain 
structure of the TET family (adapted from Rasmussen and Helin, 2016). Nuclear localization signal 
(yellow), replication foci (cyan), Cys-rich- (pink), BAH- (blue), PWWP- (red), CXXC- (orange) and 
DSBH domain (green), methyltransferase motifs (black), low complexity insert (gray), Fe(II)- (dark red) 
and D-2-HG-interacting motifs (dark green). (C) Schematic of DNMT and TET activity on DNA.  
 De novo methylation activity is recruited to repeat sequences by an unknown 
mechanism and unmethylated H3K4 harboring regions, such as inactive promoters and 
methylated sequences, by DNMT3L, which occurs in a complex with DNMT3 enzymes in 
germ cells (Edwards et al., 2017; Ooi et al., 2007). The disruption of the PIWI-interacting RNA 
pathway in male germ cells results in abrogation of de novo methylation, arguing for an 
involvement of piRNAs in DNA methylation, but the exact connection is unclear (Aravin and 
Bourc’his, 2008). Other reports suggest that DNMT3A and B are targeted to active genes by 
recognition of H3K36me3 through their PWWP domains (Baubec et al., 2015; Rondelet et al., 
2016). DNMT3A/B-deficient mESCs failed to methylate introduced retrovirus sequences and 
lost methylation from various repeat elements and genes (Chen et al., 2003; Okano et al., 
1999). Knockout of DNMT3A/B in human ESCs revealed redundant targeting of DNMT3A or 
B to intergenic regions, CpG island shores, promoters with intermediate or low CpG density 
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and introns, while selective targeting happens at CpG islands (Liao et al., 2015). Moreover, 
DNMT3A seems to play an essential role in the methylation of imprints (Kaneda et al., 2004), 
whereas DNMT3B is crucial for methylating centromeric minor satellite repeats. DNMT3A/B 
deficient mouse embryos display globally reduced methylation (Okano et al., 1999). These 
studies indicate that DNMT3A and B have overlapping as well as distinct functions during 
different developmental stages.  
1.1.2 The mammalian DNA methylation landscape 
DNA methylation predominantly occurs symmetrically in the sequence context of 5’-CpG-3’ 
(Ramsahoye et al., 2000) and 60 - 80% of these dinucleotides in adult mammalian genomes 
are usually methylated resulting in a total of ~1% methylated cytosines among all bases 
(Ehrlich et al., 1982). CpG residues are less frequent than statistically expected in 
mammalian genomes, presumably because 5mC is prone to spontaneous deamination to 
thymine, which is not recognized as an erroneous base due to its natural occurrence in DNA. 
In contrast, unmethylated cytosines are deaminated to uracil and hence would be recognized 
and repaired by uracil-DNA glycosylase (Coulondre et al., 1978).  
This phenomenon most likely resulted in the emergence of CpG islands (CGIs) – 
clustered regions of high CpG density – which are mostly devoid of methylation at any time 
point during development in many tissues and thus have been protected from C to T 
transition. Mammalian methylomes are therefore characterized by a bimodal distribution with 
the majority of CpGs being highly methylated and the remaining proportion largely 
unmethylated (Meissner et al., 2008). CGIs comprise regions of ~1000 bp average length 
with an elevated CG content (>50%) and reduced CpG depletion (observed/expected CpG 
ratio >60%; Deaton and Bird, 2011). About 72% of annotated promoters are associated with 
CGIs (Saxonov et al., 2006), suggesting functional relevance of these features. The related 
genes are often ubiquitously expressed and include nearly all housekeeping genes, many 
developmental regulators, but also tissue-specific genes with limited expression (Larsen et 
al., 1992).  
Refined analysis of CGIs and their methylation variation in cancer has led to the 
discovery of less CpG dense shores and shelves surrounding CGIs, which are interspersed 
into the open sea of single isolated CpGs (Figure 1.2A). These epigenomic elements are 
highly conserved between species and most tissue-specific and cancer-associated variation 
appears to occur in CGI shores (Doi et al., 2009; Irizarry et al., 2009). 
DNA methylation canyons (Figure 1.2B) have been recently identified as another 
poorly methylated feature of mammalian genomes (Jeong et al., 2013). In contrast to CGIs, 
these elements are considerably larger (>3.5 kb; some extending over 25 kb) and 90% of 
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them harbor at least one CGI. Identification requires at least five CpGs/kb and an average 
methylation of ≤10%. This identified 1,104 canyons in purified mouse hematopoietic stem 
cells (HSC). Canyon-associated genes are of particular developmental relevance as they are 
enriched for homeobox genes, transcriptional regulators and genes involved in embryonic 
morphogenesis. Furthermore, canyons are characterized by inter-species and cell-type 
conservation, depletion for transposable elements, 5hmC presence at their borders and 
dependency on DNMT3A (Jeong et al., 2013). 
 
 
Figure 1.2: Schematic presentation of key features of the mammalian methylome. 
(A) Conceptual scheme showing the relationship between CpG island, shore, shelf and open sea. 
Green color intensity indicates CpG density. (B) Schematic example of a DNA methylation canyon at 
the mouse PAX6 locus (adapted from Jeong et al., 2013). 
 Notably, a range of other hypomethylated elements has been identified to date. Some 
of them are probably identical to canyons such as DNA methylation valleys (Xie et al., 2013), 
but others are rather small and coincide with DNAse-hypersensitive and transcription factor 
binding sites such as low-methylated regions (LMRs; Stadler et al., 2011). Partially 
methylated domains (PMDs) are large regions with an average methylation level of <70% 
(Lister et al., 2009) and have been reported to coincide with nuclear lamina-associated 
domains (Berman et al., 2011). It was suggested that cancer cells or tissue cultures, i.e., 
systems that proliferate quickly, might progressively lose methylation from PMDs due to 
inefficient maintenance methylation in gene-poor regions (Gaidatzis et al., 2014; Hon et al., 
2012; Lister et al., 2011). 
1.1.3 Function of DNA methylation  
DNA methylation plays a major role in transcription and chromatin structure regulation, 
X-chromosome inactivation, silencing of repetitive DNA and transposable elements, and 
genomic imprinting (Bird, 2002). Since numerous studies showed the inhibition of expression 
upon methylation (Vardimon et al., 1982), it has been widely accepted that promoter DNA 
methylation is not compatible with gene expression. However, on a genome-wide level this 
correlation is not always true (e.g. Eckhardt et al., 2006), emphasizing that the mechanistic 
relationship between methylation and expression has to be further elucidated.  
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 Methylation of CGI promoters during development has been linked to permanent 
silencing and can be employed to stably repress germline, stem cell and specific genes of 
other lineages not required anymore in differentiating cells. Consistently, differentiation relies 
on the presence of DNMTs and genetically deficient ESCs fail to differentiate and regulate 
gene expression of germ layer und pluripotency markers accordingly (Jackson et al., 2004; 
Lei et al., 1996; Li et al., 1992; Okano et al., 1999). Typical pluripotency genes whose 
promoters are silenced by DNA methylation are OCT4 and NANOG. However, repression is a 
coordinated sequence of silencing events that also employ histone modification and 
nucleosome remodeling. In most cases, sequence-specific repressors initiate silencing and 
only later DNA methylation follows to inevitably lock in the repressive chromatin state. 
Nevertheless, an instructive role for DNA methylation in initiation of gene silencing is still 
conceivable (Smith and Meissner, 2013).  
 Mechanistically, DNA methylation can lead to silencing by inhibiting the recruitment of 
basal transcription machinery and methylation-sensitive transcription factors, as has been 
described for SP1, CREB, C-MYC or NRF1 (Clark et al., 1997; Domcke et al., 2015; Mancini 
et al., 1999; Prendergast et al., 1991). However, there are also a number of factors that are 
attracted by DNA methylation in their consensus sequence (Yin et al., 2017), potentially 
explaining positive correlations between methylation and transcription. The insulator protein 
CTCF can block enhancer promoter interactions, change chromatin architecture and 
attenuate POLII, which then includes exons during splicing (Ong and Corces, 2014) and thus 
translates its methylation sensitivity into transcriptional regulation (Bell and Felsenfeld, 2000; 
Narendra et al., 2015; Shukla et al., 2011). The general applicability of this principle is under 
debate, especially since CTCF also seems to create local regions of low methylation 
(Domcke et al., 2015; Feldmann et al., 2013; Stadler et al., 2011). 
 Furthermore, methylation could affect nucleosome positioning, eventually re-directing 
the transcriptional machinery and can induce the formation of heterochromatin by recruiting 
methyl-CpG-binding domain (MBD) proteins such as MeCP2. In turn, histone deacetylases or 
repressive complexes, such as the Sin3A, Mi2/NuRD or MeCP1 complex, are recruited, 
which condense the chromatin and facilitate the formation of a repressive chromatin state 
(Bird and Wolffe, 1999). 
 In contrast to promoter methylation, gene body methylation in mammals has been 
correlated with increased transcription of the corresponding genes (Baubec et al., 2015; 
Hellman and Chess, 2007; Lister et al., 2009). It has been suggested that it is essential to 
block transcription of active transposable elements while maintaining the elongation of the 
proper gene (Jones, 2012; Yoder et al., 1997), reduce transcriptional noise (Bird, 1995), 
regulate cell type specific alternative promoters (Maunakea et al., 2010) or prevent erroneous 
initiation of cryptic transcription (Neri et al., 2017). 
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While mammalian genomes are usually highly methylated, two striking waves of global 
DNA methylation reprogramming are observed during early development. The first takes 
place during germline development and the second in the early zygote. Primordial germ cell 
(PGC) demethylation is thought to enable the establishment of gender specific methylation 
patterns at imprinted genes, reset the cells to pluripotency and reduce mutational burden due 
to 5mC deamination (Reik et al., 2001). Zygotic demethylation is probably required to erase 
acquired epigenetic changes during gametogenesis due to environmental or individual 
genetic events and facilitate the expression of pluripotency-associated genes (Reik, 2007; 
Reik et al., 2001). The involvement of active and passive demethylation processes in these 
events will be introduced in chapter 1.2.3.1. 
1.1.4 DNA methylation changes in cancer 
Epigenetic dysregulation is an emerging hallmark of cancer and comprises alterations in DNA 
and histone modifications, histone modifiers and readers, chromatin remodelers, and 
microRNAs (Baylin and Jones, 2016). Together with genetic defects, it participates in tumor 
promotion and initiation and therefore genetic changes of epigenetic modifiers are now 
becoming increasingly investigated. The earliest studies on cancer epigenetics noted that 
5mC content in different cancers was globally reduced (Feinberg and Vogelstein, 1983a; 
Gama-Sosa et al., 1983). Later on, it was realized that cancer epigenomes redistribute their 
genomic methylation resulting in global hypomethylation and focused CGI hypermethylation. 
Deregulation of oncogenes, tumor suppressor, stem cell and differentiation genes, chromatin 
architecture, transposable elements, satellite DNA and genomic imprinting are the rational 
consequences, which could be observed in cancer to date (Dawson, 2017; Feinberg and 
Tycko, 2004). 
 Global hypomethylation can affect normally methylated CGIs and lead to derepression 
of associated genes (Feinberg and Tycko, 2004). These can be potential oncogenes, such as 
RAS or CCND2 (Feinberg and Vogelstein, 1983b; Oshimo et al., 2003), cancer/testis 
antigens such as MAGE-1 (De Smet et al., 1996) or even viral oncogenes among them 
HPV16 (Badal et al., 2003; de Capoa et al.). Another prominent example of promoter 
hypomethylation correlating with increased expression is the MDR1 gene, which is associated 
with increased drug resistance in AML (Nakayama et al., 1998). Hypomethylation can induce 
genomic instability, another hallmark of cancer (Hanahan and Weinberg, 2011). 
Mechanistically, affected satellites tend to break and recombine, resulting in chromosomal 
fusions of pericentromeric regions (Qu et al., 1999). Extensive transposition due to 
derepression of transposable elements might additionally facilitate DNA breaks.  
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 In contrast, hypermethylation of CGIs has been linked to the silencing of tumor 
suppressor genes. Classical examples that acquire promoter hypermethylation and decline in 
expression in cancers are RB, CDKN2A, VHL and E-Cadherin (Graff et al., 1995; Herman et 
al., 1994; Merlo et al., 1995; Sakai et al., 1991). This evolved into the concept of epigenetic 
caretakers – genes that usually prevent unlimited self-renewal and are induced upon 
differentiation but cannot be activated anymore in cancer cells and thus enable clonal 
expansion (Baylin and Jones, 2016; Feinberg and Tycko, 2004). Similarly, it has been 
observed that poised genes, which are bivalently marked (H3K4me3 and H3K27me3) in 
embryonic stem cells, have a ~12-fold increased propensity to undergo promoter 
hypermethylation in cancer (Dawson, 2017; Widschwendter et al., 2007). Moreover, silencing 
of genes involved in DNA mismatch repair, for example MLH1, has been correlated with the 
presence of mismatch repair defective cancers (Kane et al., 1997) and might facilitate mutator 
phenotypes and microsatellite instability.  
The hypermethylation of a distinctive set of CGIs in a subset of colorectal cancers was 
identified in 1999 and termed the CpG island hypermethylator phenotype (CIMP; Toyota et 
al., 1999). It was correlated with mismatch repair deficiency and BRAF mutations in colon 
cancer (Weisenberger et al., 2006) and many CIMP loci are targets of embryonic Polycomb 
group proteins (Widschwendter et al., 2007). However, the concept and underlying 
mechanisms of this coordinated acquisition of CGI hypermethylation are still controversial 
(Yamashita et al., 2003). Nevertheless, it has been extended to other cancer entities 
meanwhile, among them glioma and AML (Kelly et al., 2017; Noushmehr et al., 2010).  
Additionally, disturbed methylation in cancer hampers CTCF binding, which appears to 
result in defective insulator function and chromatin architecture (Flavahan et al., 2015). 
 These observations implicate DNA methylation as a contributing, if not causative 
factor in the deregulation of gene expression and genomic integrity in cancer. It is thus not 
surprising that the epigenetic modifiers DNMT3A and TET2 are among the most frequently 
mutated genes in clonally expanded stem cell populations of the hematopoietic system 
(Dawson, 2017). Even so, it is still an unresolved issue whether a driving role in pathogenesis 
is attributable to aberrant DNA methylation or it is merely a reflection of cellular history and 
differentiation state. 
1.2 The mammalian DNA demethylation machinery 
The unique maintenance activity of DNMT1 implies not only stable inheritance of 5mC, but 
also its theoretically indefinite propagation. Demethylation would thus have to rely on the tight 
regulation of DNMT1 or its targeting factors and dilution of 5mC during cell divisions, removal 
of methylated cytosines or deaminated products by repair mechanisms or direct enzymatic 
reversal. The discovery of 5hmC in mammalian DNA opened up a new avenue for passive 
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and active DNA demethylation since hydroxymethylated CpGs are poorly recognized by 
DNMT1 (Hashimoto et al., 2012).  
1.2.1 DNA hydroxymethylation 
DNA hydroxymethylation has first been described in bacteriophage nucleic acids (Wyatt and 
Cohen, 1952) and in the 1970s in vertebrate DNA (Penn et al., 1972). In 2009 it was 
demonstrated that 5hmC is present in mouse brain (Kriaucionis and Heintz, 2009) and ESCs 
and that the ten-eleven translocation 1 (TET1) enzyme is responsible for the conversion of 
5mC to 5hmC (Tahiliani et al., 2009). It was also speculated that this conversion might 
represent part of an active DNA demethylation pathway (Tahiliani et al., 2009). 
 The 5hmC mark is highly conserved among animals ranging from mammals to 
chicken and sea urchin and is also present in plants, albeit levels are quite variable between 
these species (Terragni et al., 2012). Overall levels of 5hmC are variable between tissues 
and cell types. In most mouse and human tissues, including mESCs and several human cell 
lines, the total 5hmC percentage in the genome ranges from roughly 0.1 to 0.3. The highest 
levels were observed in neuronal tissues, i.e., human and mouse adult brains, with 0.48% 
and 0.9%, respectively, resulting in 1 – 2% 5hmC among all cytosines (Terragni et al., 2012). 
It was claimed that in Purkinje cells, 5hmC reached almost 40% of 5mC levels (Kriaucionis 
and Heintz, 2009), suggesting that post-mitotic cells accumulate particularly high 5hmC 
levels. The content of 5hmC does not correlate with 5mC levels or TET expression and 
declines in cultured cells (Nestor et al., 2012). It was further noted that 5hmC levels were 
decreased in different cancer tissues and cell lines (Globisch et al., 2010; Kriaucionis and 
Heintz, 2009; Terragni et al., 2012).  
 Since its discovery, 5hmC has been implicated in DNA demethylation and epigenetic 
signaling. The evidence for active DNA demethylation originates from in vitro and cell culture 
studies describing TET-mediated 5mC oxidation followed by excision of 5fC and 5caC 
employing thymine DNA glycosylase (TDG) and base excision repair (He et al., 2011; Maiti 
and Drohat, 2011). Consistently, 5caC and 5fC accumulate to detectable levels in TDG-
deficient cells (He et al., 2011; Shen et al., 2013). Evidence for active DNA demethylation in 
vivo comes from reports showing the accumulation of oxidized mC forms, the activation of 
base excision repair and enrichment of single-strand breaks during zygotic and germ cell 
DNA methylation reprogramming (Hajkova et al., 2010; Ladstätter and Tachibana-Konwalski, 
2016; Wossidlo et al., 2010). Passive demethylation by dilution has been supported by 
strongly reduced DNMT1 activity on hemimodified 5hmC, 5fC and 5caC compared to 5mC 
(Hashimoto et al., 2012) and has for example been observed in zygotic methylation erasure 
(Inoue and Zhang, 2011). 
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 While in DNA demethylation 5hmC would be a short-lived intermediate, epigenetic 
signaling would require reasonable turn over times of 5hmC. Analysis of steady states of 
5hmC, 5fC and 5caC suggested that 5hmC is slowly established on the replicated strand and 
stably maintained over several days in cultured cells and in vivo (Bachman et al., 2014). 
Global 5fC and 5caC content was not detectable in mouse olfactory bulb DNA using HPLC-
MS (Globisch et al., 2010), indicating that the levels of conversion products of 5hmC are 
negligible (0.3 to 1.4% of 5hmC) and thus are either very short-lived or cannot be responsible 
for large-scale DNA demethylation. The kinetics of TET processivity also argue against a 
systematic, iterative and thus demethylating oxidation process (Tamanaha et al., 2016). Base 
resolution analysis of 5hmC, 5fC and 5caC using TDG-deficient mESCs suggested that 
distinct regions of the genome carry different oxidized 5mC forms and that TET processivity 
correlates with local chromatin accessibility, suggesting targeted conversion at functionally 
relevant regions (Shen et al., 2013; Wu and Zhang, 2017; Wu et al., 2014). Consistent with a 
signaling role of oxidized 5mC forms, specifically interacting reader proteins, such as MeCP2, 
MBD3, Uhrf2, CTCF, SALL4A and RNA polymerase II elongation complex, which are 
involved in transcriptional regulation, have been discovered (Iurlaro et al., 2013; Marina et al., 
2016; Mellén et al., 2012; Spruijt et al., 2013; Wang et al., 2015a; Xiong et al., 2016; Yildirim 
et al., 2011). It was also suggested that 5hmC could function in marking DNA damage sites 
(Kafer et al., 2016). 
 To elucidate the genomic location of 5hmC conversion and demethylation, numerous 
studies mapped the 5hmC distribution by various methods. Whole genome bisulfite 
sequencing, which is the gold standard for base resolution 5mC mapping, has been used to 
monitor regions of demethylation in TET-deficient models – assuming that 5mC accumulates 
in regions where it would usually be removed by TETs. However, it can neither distinguish 
5hmC from 5mC nor 5fC and 5caC from unmodified C (Booth et al., 2012; He et al., 2011; Yu 
et al., 2012). Advanced technologies have thus been developed to directly map 5hmC, such 
as 5hmC-DNA-IP, oxidative or TET-assisted bisulfite sequencing.  
Firstly, 5hmC is widespread in the mammalian genome occurring at inter- and 
intragenic, DNAse hypersensitive regions, TSS, CTCF and p300 sites. In ESCs, 5hmC 
deposition seems to correlate negatively with CpG density, so that promoters with low or 
intermediate CpG density are enriched, while unmethylated, H3K4me3-marked CGI 
promoters of highly expressed genes are depleted of 5hmC (Booth et al., 2012; Pastor et al., 
2011; Wu et al., 2011a; Xu et al., 2011b; Yu et al., 2012). Elevated levels of 5hmC were also 
found at bivalent promoters of poised genes, enhancers and gene bodies (Hon et al., 2014; 
Stroud et al., 2011; Sun et al., 2015; Williams et al., 2011). Immediate transcription factor 
binding sites are depleted of 5hmC, but flanking areas are enriched (Yu et al., 2012). TET1 
and TET2 activity have been assigned to TSS and gene bodies, respectively (Huang et al., 
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2014). Together, these correlations suggest relevance of 5mC oxidation at various genomic 
functional elements either by demethylation or conferring specific epigenetic signals. 
1.2.2 Ten-eleven translocation enzymes 
The mammalian TET enzyme family comprises three members – TET1, TET2 and TET3 – all 
of which can successively convert 5mC to 5hmC, 5fC and 5caC (Ito et al., 2010, 2011; 
Tahiliani et al., 2009). TET proteins require α-ketoglutarate, oxygen and iron (Fe(II)) as 
cofactors to exert their dioxygenase activity (Figure 1.3). According to biochemical studies, 
TET enzymes display the highest affinity for mCpG compared to other neighboring bases (Hu 
et al., 2013) and 5hmC consistently occurs almost exclusively in a CpG context in mammalian 
genomes (Yu et al., 2012). Moreover, TET proteins prefer binding to 5mC over 5hmC and 5fC 
(Hu et al., 2015; Ito et al., 2011) and display similar conversion rates independently of 
different modification combinations or hemimodification of a CpG dyad (Wu and Zhang, 
2017).  
 
Figure 1.3: Mechanisms of DNA methylation and active and passive demethylation.  
DNMTs establish 5mC from unmodified cytosines (C). All successive oxidation steps can be mediated 
by TET1, TET2 and TET3 and require the indicated cofactors (adapted from Wu and Zhang, 2017). 
The TET1 gene was initially identified in a translocation between chromosomes 10 
and 11 resulting in a fusion with the MLL gene in acute myeloid leukemia (AML; Ono et al., 
2002). All three TET enzymes have a C-terminal catalytic domain consisting of a double-
stranded β-helix (DSBH) domain, a cysteine-rich domain and an Fe(II)-interacting HxD motif. 
The N-terminal CXXC domain, which includes two zinc finger motifs, is present only in TET1 
and TET3 and allows DNA binding (Figure 1.1B). The C-terminus of TET2 most likely was 
separated from its putative CXXC domain by a chromosomal inversion during evolution 
yielding the gene IDAX. However, IDAX binds to unmethylated DNA and is able to recruit 
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TET2 (An et al., 2017; Ko et al., 2013). Both TET1 and TET3 also express truncated isoforms 
at certain developmental stages lacking the CXXC domain (Zhang et al., 2016a) and these 
forms have differential demethylation activity (Wu and Zhang, 2017), suggesting that their 
distinct expression during developmental stages might serve to adapt overall oxidative 
conversion activity. 
 TET enzymes are subject to many regulatory processes including substrate and 
cofactor availability, transcriptional, posttranscriptional and -translational regulation, cellular 
and genomic localization. TET activity is linked to cellular metabolism via α-ketoglutarate, 
which is provided by isocitrate dehydrogenase (IDH) enzymes. As evidenced by two studies, 
5hmC levels directly seem to correlate with IDH expression, suggesting that α-ketoglutarate is 
a limiting factor in 5hmC generation (Lian et al., 2012; Xu et al., 2011a). Consistent with this, 
enhanced glucose metabolism in mice was found to elevate α-ketoglutarate in conjunction 
with 5hmC (Yang et al., 2014). In contrast, accumulation of fumarate and succinate due to 
cancer-associated mutations in fumarase and succinate dehydrogenase negatively impact on 
TET-dependent oxidation due to competition with α-ketoglutarate (Xiao et al., 2012). TET 
activity furthermore depends on oxygen, as hypoxia was shown to induce DNA 
hypermethylation by reducing 5mC oxidation (Thienpont et al., 2016). Conversely, vitamin C 
stimulates TET catalytic activity (Blaschke et al., 2013). 
Another layer of regulation is provided by miRNA-dependent TET transcript 
degradation, various posttranslational modifications affecting DNA binding or enzymatic 
activity as well as caspase, calpain and proteasome-mediated TET protein degradation (Wu 
and Zhang, 2017). The TET1 gene is furthermore subject to regulation by a network of 
pluripotency factors and rapidly downregulated upon ESC differentiation (Ficz et al., 2011; Ito 
et al., 2010; Koh et al., 2011; Neri et al., 2015). 
Lastly, ChIP-seq studies have determined the genomic localization of TET1, 
identifying CGIs, active and bivalent promoters as preferentially bound (Williams et al., 2011; 
Wu et al., 2011b; Xu et al., 2011b). However, the assumption that the DNA binding domain of 
TET1 dictates its localization was disproven, since full-length and CXXC-deficient TET1 
displayed very similar binding patterns (Zhang et al., 2016a). Instead, certain chromatin 
states or other proteins could recruit TET proteins by physical interaction, as was shown for 
NANOG (Costa et al., 2013), PRDM14 (Okashita et al., 2014), PRC2 (Neri et al., 2013), WT1 
(Rampal et al., 2014; Wang et al., 2015b), REST (Perera et al., 2015), PPARγ (Fujiki et al., 
2013), CTCF (Dubois-Chevalier et al., 2014), TDG (Weber et al., 2016; Zhang et al., 2017) or 
the SIN3A complex (Williams et al., 2011). 
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1.2.3 Biological roles of TET enzymes 
1.2.3.1 Developmental role 
TET enzymes are involved in many developmental processes and stages. TET1 and TET2 
are highly expressed in mouse ESCs, but rapidly decline while TET3 is upregulated upon in 
vitro differentiation (Ito et al., 2010; Koh et al., 2011). High levels of TET1 and TET2 are also 
found in the inner cell mass of blastocysts and developing PGCs. In mouse oocytes and 
zygotes of the one cell stage TET3 is exclusively and highly expressed, but is downregulated 
with progressing cell cleavage (Iqbal et al., 2011). TET2 and TET3 are the major adult forms 
with wide-spread expression in many tissues (Wu and Zhang, 2014). 
Phenotypes of TET-deficient mice 
Phenotypic characterization of TET-deficient mice suggested a role for TET enzymes in 
differentiation and imprinting. TET1 KO mice appear viable, healthy and fertile, but display 
reduced body size, weight and litter (Dawlaty et al., 2011). However, when TET1-deficient 
males were mated with WT females in a different study, paternal imprinting erasure failed and 
various imprinting-related phenotypic defects were observed (Yamaguchi et al., 2013). These 
data suggest a requirement for TET1 in imprinting regulation, whereas it is not essential for 
pluripotency maintenance or development. Similarly, TET2-deficient mice developed overtly 
normal, but had an augmented stem cell pool in the bone marrow accompanied by increased 
proliferation and impaired differentiation leading to the frequent emergence of a range of 
myeloid malignancies (Li et al., 2011). TET1/2-deficient mice displayed stochastic 
developmental plasticity with frequent perinatal lethality due to malformations or growth 
retardation, but some individuals developed normally. These exhibited hypermethylation in 
various tissues, disturbed methylation at several imprinted loci and reduced fertility in 
females. As TET3 deletion in mice is neonatally lethal, a conditional germline-specific TET3 
KO mouse model was established (Gu et al., 2011). This revealed maternal contribution of 
TET3 to the zygote, which is then recruited to the paternal pronucleus. Female mice with 
germline TET3-deficiency were less fertile and descending embryos showed a pronounced 
increase of developmental failure. Recently however, TET3 haploinsufficiency rather than 
TET3-dependent 5mC conversion was determined to be causative for the observed 
phenotypes (Inoue et al., 2015). TET triple-deficient (TKO) ESCs are completely devoid of 
5hmC, display gastrulation defects and cannot contribute to embryonic development (Dai et 
al., 2016; Dawlaty et al., 2014). Together, these phenotypes suggest that TET enzymes have 
redundant, but also specific, context-dependent functions. Whether these solely depend on 
their dioxygenase activity or on potential non-catalytic functions remains to be studied. 
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Involvement in pluripotency and differentiation 
The embryonic stem cell state, self-renewal and pluripotency seem to be unaffected by TET-
deficiency. However, TET1 KO or KD in mESCs skews their differentiation (Dawlaty et al., 
2011; Ficz et al., 2011; Koh et al., 2011) and TET2-deficiency delays transcriptional 
adaptation during differentiation by enhancer suppression (Hon et al., 2014). DKO for TET1 
and TET2 in mESCs likewise retained pluripotency and three germ layer competence. 
However, differentiation was skewed similar to TET1-deficient cells (Dawlaty et al., 2013). 
TKO mESCs are characterized by normal morphology and pluripotency gene expression, 
however they cannot differentiate properly (Dawlaty et al., 2014). Furthermore, TDG-deficient 
mice are embryonic lethal, but their ESCs self-renew normally, suggesting that demethylation 
is not essential for ESC maintenance but differentiation (Cortázar et al., 2011; Cortellino et 
al., 2011; Shen et al., 2013). 
 DNA methylation seems to be an obstacle in somatic cell reprogramming. Indeed, it 
was found that during Yamanaka factor-mediated reprogramming, TET enzymes are 
essential to induce NANOG and ESRRB expression (Doege et al., 2012) and to activate 
some key miRNAs required for mesenchymal-to-epithelial transition (Hu et al., 2014). 
Interestingly, TET1 was also able to substitute OCT4 as one of the four reprogramming 
factors and additionally augment reprogramming efficiency (Costa et al., 2013; Gao et al., 
2013). 
 In the adult organism, constitutive differentiation processes take place for instance in 
the hematopoietic compartment. TET enzymes were found to be essential for normal myeloid 
and B-cell differentiation (Li et al., 2011; Orlanski et al., 2016) as well as proper NK cell 
differentiation (Tsagaratou et al., 2017). Furthermore, TET-dependent demethylation occurs 
in a variety of hematopoietic cell types and differentiation scenarios (Kallin et al., 2012; Klug 
et al., 2013; de la Rica et al., 2013; Yue et al., 2016). 
 In conclusion, TET enzymes seem to be dispensable for maintaining the pluripotent 
state, but crucial for proper differentiation due to their activities on genomic regulatory 
elements. 
Involvement in methylation reprogramming 
The two prominent DNA methylation reprogramming events in primordial germ cells and the 
zygote represent interesting settings to study demethylation and thus have been revised 
since the discovery of TET activity. While the maternal genome is successively demethylated 
during cell division suggestive of a dilution-dependent mechanism, the paternal genome 
displays immediate 5mC loss after fertilization but before replication (Mayer et al., 2000), 
indicating active removal. At this time TET3 specifically localizes to the paternal pronucleus 
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and large-scale generation of all oxidized mC forms takes place (Gu et al., 2011; Inoue and 
Zhang, 2011; Inoue et al., 2011; Iqbal et al., 2011; Wossidlo et al., 2011). However, the 
driving force of demethylation nevertheless was suggested to be replication-dependent 
dilution (Inoue and Zhang, 2011; Inoue et al., 2011), as inhibition of DNA synthesis resulted in 
a greater reduction of DNA demethylation than TET3 abrogation (Guo et al., 2014; Shen et 
al., 2014a). Interestingly, a recent study provided evidence that the paternal genome might 
undergo methylation loss even before 5mC oxidation, which argues for a completely TET-
independent demethylation mechanism (Amouroux et al., 2016). 
 Once zygotic genomes are demethylated, they completely remethylate and only then 
PGCs emerge, which demethylate their genomes again in two subsequent waves. While the 
first major wave employs mainly dilution of 5mC by downregulating UHRF1, DNMT3A and B 
(Kagiwada et al., 2013; Kurimoto et al., 2008), the second one makes use of TET1/2-
mediated 5hmC production followed by replication-dependent dilution. Consistently, TET1 
and TET2 are upregulated during this phase in PGCs (Hackett et al., 2013). Most global 
demethylation in PGCs is however TET-independent as TET1/2-deficiency has only locus-
specific effects on methylation. For instance, TET1 is important to demethylate specific 
imprinted genes (Yamaguchi et al., 2012, 2013). 
Involvement in DNA damage repair 
Recent studies indicate that TET activity might be required for DNA damage repair. Firstly, 
transcriptional regulation of DNA repair genes seems to rely on TET enzymes and thus TET 
deficiency results in impaired telomeres, increased chromosomal abnormalities and the 
accumulation of DNA breaks and γH2AX (An et al., 2015; Cimmino et al., 2015; Kafer et al., 
2016; Lu et al., 2014; Yamaguchi et al., 2012; Yang et al., 2016a). Secondly, a direct role for 
5hmC has been suggested as it was enriched at DNA damage sites and mitotic chromosome 
segregation defects were observed in replication-stressed TKO mESCs (Kafer et al., 2016).  
1.2.3.2 Role in disease 
Somatic mutations of TET enzymes have been detected in a variety of cancers, particularly in 
hematological malignancies. While TET1 and TET3 mutations are rare, TET2 mutations have 
been frequently identified in a spectrum of hematological diseases with both myeloid and 
lymphoid origin (Abdel-Wahab et al., 2009; Delhommeau et al., 2009; Gaidzik et al., 2012; 
Nibourel et al., 2010; Quivoron et al., 2011; Scopim-Ribeiro et al., 2015; Tefferi et al., 2009). 
CMML (20-58%), AML (2-32%), MDS (6-26%) and T-cell lymphoma (20-83%) are the 
diseases with the highest observed mutation frequency in TET2 (Scourzic et al., 2015). As 
the phenotype of TET2-deficient mice was dominated by the development of myeloid 
malignancies after long latency, a tumor suppressor role was attributed to TET2 (Ko et al., 
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2011; Li et al., 2011; Moran-Crusio et al., 2011; Quivoron et al., 2011). However, it was 
hypothesized that other oncogenic hits are required for malignant transformation. 
Consistently, TET2 mutations were also observed in healthy elderly individuals with clonal 
hematopoiesis (Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014). 
TET1 seems to have context-dependent functions in leukemogenesis. While its 
deficiency alone or in combination with TET2 has been associated with the development of B-
cell malignancies (Cimmino et al., 2015; Zhao et al., 2015), another study reported that it has 
a critical oncogenic role in MLL-rearranged leukemia (Huang et al., 2013a).  
Since TET2 and TET3 are the major expressed forms in the hematopoietic system, a 
mouse model with inducible DKO in hematopoietic precursor cells was established recently, 
resulting in the rapid emergence of aggressive myeloid leukemia. This was accompanied by 
skewed differentiation towards the myeloid lineage and accumulation of DNA damage (An et 
al., 2015), suggesting TET requirement for lineage priming and genomic integrity.  
In solid cancers, all three TET enzymes have been found mutated, but with low 
frequencies. The functional importance of these mutations remains to be clarified, especially 
since these tumors accumulate many somatic mutations. However, reduced TET enzyme and 
global 5hmC levels are a general hallmark of a wide range of cancers (Rasmussen and Helin, 
2016; Shen et al., 2014b), but it is currently unclear whether this is due to increased 
proliferation rates that have been shown to negatively correlate with 5hmC amounts 
(Bachman et al., 2014). 
1.3 The interaction between IDH und TET enzymes 
1.3.1 Molecular functions of IDH and mutated IDH (mIDH) 
Isocitrate dehydrogenases (IDH) are metabolic enzymes that decarboxylate isocitrate to α-
ketoglutarate. There are three members comprising IDH1, IDH2 and IDH3. While IDH1 is 
located in the cytosol, IDH2 and IDH3 localize to the mitochondria, where they participate in 
the tricarboxylic acid cycle. IDH1 and IDH2 form homodimers and use NADP+ as a cofactor, 
whereas IDH3 requires NAD+ (Figure 1.4). In addition to crucial metabolites for cellular 
anabolism, IDH synthesize NADH for respiration and NADPH for fatty acid metabolism and 
redox homeostasis (Dang et al., 2016). Over 80 dioxygenases rely on α-ketoglutarate to exert 
their catalytic functions, including TET enzymes, histone demethylases and a range of protein 
hydroxylases (Inoue et al., 2016a). 
 Recurrent cancer-associated mutations occur exclusively in IDH1 and IDH2 and 
invariably affect key arginines of the enzyme´s active site – R132 in IDH1 and R140 or R172 
in IDH2. These mutations occur early in clonal expansion, are heterozygous and mostly 
mutually exclusive, suggesting an oncogenic gain of function (Dang et al., 2016; Medeiros et 
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al., 2017). Indeed, it was shown that the observed mutations confer neomorphic activity, 
allowing the conversion of α-ketoglutarate into D-2-hydroxyglutarate (D-2-HG) using NADPH 
(Figure 1.4; Dang et al., 2009; Gross et al., 2010; Ward et al., 2010). Since all of the reported 
mutations converge to the accumulation of D-2-HG to millimolar concentrations in cancer 
cells, it has been recognized as an oncometabolite (Dang et al., 2016). 
 
 
Figure 1.4: Actions of WT IDH enzymes in homeostasis and mutant IDH1/2 in disease. 
αKG – α-ketoglutarate, 2-HG – D-2-hydroxyglutarate (adapted from Dang et al., 2016). 
 D-2-HG was subsequently shown to impair a variety of cellular processes. Firstly, it 
was reported to competitively inhibit histone demethylases (Chowdhury et al., 2011) and TET 
enzymes (Koivunen et al., 2012; Xu et al., 2011a), thereby affecting epigenetic regulation 
(Figure 1.4). Secondly, it seems to affect HIF prolyl-4-hydroxylases, which regulate the 
stability of hypoxia-inducible factor (HIF) and thereby might aberrantly influence hypoxia 
signaling (Koivunen et al., 2012; Xu et al., 2011a; Zhao et al., 2009). In addition, D-2-HG 
inhibited certain prolyl-hydroxylases involved in proper basement membrane function in the 
brain (Sasaki et al., 2012a), cytochrome c oxidase IV of the respiratory chain in AML cells 
(Chan et al., 2015) and fumarase as well as succinate dehydrogenase, resulting in 
hypersuccinylation of lysine residues, mitochondrial depolarization, impaired respiration and 
increased apoptosis resistance (Li et al., 2015). In another study D-2-HG was associated with 
paracrine stimulation of NFkB-signaling in bone marrow stromal cells, which supported AML 
cell proliferation and chemoresistance (Chen et al., 2016). Finally, mIDH produces NADP+ 
instead of NADPH, which potentially hampers the removal of reactive oxygen species and 
confounds the tricarboxylic acid cycle by reducing α-ketoglutarate levels. Eventually, this may  
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compromise the normal synthesis of several biomolecules (Inoue et al., 2016a). Together, 
these effects result in a pronounced disturbance of the cellular homeostasis.  
1.3.2 IDH mutations in cancer 
Neomorphic IDH mutations have been observed in glioma, AML, cholangiocarcinoma, 
chondrosarcoma and premalignant disorders like MDS and myeloproliferative neoplasms 
(Inoue et al., 2016a). In glioma, CIMP was associated with mIDH (Noushmehr et al., 2010) 
and it was claimed that mIDH1 is sufficient to establish this hypermethylation pattern (Turcan 
et al., 2012). Similar reports showed mIDH-associated genomic hypermethylation in AML 
(Akalin et al., 2012) that supposedly was caused by inhibition of the demethylating TET 
activity (Figueroa et al., 2010; Turcan et al., 2012). A number of studies since then have 
confirmed the association of mIDH with hypermethylation in AML and glioma patients, mouse 
and in vitro models (Chaturvedi et al., 2016; Duncan et al., 2012; Flavahan et al., 2015; 
Kernytsky et al., 2014; Sasaki et al., 2012b; Sturm et al., 2012; Voigt and Reinberg, 2013). 
 Additionally, mIDH has been connected to histone hypermethylation and a block in 
cellular differentiation using different in vitro and in vivo models (Figueroa et al., 2010; 
Kernytsky et al., 2014; Losman et al., 2013; Lu et al., 2012; Sasaki et al., 2012b). For 
example, a mouse model of conditional myeloid-specific mIDH1 knock-in showed an 
increased hematopoietic progenitor pool, splenomegaly and anemia resembling human MDS 
with concurrent histone and DNA hypermethylation (Sasaki et al., 2012b). Recently, long-term 
HSCs were shown to downregulate DNA damage repair and self-renewal using the same 
model. Interestingly, this was independent of TET2 (Inoue et al., 2016b). Other transgenic 
mice expressing mIDH2 developed AML or resembling malignancies upon cooperation with 
oncogenic FLT3/NRAS mutations or overexpression of HOXA9/MEIS1A. This suggests a 
proto-oncogenic role for mIDH that requires additional driving mutations or gene expression 
changes (Chen et al., 2013a; Kats et al., 2014). Additionally, D-2-HG itself was shown to 
promote proliferation, cytokine independence and differentiation inhibition in cultured cells 
(Losman et al., 2013) and this was supported by a recent study using a patient-derived AML 
xenotransplantation mouse model, in which administration of D-2-HG accelerated the onset of 
leukemia (Chaturvedi et al., 2016). Together, these data established the hypothesis that 
epigenetic deregulation is the driving factor in cancers with mIDH. 
The mIDH-associated differentiation block can be resolved by suppressing D-2-HG 
production using small molecule inhibitors against mIDH (Losman et al., 2013; Rohle et al., 
2013; Wang et al., 2013a). In two recent studies, the primary effect of mIDH inhibition was 
differentiation of AML cells ex vivo, in xenograft mouse models and in in vitro models (Shih et 
al., 2017; Yen et al., 2017). However, it is currently unclear how this is mediated: Several 
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studies claim that histone and DNA methylation patterns normalize under small molecule 
treatment (Kernytsky et al., 2014; Shih et al., 2017), whereas others find no reversal of DNA 
hypermethylation although efficiently depleting D-2-HG (Chaturvedi et al., 2017; Pusch et al., 
2017; Rohle et al., 2013).  
1.3.3 The hematopoietic system and acute myeloid leukemia (AML) 
Hematopoiesis provides the organism with all blood and immune cells and occurs throughout 
lifetime. Adult hematopoietic stem cells mainly reside in the bone marrow and constantly give 
rise to self-renewing and differentiating daughter cells through asymmetric cell divisions. In a 
stepwise differentiation hierarchy, cells successively restrict their lineage potential and 
commit to multipotent progenitors (MPPs) from which precursors of the myeloid (common 
myeloid progenitors - CMPs) and lymphoid (common lymphoid progenitors - CLPs) lineages 
arise. Through multiple intermediate states including granulocyte macrophage progenitors 
(GMPs) and promyelocytes (PMNs), the specialized cells of the myeloid compartment, such 
as macrophages or granulocytes (PMC – polymorphonuclear cell), are generated. CLPs in 
turn give rise to natural killer cells, B-, and T-lymphocytes (Figure 1.5).  
The different cell fates are accompanied by dynamic changes in the methylation 
landscape and it has been proposed that DNA methylation plays an important role in 
hematopoietic lineage choice (Bröske et al., 2009). Indeed, the methylomes of hematopoietic 
cells are distinct (Bock et al., 2012; Farlik et al., 2016). For example, HSCs change their 
methylation levels gradually during differentiation with a general loss of methylation upon 
myelopoiesis (Figure 1.5). In contrast, lymphoid cells become hypermethylated compared to 
HSCs and myeloid cells (Accomando et al., 2014; Bocker et al., 2011; Hodges et al., 2011; Ji 
et al., 2010; Rönnerblad et al., 2014). Using conditional DNMT1 hypomorphic or KO mice, it 
was shown that DNMT1-mediated DNA methylation is required to maintain the HSC pool and 
silence premature expression of myeloid-specific genes. Impairment of maintenance 
methylation consequently prevented the generation of lymphoid progeny (Bröske et al., 2009; 
Trowbridge et al., 2009). In contrast, DNMT3A and DNMT3B are required to methylate and 
silence HSC specific genes like RUNX1 or GATA3. Conditional ablation of DNMT3A alone or 
in combination with DNMT3B conferred enhanced self-renewal and repopulating capacity to 
HSCs and impaired their differentiation (Challen et al., 2014, 2011). Therefore, initial 
increases in methylation upon early progenitor commitment might be related to the silencing 
of stem cell genes and restriction of pluripotency (Álvarez-Errico et al., 2014).  
AML is a malignant disease of the myeloid compartment that is characterized by the 
abnormal expansion of immature myeloid progenitor cells due to an early differentiation block 
and increased proliferative capacity. These cells mostly originate from the highly proliferative 
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progenitor pool (CD34+/CD38+) or even the HSC pool (CD34+/CD38-). As a result, various 
tissues are infiltrated with aberrantly or poorly differentiated hematopoietic cells, while normal 
hematopoiesis is prevented. To diagnose AML the percentage of immature blasts in bone 
marrow or blood has to exceed ~25% (Passegué et al., 2003).  
 
 
Figure 1.5: Schematic of human hematopoiesis and accompanying DNA methylation changes. 
Major cell fates during adult hematopoiesis are shown (modified from Farlik et al., 2016). Alterations in 
global DNA methylation at certain transitions were adapted from Álvarez-Errico et al., 2014. 
AML is marked by inter-individual, cytogenetic, molecular, morphological and clonal 
heterogeneity (Döhner et al., 2015; Heuser et al., 2011). Frequently recurring mutations in 
AML affect FLT3, NPM1, N- or KRAS, RUNX1, TP53, WT1, PTPN11, KIT, CEBPA, TET2, 
DNMT3A and IDH1 or IDH2 (Voigt and Reinberg, 2013). Functionally, these genes relate to 
different categories among them tumor suppressor genes, receptor tyrosine kinase signaling 
proteins, transcriptional regulators and epigenetic modifiers (Döhner et al., 2015). The 
comparison of mutational status in different AML subtypes and healthy adult HSCs suggested 
that many of the mutations in epigenetic regulators including IDH1, IDH2, TET2 and DNMT3A 
are found in preleukemic cells and early stages of AML. Consequently, it was hypothesized 
that these mutations and epigenetic deregulation might be initiating events in leukemogenesis 
(Corces-Zimmerman et al., 2014; Shlush et al., 2014; Welch et al., 2012). DNMT3A mutations 
occur in roughly a quarter of newly diagnosed AML patients and of these more than half 
Introduction 
20 
 
display a mutation in arginine 882, most commonly R882H (Ley et al., 2010; Voigt and 
Reinberg, 2013). These heterozygous mutations hamper the homotetramerization of 
DNMT3A, inhibit remaining WT activity in a dominant-negative manner and lead to focal 
methylation loss (Holz-Schietinger et al., 2012; Russler-Germain et al., 2014). Recent studies 
have indicated that TET2 and DNMT3A mutations cooperate to induce leukemia (Scourzic et 
al., 2016; Zhang et al., 2016b), suggesting that antagonizing molecular functions might 
exacerbate epigenetic deregulation and accelerate the onset of transformation. In contrast, 
TET2 and IDH mutations have been described as mutually exclusive in AML (Figueroa et al., 
2010) and it was thus hypothesized that both contribute by similar mechanisms – aberrant 
DNA hypermethylation – to leukemogenesis. There is currently no consensus on the 
prognosis of IDH mutated AML patients as results are diverging across studies and seem to 
vary with the specific amino acid substitution and enzyme. However, a recent study did not 
find differences in overall survival between AML patients with mIDH or IDH WT status (Dang 
et al., 2016; DiNardo et al., 2015). 
1.4 Aims of the thesis 
TET enzymes provide a novel mechanism of epigenetic regulation antagonizing DNA 
methylation in mammals. While the majority of studies focused on early developmental stages 
to examine the functions of TET enzymes, their biological roles in differentiated cells are not 
well described. This is also valid in cancer cells, where their impairment through mutations in 
cofactor providing metabolic enzymes remains controversial. The aims of this thesis were to 
characterize the effects of TET-deficiency and inhibition in a selected developmental stage 
and relevant disease scenario, respectively, with special emphasis on DNA methylation 
changes as a result of defective DNA demethylation.  
1. The majority of TET1/2 deficient mice die perinatally due to developmental failures, 
suggesting a biological role of TET enzymes also in later developmental stages. The 
aim of this project was to characterize the phenotype and methylome of DKO mouse 
embryonic fibroblasts as a paradigm of a differentiated primary cell type with a 
disrupted DNA demethylation pathway. 
 
2. Neomorphic IDH mutations have been associated with DNA hypermethylation in 
cancer. The goal of this work was to examine IDH-dependent DNA methylation 
changes in AML and improve the understanding of their origin with special regard to 
TET impairment. 
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2 Results 
2.1 TET function in mouse development 
DNA methylation patterns are dynamically changing during mammalian development and are 
essential to regulate pluripotency and lineage-specific genes (Smith and Meissner, 2013). In 
Tet-deficient mice developmental defects mainly occur during embryogenesis (Dawlaty et al., 
2011, 2013, 2014). While Tet triple KO ESCs do not contribute to embryonic development 
(Dawlaty et al., 2014), Tet1/2 double deficient ESCs remain pluripotent, but embryos exhibit 
developmental plasticity with various defects and frequent perinatal lethality (Dawlaty et al., 
2013). This is accompanied by global DNA hypermethylation in all analyzed tissues. These 
phenotypes suggest a role for TET enzymes in early development. In order to analyze the 
role of TET enzymes in somatic cells, primary mouse embryonic fibroblasts (MEFs) 
representing a differentiated embryonic cell type, were isolated from Tet1/2 KO mice and 
characterized with regard to phenotype, gene expression and DNA methylation. The following 
data have partially been published in Wiehle et al., 2016. 
2.1.1 Phenotypic characterization of Tet1/2-deficient MEFs 
Tet1/2-deficient (DKO) mice were created previously by intercrossing Tet1- with Tet2-
deficient mice (Dawlaty et al., 2013). These mice had been generated before by gene 
targeting in mESCs. In the case of Tet1, exon 4 was deleted resulting in an out of frame 
fusion of exons 3 and 5, which truncated the TET1 protein and led to the loss of its catalytic 
domain (Dawlaty et al., 2011). The Tet2 gene was disrupted by insertion of a GFP-cassette 
into exon 3, which destroyed the endogenous start codon and resulted in the expression of a 
truncated, non-functional protein (Li et al., 2011). Primary MEFs were isolated from DKO 
animals at embryonic day 13.5 according to standard procedures by M. Dawlaty and 
transferred to Germany for further analysis. 
To confirm the disruption of Tet1 and Tet2 genes in the primary MEF model, qRT-PCR 
analysis of Tet transcripts was conducted using primers annealing to the corrupted regions. 
DKO MEFs were devoid of detectable Tet1 and Tet2 mRNA, whereas Tet3 transcript 
amounts were not significantly changed compared to WT MEFs (Figure 2.1A). This was 
confirmed by Tet3 transcript levels detected in RNA-seq analysis (Figure 2.1A, right panel). 
These data confirm Tet1/2 transcript disruption and the absence of compensatory Tet3 
upregulation in response to genetic Tet1- and Tet2-deficiency. 
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Figure 2.1: Validation of the Tet1/2-deficient MEF model. 
(A) Expression of the three Tet enzymes in WT and DKO MEFs was measured by qRT-PCR. The right 
panel shows FPKM values for Tet3 extracted from RNA-seq data. (B) Immunostaining of 
hydroxymethylation in genomic DNA of WT and DKO MEFs. Methylene blue staining was used as 
loading control. 
TET enzymes catalyze the oxidative conversion of 5mC to 5hmC. To confirm 
functional impairment of TET enzymes in the DKO model, global 5hmC levels were 
examined. To this end genomic DNA of WT and DKO MEFs was immobilized by dotblotting 
and stained with an antibody specific to 5hmC. This showed a moderate overall reduction of 
the 5hmC mark in the DNA of Tet1/2-deficient MEFs (Figure 2.1B). DNA hydroxymethylation 
was not completely abrogated though, indicating remaining TET3 activity. Together, these 
data demonstrate disruption of the Tet1 and Tet2 genes in DKO MEFs, which is accompanied 
by reduced DNA hydroxylating activity. Thus these cells are a valid model to investigate 
further Tet1/2-dependent changes.  
Phenotypic characterization of DKO MEFs revealed a flattened morphology with 
widespread protrusions (Figure 2.2A) and a reduced growth rate (Figure 2.2B), indicating that 
DKO MEFs have reduced proliferation capacity. 
Previous studies have reported that mESCs display skewed or defective differentiation 
upon Tet -deficiency (Dawlaty et al., 2013, 2014; Hon et al., 2014; Ito et al., 2010; Koh et al., 
2011; Li et al., 2014). MEFs isolated between embryonic day 12 and 14 are mesenchymal 
cells that generate normal tissue fibroblasts and fibrocytes. However, they are still multipotent 
and retain the capacity to differentiate into adipocytes, chondrocytes and osteoblasts 
(Rastegar et al., 2010; Rosen and MacDougald, 2006).  
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Figure 2.2: Phenotypic changes in Tet1/2-deficient MEFs. 
(A) Representative bright field microscopic image of WT and DKO MEFs. (B) Growth curve of WT and 
DKO MEFs based on metabolic activity. 
In order to test the differentiation potential of Tet1/2-/- MEFs, in vitro adipogenesis was 
performed by incubating the cells in adipogenic differentiation medium (ADM). While WT 
MEFs started to form microscopically visible lipid droplets around day 7 of treatment, the 
amount of droplets generated in DKO MEFs was significantly decreased (Figure 2.3), 
indicating inefficient adipogenesis in Tet1/2-/- MEFs. 
 
 
Figure 2.3: Incomplete adipogenesis in Tet1/2-deficient MEFs. 
(A) Bright field microscopic images of Oil Red O stained MEFs that were incubated in standard culture 
medium (untreated) or ADM for 21 days. (B) Quantification of lipid droplets at the indicated time points. 
Shown are the means of the numbers of lipid droplets counted in five view fields ± standard deviations. 
To test whether this was due to a failure in transcriptional adaptation, essential 
adipogenic transcription factors and effector genes were analyzed by qRT-PCR. 
Adipogenesis was accompanied by the ADM-dependent transcriptional induction of the 
established adipogenic markers genes Pparγ, C/Ebpα and Igf1 in WT MEFs (Rosen and 
MacDougald, 2006). However, induction of all three genes was strongly reduced in DKO 
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MEFs (Figure 2.4), suggesting that the cells fail to efficiently activate adipogenic 
differentiation genes.  
 
 
Figure 2.4: Inefficient transcription of adipogenic marker genes in Tet1/2-deficient MEFs. 
Expression of adipogenic markers Pparγ (A), C/Ebpα (B) and Igf1 (C) was analyzed by qRT-PCR in 
WT and DKO MEFs before (d0) and at day 7, 14 and 21 of ADM treatment. Actb and Gapdh were used 
as reference genes. Bars represent means and error bars standard deviations of three replicates. 
As TET1 and TET2 seemed to be required for adipogenesis their expression 
dynamics were analyzed during this process. All three Tet transcripts were upregulated 
during adipogenesis in WT MEFs (Figure 2.5). While Tet1 and Tet3 were only transiently 
induced (Figure 2.5A, C), Tet2 expression was continuously increasing over time (Figure 
2.5B). Overall transcript amounts of Tet2 and Tet3 were higher than Tet1, consistent with 
predominant Tet3 (and depending on the tissue Tet2) expression upon differentiation (Koh et 
al., 2011; Wu and Zhang, 2014). Interestingly, DKO MEFs expressed increased amounts of 
Tet3 upon adipogenesis, suggesting that in a setting where dynamic adaptation of TET levels 
is required, the cell might try to compensate for the loss of Tet1 and Tet2 by upregulating 
Tet3.  
Taken together, these data indicate an altered phenotype with a pronounced 
differentiation and gene expression defect in Tet1/2-deficient MEFs. Moreover, they point 
towards a functional requirement of TET enzymes in adipogenesis.  
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Figure 2.5: Tet expression is induced during adipogenesis. 
Tet1 (A), Tet2 (B) and Tet3 (C) expression dynamics during adipogenic differentiation were analyzed 
by qRT-PCR in WT and DKO MEFs. Actb and Gapdh were used as reference genes. Bars represent 
means and error bars standard deviations of three replicates. 
2.1.2 DNA methylation changes in Tet1/2-deficient MEFs 
The observed differentiation and gene regulation defects in DKO MEFs together with the 
reported demethylating activity of TET enzymes (He et al., 2011; Inoue and Zhang, 2011) 
suggested defects in epigenetic programming upon Tet1/2 KO. To investigate potential 
alterations due to reduced DNA demethylation in the methylomes of WT and Tet1/2-deficient 
MEFs, whole genome bisulfite sequencing was performed. This technique yields a genome-
wide base resolution map of methylated cytosines and, depending on the coverage, high 
confidence methylation ratios.  
Analysis of two independent biological replicates per genotype yielding a combined 
average coverage of 20x for each WT and DKO methylome showed that average methylation 
levels were comparable between replicates, but moderately increased in DKO MEFs (Figure 
2.6A). To conduct an unbiased analysis of the distribution of hypermethylation within the DKO 
genome, it was segmented into different subgenomic features based on the presence of 
certain histone modifications, PolII and CTCF. To this end, previously published genome-wide 
maps of these marks in WT MEFs were used (Mikkelsen et al., 2007; Shen et al., 2012). The 
combined patterns of modified histones, PolII and CTCF allowed assigning 15 functional 
classes and the average methylation level of each class was calculated. This revealed 
widespread hypermethylation in DKO MEFs, which affected almost all analyzed features 
(Figure 2.6B). Enhancers and promoters showed the most pronounced hypermethylation. 
These results demonstrate hypermethylation of functional regulatory elements upon Tet1/2-
deficiency, suggesting a demethylating activity for TET1 and TET2 at these regions.  
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Figure 2.6: Tet1/2-deficient MEFs show widespread DNA hypermethylation. 
(A) Average methylation ratios determined by whole genome bisulfite sequencing of two WT and DKO 
replicates. (B) Fold change of average methylation between DKO and WT MEFs of 15 subgenomic 
features identified by analysis of chromatin states. Error bars represent standard deviations of the two 
biological replicates. The right panel shows the 15 identified segments. The intensity of blue color 
reflects the appearance of histone modifications, PolII and CTCF in each segment. Functional 
elements were identified by the combined histone modification and protein patterns and are indicated 
on the right. These analyses were performed by Günter Raddatz. 
 As promoters were the most prominently hypermethylated elements in DKO MEFs, 
these features were analyzed in more detail. Previously described DNA methylation canyons 
are associated with the genes of developmentally important transcriptional regulators, mostly 
harbor at least one CGI and their borders are enriched for 5hmC (Jeong et al., 2013). As such 
they represented interesting promoter-associated features to be analyzed in a Tet-deficient 
context.  
Mapping of DNA methylation canyons in WT MEFs showed that 95% of canyons 
overlapped with a transcriptional start site (Figure 2.7A). The methylome of WT MEFs 
exhibited on average 1330 canyons. In DKO MEFs fewer canyons were detected, possibly 
due to the failure to meet the minimal size of 3.5 kb (Figure 2.7B). Next, the average 
methylation levels of WT and DKO canyons were analyzed. As expected, methylation ratios 
of canyons in general were very low. However, DKO MEFs showed a significantly increased 
median canyon methylation compared to WT MEFs (Figure 2.7C). Determination of canyon 
sizes in WT and DKO MEFs revealed that the majority of canyons in DKO cells were smaller 
than in WT MEFs (30%) or completely disappeared (38%) from the analysis as they did not 
meet the minimal size criterion (Figure 2.7D). A quarter of the canyons detected in WT MEFs 
were expanded in DKO MEFs and 7% did not display significant changes. These findings 
show that canyon hypermethylation leading to canyon shrinkage or collapse is a prominent 
feature of the methylome of Tet1/2-deficient MEFs. 
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Figure 2.7: Tet1/2-deficiency in MEFs results in canyon hypermethylation. 
(A) Association of canyons with transcriptional start sites (gene). Significance level was calculated 
using the chi-squared test (**: P<0.01). (B) Numbers of canyons in the two WT and DKO replicates. (C) 
Average methylation of canyons identified in the two WT and DKO replicates. The two-sided paired t-
test was used to calculate the significance level of the difference between the two groups (***: P=2.2 x 
10-16). (D) Piechart showing size changes of canyons in DKO MEFs compared to the corresponding 
canyons in WT MEFs. These analyses were performed by Günter Raddatz. 
The loss and size reductions of canyons in DKO cells suggested that they are 
collapsing due to invading hypermethylation at canyon borders. To confirm this, methylation 
profiles were visually examined at canyons. A prominent example of a large canyon with 
border hypermethylation was the one at the anterior Hoxa gene cluster (Figure 2.8A). This 
canyon did not only show increased methylation at the margins but also in the center. This is 
in accordance with Tet2 hydroxylating and potentially removing 5mC in the HOXA cluster 
during differentiation of NT2 cells (Bocker et al., 2012) and suggests that Tet enzymes have 
conserved functions at the Hoxa cluster in humans and mice.  
To examine canyon borders on a global scale, all canyons were size-normalized and 
the average methylation ratio at each relative position was displayed. This showed a general 
increase of average methylation in both DKO replicates, which was enhanced at the margins 
of the canyons (Figure 2.8B), indicating that hypermethylation from adjacent methylated 
regions invades the canyon due to the lack of TET1/2 activity.  
To validate canyon border hypermethylation, amplicon bisulfite sequencing was 
performed targeting selected canyon margins. Individual amplicons were covered by at least 
100 reads providing high confidence information on the methylation status of the examined 
CpGs. All selected loci displayed hypermethylation at all the interrogated CpG residues in 
DKO MEFs (Figure 2.9), confirming canyon border hypermethylation independently of whole 
genome bisulfite sequencing. 
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Figure 2.8: Canyon borders are maintained by TET1/2. 
(A) Example of a hypermethylated canyon at the Hoxa gene cluster. Methylation ratios of individual 
CpGs in WT-1 (top) and DKO-1 (bottom) MEFs are indicated by vertical blue lines. Red squares show 
the positions of the first two amplicons analyzed in Figure 2.9. (B) Superposition of the methylation 
profiles of all size-normalized canyons in WT and DKO MEFs. This analysis was performed by Günter 
Raddatz. 
Taken together, these results show that TET1 and TET2 prevent genomic 
hypermethylation of enhancers, promoters and specifically DNA methylation canyons. In 
particular, their demethylating activity is critical to protect canyon borders from aberrantly 
invading methylation.  
 
 
Figure 2.9: Validation of canyon border hypermethylation. 
Targeted amplicon bisulfite sequencing at borders of canyons associated with the genes Hoxa1, 
Hoxa3, Foxc1 and Foxc2. Data are displayed in heatmaps with each row representing a sequencing 
read and each column a CpG within this read. Individual CpGs are numbered and blue boxes indicate 
methylated and yellow boxes unmethylated cytosines. Positions of the analyzed regions are shown in 
Figure 2.8A and Figure S1. 
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2.1.3 Gene regulation defects in Tet1/2-deficient MEFs 
In order to investigate the functional consequences of Tet1/2-dependent hypermethylation 
comprehensively, transcriptomes of WT and DKO MEFs were analyzed using RNA-seq. This 
identified 301 differentially expressed genes (q-value<0.05) with both up- and downregulated 
transcripts being present in DKO MEFs (Figure 2.10A). Transcriptional silencing by promoter 
hypermethylation is thus not the sole mechanism of gene deregulation upon Tet1/2 KO. 
Pathway analysis of deregulated genes revealed strong enrichment for developmental 
categories (Figure 2.10B). This included “growth and proliferation” as well as “(connective) 
tissue development” among the top downregulated pathways, which is consistent with the 
observed reduction in growth rate and differentiation potential in DKO MEFs. These findings 
are also in accordance with a published study on the involvement of TET1 in cell cycle 
progression in somatic cells (Huang et al., 2013b).  
 
 
Figure 2.10: Tet1/2-deficiency disturbs gene expression in MEFs. 
(A) MA plot showing the fold change [log2(FC)] of each gene as a function of the averaged WT and 
DKO normalized read counts [log2(base mean)] per gene. Differentially expressed transcripts based on 
a q-value<0.05 are shown in red. This analysis was performed by Günter Raddatz. (B) Top ten 
biological pathways significantly enriched among downregulated (left panel) and upregulated (right 
panel) genes in DKO MEFs. 
To validate gene expression changes detected by RNA-seq, qRT-PCR for selected 
deregulated genes was performed. This confirmed the up- and downregulation of several 
genes in DKO MEFs observed by RNA-seq (Figure 2.11), of which many are involved in 
transcriptional regulation (e.g. the Hox and Fox transcription factors). In summary, these data 
indicate that Tet1/2-deficient MEFs exhibit disturbed gene expression patterns, which 
potentially alter their developmental state and differentiation capacity.  
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Figure 2.11: Validation of gene expression changes in Tet1/2-deficient MEFs. 
(A) FPKM values of selected genes extracted from RNA-seq analysis are shown. In the left panels 
upregulated and in the right panels downregulated genes in DKO MEFs are displayed. (B) QRT-PCR 
analysis of the corresponding genes from (A). Actb and Gapdh were used as reference genes. Bars 
represent means and error bars standard deviations of three replicates. All genes except of Foxc2 
were significantly changed in RNA-seq (***: Q<0.001, **: Q<0.01, *: Q<0.05), but the reduction in 
Foxc2 expression was found to be significant in qRT-PCR (+++: P<0.001). 
2.1.4 Dysregulation of canyons and associated genes during adipogenesis 
To examine the correlation between canyon hypermethylation and defective gene expression 
in MEFs, the overlap between gene deregulation and localization of the respective gene in a 
hypermethylated canyon was analyzed.  
 
 
Figure 2.12: Association of gene deregulation and localization in a hypermethylated canyon. 
The overlap between all differentially expressed genes (diff. exp. genes) with a |log2(FC)|≥0.5 and all 
genes associated with a hypermethylated canyon (hypermeth. genes) is shown. Statistical significance 
was determined using the hypergeometric test (P=7.55 x 10-7). Analysis and statistical testing were 
performed by Günter Raddatz. 
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To this end, all differentially expressed genes with a |log(FC)|≥0.5 were determined (6200). 
Furthermore all genes residing in a hypermethylated canyon were identified (84). More than 
half of these genes overlapped with the group of differentially expressed genes and this 
intersection was statistically significant (P=6.26 x 10-9; Figure 2.12), indicating that the 
presence of a gene promoter in a hypermethylated canyon likely leads to deregulation of the 
respective gene. However, the majority of deregulated genes was not associated with a 
hypermethylated canyon, indicating that additional mechanisms lead to gene deregulation 
upon Tet1/2-deficiency.  
 
 
Figure 2.13: Promoter hypermethylation correlates with defective gene induction during 
adipogenesis in Tet1/2-deficient MEFs. 
(A) Targeted amplicon bisulfite sequencing of promoters of four canyon-associated adipogenic marker 
genes during adipogenesis in WT and DKO MEFs. Untreated and cells treated with ADM for 14 days 
were analyzed. Localization of PCR amplicons in the canyon is shown in Figure S1. (B) QRT-PCR of 
the corresponding genes in untreated (u.t.) and cells treated with ADM for 14 days. Actb and Gapdh 
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were used as reference genes. Bars represent means and error bars standard deviations of three 
replicates. 
To investigate the contribution of hypermethylation to the observed differentiation 
defect, methylation dynamics at DNA methylation canyons during adipogenesis were 
analyzed. For this purpose, four adipogenic marker genes that were associated with a 
canyon – Pparγ, Igf1, Foxc1 and Foxc2 - were selected. Promoter methylation and 
expression dynamics of these genes were analyzed by targeted amplicon bisulfite 
sequencing and qRT-PCR, respectively, during the course of adipogenesis. After 14 days of 
ADM treatment the initial hypermethylation of these promoters present in undifferentiated 
DKO cells was greatly exacerbated (Figure 2.13A), leading for example to almost complete 
methylation of the Foxc1 promoter in contrast to WT MEFs. In conjunction with this, the 
expression of the corresponding genes was induced in WT cells, but impaired in DKO MEFs 
(Figure 2.13B). 
In summary, these data indicate that canyon gene dysregulation is significantly 
associated with hypermethylation of its respective canyon and correlated with promoter 
hypermethylation during adipogenesis. These observations suggest a protective role for TET1 
and TET2 in maintaining canyon-associated genes in a state, in which they can be activated 
upon differentiation cues.  
2.1.5 Cooperative role of TET1 and TET2 in canyon maintenance 
Previous studies have suggested distinct genomic target regions for TET1 and TET2 in 
mESCs based on depletion of hydroxymethylcytosine upon Tet1 or Tet2 knockdown (Huang 
et al., 2014). To dissect the individual contributions of TET1 and TET2 to canyon 
hypermethylation, single Tet1 and Tet2 KO MEFs were analyzed by targeted amplicon 
bisulfite sequencing of selected canyon borders as described above.  
 Comparison of single KO MEFs with WT MEFs showed that both, TET1 and TET2, 
contributed to canyon hypermethylation, as methylation ratios were higher in each single KO 
than in WT MEFs (Figure 2.14). However, TET2-dependent hypermethylation was always 
stronger than the TET1-mediated methylation increase, suggesting minor TET1 activity. 
There was no synergistic effect of Tet-double deficiency. These data indicate that TET1 and 
TET2 cooperate at canyon borders to maintain an adequate methylation state with a major 
role for TET2. In conclusion, the findings presented in this chapter attribute an essential and 
cooperative role to TET1 and TET2 in safeguarding DNA methylation canyons from 
erroneous methylation, thereby preventing the permanent silencing of important 
developmental genes. 
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Figure 2.14: TET1 and TET2 cooperate to maintain canyon borders.  
Targeted amplicon bisulfite sequencing of canyon borders as in Figure 2.9, comparing WT, Tet1-/- 
(T1KO), Tet2-/- (T2KO) and Tet1/2-/- MEFs. The small rectangular panels show color-coded average 
methylation ratio per individual CpG of the amplicon. The color scale is shown below the heatmaps. 
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2.2 TET function in human hematological disease with IDH mutation 
Tet2-deficient mice are characterized by impaired differentiation of the hematopoietic lineage, 
leading to an enlarged stem cell pool and induction of myeloid leukemogenesis over time or 
together with cooperating mutations (Ko et al., 2011; Li et al., 2011; Moran-Crusio et al., 
2011; Quivoron et al., 2011; Rasmussen et al., 2015). Consequently, TET2 mutation or 
downregulation has been recurrently observed in various types of human hematopoietic 
malignancies (Abdel-Wahab et al., 2009; Delhommeau et al., 2009; Gaidzik et al., 2012; 
Nibourel et al., 2010; Quivoron et al., 2011; Scopim-Ribeiro et al., 2015; Tefferi et al., 2009). 
As hypermethylation is a hallmark of many cancers (Jones and Baylin, 2007), it was 
speculated that TET impairment might be mechanistically related to cancer-specific 
methylation gain. 
 Recurrent mutations in IDH genes have been associated with genomic 
hypermethylation or CIMP in different cancer entities (Figueroa et al., 2010; Noushmehr et al., 
2010; Wang et al., 2013b). It was then shown that the oncometabolite 2-HG produced by 
mIDH can inhibit TET enzymes (Koivunen et al., 2012; Xu et al., 2011a). This prompted the 
hypothesis that mIDH causes pathogenic hypermethylation by inhibiting TET-dependent DNA 
demethylation (Figueroa et al., 2010; Turcan et al., 2012). However, TET activity is only 
weakly inhibited by 2-HG (Xu et al., 2011a). Moreover, prior analyses of mIDH-dependent 
DNA methylation changes in AML relied on comparisons between unsorted bone marrow 
aspirates and healthy donor tissues (Akalin et al., 2012; Figueroa et al., 2010). The possible 
contribution of cell type specific methylation patterns to AML methylomes was neglected, 
although an mIDH-dependent differentiation block had been repeatedly reported (Figueroa et 
al., 2010; Losman et al., 2013; Lu et al., 2012; Sasaki et al., 2012b). In order to dissect 
TET2-, mIDH- and differentiation-dependent methylation changes in AML methylation profiles 
of AML patients expressing mIDH or mutant TET2 were analyzed and compared to IDH/TET2 
WT AML methylomes. This was supported by methylation profiling of leukemia cell lines 
expressing mIDH and comparisons to various methylomes of normal hematopoietic cell 
types. The following data are part of a manuscript in preparation by Wiehle et al.. 
2.2.1 DNA methylation changes in IDH mutant AML patients 
To investigate the direct effect of IDH mutations on the methylome of AML patients, a 
previously collected patient cohort of adult de novo AML was analyzed (Voigt and Reinberg, 
2013). The data from this study are publically available and comprise clinical parameters, 
mutational status, gene expression and DNA methylation profiles of each patient. DNA 
methylation was assessed using the Illumina Infinium 450K array. This platform monitors the 
methylation status of 485,577 CpG sites in the human genome and thereby provides 
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coverage for 99% of annotated RefSeq genes and 96% of CpG islands. The 450K intensity 
data (IDAT) files containing raw beta values were extracted for 28 IDH mutant and 112 IDH 
WT AML patients and normalized, quality-filtered and statistically analyzed. This identified 
70,137 significantly (P<0.05) differentially methylated probes between IDH mutant and WT 
AML patients (Figure 2.15A). The vast majority (68,863 probes) of these probes was 
hypermethylated in mIDH carrying patients indicating a pronounced hypermethylation 
phenotype in AML patients with mIDH status. The significantly differentially methylated 
probes showed a distinct distribution in the two groups of AML patients (Figure 2.15B). While 
half of the average beta values in IDH WT patients ranged from 0.15 to 0.75 with a median of 
approximately 0.45, this range was increased by 10% in mIDH patients with a skewed 
distribution towards higher beta values (median approximately 0.65). To analyze the genomic 
distribution of hypermethylation in mIDH AML patients, average methylation ratios of 
significantly changed probes associated with CGI-related epigenomic features were assessed 
(Figure 2.15C). As expected, CGIs had low average beta values consistent with their largely 
unmethylated state in mammals. Shores had intermediate methylation levels, whereas 
shelves and open sea exhibited the highest methylation. IDH-mutated methylomes displayed 
increased average beta values in all the elements, indicating that hypermethylation was 
widespread and uniformly affecting different genomic regions. However, shores showed the 
greatest methylation increase compared to the other elements (Figure 2.15C). 
 
 
Figure 2.15: AML patients with mutations in IDH1/2 display genomic hypermethylation. 
(A) Scatterplot comparing 28 AML patients with IDH mutation to 112 AML patients with IDH WT status. 
Each dot shows the average beta value of an individual CpG probe of the 450K array retained after 
filtering in the two groups. Blue dots represent significantly (P<0.05) differentially methylated probes 
(DMPs). (B) Boxplot showing the average beta values of the identified significantly differentially 
methylated probes in the two groups. (C) Boxplot showing the average beta values of the significantly 
differentially methylated probes associated with different epigenomic features in the two patient groups. 
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 To compare methylation profiles of AML patients with mutant and WT IDH on a global 
scale, principal component and clustering analyses were conducted. Standard pre-processing 
of the array data removed all probes present on sex chromosomes, thereby avoiding the 
detection of sex-related methylation differences. Principal component analysis based on all 
450K probes remaining after pre-processing and quality-filtering revealed a separation of 
mIDH from IDH WT samples (Figure 2.16A), indicating the acquisition of characteristic 
methylation changes upon IDH mutation. Hierarchical clustering using the 5000 most 
significantly differentially methylated probes placed the AML patients into two major groups in 
a dendrogram (Figure 2.16B). One group comprised mostly mIDH patients (red, major left 
branch), while the other group mainly contained IDH WT patients (green, major right branch). 
The probes used for clustering showed a bimodal distribution. Roughly half of the probes 
were rather lowly methylated in IDH WT patients (reddish boxes; low beta values), whereas 
the other half displayed high methylation (blue boxes, high beta values), consistent with the 
typical binary state of methylation observed in mammalia (either methylated or unmethylated). 
Almost all of these probes gained methylation in the cluster of mIDH patients. In summary, 
these data demonstrate that mIDH-associated methylation patterns are sufficient to segregate 
most AML patients into two classes according to IDH mutational status.  
 
 
Figure 2.16. MIDH confers specific methylation patterns to AML cells. 
(A) Principal component analysis of mIDH (red) and IDH WT (green) AML patients with all 450K CpG 
probes retained after quality filtering. The first two components covering the dimensions with the 
highest variance are displayed. (B) Heatmap of the 5000 most significantly differentially methylated 
probes identified between mIDH and IDH WT AML patients. Dendrograms of patients and probes were 
obtained using hierarchical clustering by similarity with each column showing one patient and each row 
one probe. The color scale indicates beta values. 
 Inspection of the mutational status of mIDH patients that did not cluster into their 
correct group revealed that many of them carried co-occurring mutations in other epigenetic 
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modifiers such as DNMT3A. Of a total of 28 mIDH patients 12 had co-occurring mutations in 
DNMT3A with five displaying the R882H substitution that disrupts catalytic methyltransferase 
activity (Holz-Schietinger et al., 2012). As the lack of the methyltransferase activity of 
DNMT3A might result in hypomethylation and thus antagonize mIDH-associated 
hypermethylation, the effect of DNMT3A mutation on the methylome of AML patients was 
analyzed. This revealed global hypomethylation in DNMT3A mutant AML patients with 23,795 
out of 26,334 significantly differentially methylated probes being hypomethylated (Figure 
S2A), which reduced the median methylation of these patients by about 5% (Figure S2B). 
The patients with co-occurring DNMT3A and IDH mutations comprised some of the outliers 
observed in the PCA in Figure 2.16A and patients with mutations in DNMT3A generally 
appeared to cluster to the right of the area although the group was not well separated (Figure 
S2C). These findings demonstrate that mutations in epigenetic modifiers do not generally 
yield genomic hypermethylation. Consequently, patients with mutations in DNMT3A were 
entirely removed from the IDH dataset and hierarchical clustering was repeated. This resulted 
in an improved clustering with most of the patients being assigned to their correct mutational 
groups (Figure S2D). In conclusion, co-occurring mutations in various epigenetic modifiers 
can have distinct effects on the AML methylome, which strongly increases the complexity of 
the observed methylation patterns in AML. In the case of DNMT3A and IDH, this can explain 
some of the imperfect clustering by mutational status. 
2.2.2 Generation of IDH mutant AML cell lines 
In order to exclude confounding factors on methylomes of AML patients, such as additional 
mutations, age-related effects or tumor heterogeneity, and to establish the causality between 
mIDH and hypermethylation, cell-based (m)IDH-expressing models were generated. To this 
end, two leukemia cell lines, NOMO-1 (an acute myeloid leukemia cell line) and HL-60 (an 
acute promyelocytic leukemia cell line), were lentivirally transduced to stably integrate the WT 
or mutant IDH gene into their genomes. The employed vectors co-expressed GFP or 
ZsGreen allowing FACS-sorting of successfully transduced and transgene-expressing cell 
populations. These populations were screened by qRT-PCR for overexpression of the (m)IDH 
genes and 2-HG measurement for production of the oncometabolite D-2-HG.  
Expression of IDH1 WT or IDH1 R132C controlled by the phosphoglycerate kinase 
(PGK) promoter (Figure 4.1 for vector details) in HL-60 cells resulted in a modest increase of 
IDH1 expression by roughly 2-fold compared to cells transduced with empty vector, while 
IDH2 expression levels remained unchanged. Concomitantly, extracellular D-2-HG levels 
were increased 25-fold to ~10 µM in mIDH1-expressing HL-60 cells (Figure 2.17A). Although 
overexpression of IDH1 could not be detected by qRT-PCR in NOMO-1 cells transduced with 
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(m)IDH1, extracellular D-2-HG levels were moderately increased in these cells compared to 
transduction with IDH1 WT or empty vector (Figure 2.17B). Conversely, IDH1 expression 
dropped upon transduction with WT or mIDH1 and also endogenous IDH2 expression levels 
were reduced. These data indicate that already minor expression of mIDH1 leads to 
substantial D-2-HG secretion mimicking the situation in IDH mutated AML patients. However, 
cell lines reacted differently to introduction of IDH1 enzymes, indicating that transgene 
expression might be detrimental to certain cell types and thus strategies to downregulate its 
expression might quickly evolve.  
 
 
Figure 2.17: Overexpression of mIDH1 but not WT IDH1 leads to D-2-HG secretion.  
Expression of IDH1 and IDH2 transcripts (left panels) and extracellular D-2-HG (right panels) were 
measured in HL-60 (A) and NOMO-1 cells (B) transduced with empty vector, IDH1 WT or mIDH1. 
QRT-PCR was conducted with primers amplifying endogenous as well as exogenous IDH transcripts 
and ACTB as reference gene. Bars represent means and error bars standard deviations of three 
replicates. 
The increase of D-2-HG in the medium of NOMO-1 cells transduced with mIDH1 
suggested that mIDH1 was present, although its overexpression was not detectable. In order 
to confirm this, the base composition at the specific mutated position of the IDH1 mRNA was 
examined by cDNA sequencing. The WT base C was detected in NOMO-1 cells transduced 
with empty vector or IDH1 WT and a mixture of C and T bases was present in mIDH1-
transduced cells with the T base comprising the minor fraction (Figure S3A). This 
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demonstrates the presence of mutated IDH1 R132C transcripts in NOMO-1 cells. The same 
was true for HL-60 cells, albeit with roughly equal representation of the WT and mutated base 
(Figure S3B). This is consistent with the 2-fold increased expression of IDH1 (Figure 2.17A) 
and indicates that WT and mutant IDH1 transcripts were present at similar amounts in HL-60 
cells. Since IDH mutations are usually heterozygous in AML (Figueroa et al., 2010; Ward et 
al., 2010), this ratio of expression is likely to be a good approximation of the situation in AML 
patients. 
 As primers initially used for qRT-PCR did not distinguish between endogenous and 
exogenous IDH transcripts, potential downregulation of endogenous IDH transcription upon 
introduction of exogenous IDH1 was neglected. To distinguish these transcripts, qRT-PCR 
was repeated with primers amplifying specifically the endogenous IDH1 or the introduced 
transgene. Endogenous IDH1 transcript was indeed downregulated upon introduction of 
(m)IDH1 compared to empty vector. Expression of exogenous IDH1 could not be detected in 
cells treated with empty vector, but was present in cells transduced with WT or mIDH1 
(Figure S3C). Furthermore, determination of intracellular D-2-HG levels in mIDH1-expressing 
NOMO-1 cells revealed a roughly 11-fold increase of 2-HG levels (Figure S3D) compared to 
empty vector, which strongly exceeded the 4-fold increase in extracellular 2-HG (Figure 
2.17B, right panel). These data indicate that NOMO-1 cells expressed introduced transgenes 
and produced D-2-HG upon expression of mIDH1, but responded with downregulation of 
endogenous IDH. Also, they exhibited relatively weak export capacities for 2-HG, leading to 
modest extracellular D-2-HG concentrations, although substantial 2-HG amounts were 
intracellularly produced.  
 
 
Figure 2.18: Overexpression of mIDH2 results in robust D-2-HG production.  
(A) QRT-PCR of total IDH1 and IDH2 in HL-60 cells transduced with empty vector or mIDH2 (R140Q). 
ACTB was used as reference gene. Error bars show standard deviations (n=3). (B) Analysis of D-2-HG 
concentrations in the medium of HL-60 cells transduced with empty vector or mIDH2. Error bars show 
standard deviations of three replicates.  
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To similarly express mIDH2 in leukemia cell lines, IDH2 R140Q was cloned into a 
lentiviral construct controlling IDH expression by the CMV promoter (Figure 4.1 for vector 
details). Introduction of mIDH2 into HL-60 cells increased total IDH2 levels roughly 5-fold 
compared to cells transduced with empty vector, while IDH1 expression remained almost 
stable (Figure 2.18A). This was accompanied by a more than 30-fold increase in D-2-HG 
concentrations to approximately 11 µM in the medium of mIDH2-expressing cells (Figure 
2.18B). This level (~2110 ng/ml) was comparable to the median serum 2-HG concentration 
found in AML patients with mutant IDH (1863 ng/ml; Fathi et al., 2012), indicating that patient-
relevant 2-HG concentrations can be obtained with this model. These results furthermore 
show that both mIDH1 and mIDH2 overexpression result in substantial production of D-2-HG 
in cell-based models.  
 
 
Figure 2.19: MIDH2-expressing HL-60 cells show no overt phenotypic alterations.  
Bright field microscopy (A) and proliferation analysis (B) of HL-60 cells transduced with empty vector or 
mIDH2.  
In AML IDH2 mutations are more frequent than IDH1 mutations and have been shown 
to produce higher levels of D-2-HG (Ward et al., 2010, 2013). Thus, further analysis focused 
on mIDH2-expressing HL-60 cells. To monitor how mIDH2 overexpression and 
accompanying D-2-HG levels would affect cells, phenotypic characterization was carried out. 
Morphologically, mIDH2-expressing cells were indistinguishable from cells transduced with 
empty vector (Figure 2.19A) and showed similar growth kinetics (Figure 2.19B). 
Since mutant IDH enzymes have been reported to inhibit differentiation (Figueroa et 
al., 2010; Losman et al., 2013; Lu et al., 2012), gene expression of hematopoietic stem cell 
and myeloid lineage-specific markers were compared between mIDH2-expressing cells and 
empty vector cells. This uncovered a gene expression pattern reminiscent of myeloid 
progenitor cells. For instance, transcripts specifically expressed in macrophages, monocytes 
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or granulocytes, such as CD14 or CD11B, were reduced (Figure 2.20A), whereas genes 
expressed mainly during early stages of hematopoiesis (i.e., in HSCs, MPPs, CMPs and 
GMPs), such as MEIS1 or C-KIT, were significantly increased in mIDH2-expressing cells 
(Figure 2.20B).  
Taken together, in a leukemia cell line model no major phenotypic but moderate gene 
expression changes are caused by overexpression of mIDH2, hinting at an altered 
differentiation state of the engineered cells.  
 
 
Figure 2.20: MIDH2-expressing HL-60 cells display gene expression changes.  
QRT-PCR analysis of (A) myeloid differentiation and (B) hematopoietic stem cell markers in HL-60 
cells transduced with empty vector (EV) or mIDH2. ACTB served as reference gene for qRT-PCR 
normalization and error bars show standard deviations of three replicates. 
2.2.3 DNA methylation changes in an IDH mutant AML cell line 
The presence of mIDH2 changed gene expression patterns, suggesting that it affects the 
underlying epigenetic regulatory landscape. To test whether overexpression of mIDH2 and 
associated D-2-HG production resulted in changes to the global DNA (hydroxy)methylation 
level, immunostainings were performed on genomic DNA of transduced HL-60 cells. IDH2 
R140Q-expressing HL-60 cells had increased global 5mC levels compared to cells 
transduced with empty vector (Figure 2.21A), however 5hmC levels were largely unchanged 
(Figure 2.21B), indicating that the presence of mIDH2 is associated with a global increase of 
DNA methylation marks. The stable 5hmC levels suggested that TET activity was not 
drastically reduced upon mIDH2 introduction.  
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To investigate mIDH2-associated methylation changes in detail, Infinium methylation 
analysis of HL-60 cells was conducted. In mIDH2-expressing HL-60 cells 59,612 significantly 
differentially methylated probes were identified compared to cells transduced with empty 
vector (Figure 2.22B). However, only 65% of these probes were hypermethylated in cells 
expressing mIDH2. Comparison of the two scatterplots from AML patients and HL-60 cells 
demonstrated that methylation changes in the cellular model were quite distinct from those in 
AML patients including a wider range of methylation changes and hyper- as well as 
substantial hypomethylation (compare Figure 2.15A and Figure 2.22A). Calculating the 
overlap between cells and patients revealed that only a small fraction of all differentially 
methylated probes was shared between HL-60 cells and AML patients with IDH mutations 
(Figure 2.22B).  
Together, these data show that introduction of mIDH2 into HL-60 cells does not 
phenocopy the methylation changes in AML patients with IDH mutations, indicating that 
additional mechanisms contribute to the hypermethylation phenotype observed in IDH-
mutated AML. 
 
 
Figure 2.21: MIDH2-expressing HL-60 cells display globally increased DNA methylation. 
Immunostaining of 5mC (A) and 5hmC (B) in genomic DNA of HL-60 cells transduced with empty 
vector or mIDH2. Methylene blue staining was used as loading control (loading ctrl). Negative control 
wells were loaded with buffer (neg ctrl). 
 PMDs have been reported as large regions of low methylation in human cancers and 
cell lines, possibly due to inefficient maintenance methylation in quickly proliferating systems 
(Berman et al., 2011; Gaidatzis et al., 2014; Hon et al., 2012; Lister et al., 2009, 2011). To 
exclude the possibility that hypomethylation upon introduction of mIDH2 into HL-60 cells 
could be caused by the slightly increased proliferation rate of these cells (Figure 2.19B), 
PMD-associated CpG probes were identified. An approximation of PMD coordinates was 
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retrieved from publically available nuclear lamina-associated domain profiles (Guelen et al., 
2008), which have been shown to coincide with PMDs (Berman et al., 2011). Removal of the 
PMD-associated probes from the analysis did not affect mIDH2-associated methylation 
changes in HL-60 cells. Despite reducing the total number of significantly differentially 
methylated probes to 44,015, hypomethylation of a large proportion of probes was retained 
(Figure S4A). The distribution of average beta values was unchanged compared to the 
analysis including PMD probes (Figure S4B) and the amount of hypomethylated probes was 
even increased to 37% (Figure S4C; compared to 35% in the analysis including PMD 
probes). Hence, loss of methylation from PMDs cannot explain the hypomethylation observed 
in mIDH2-expressing HL-60 cells. This emphasizes the distinct effects of mIDH on the 
methylomes of AML patients in vivo and HL-60 cells in vitro.  
 
 
Figure 2.22: DNA methylation changes in AML patients and HL-60 cells with mIDH are distinct. 
(A) Comparison of average beta values between HL-60 cells expressing mIDH2 and empty vector. 
Each probe is represented in a dot with DMPs (P<0.05) colored in blue. (B) Overlap of the significantly 
differentially methylated probes identified in AML patients and HL-60 cells upon presence of mIDH. 
2.2.4 DNA methylation changes in AML patients with TET mutations 
Since neomorphic IDH mutations were suggested to inhibit the demethylating activity of TET 
proteins (Figueroa et al., 2010; Turcan et al., 2012), the loss of TET enzymes by inactivating 
mutations in AML should mimic the methylation changes observed in mIDH patients. To 
address this issue, all patients with mutations in TET2 were selected from the AML dataset. 
These 12 patients exhibited exclusively frameshift or nonsense mutations occurring before 
the catalytic domain, therefore abrogating the dioxygenase activity of TET2. It was previously 
reported that TET2 mutations (heterozygous, hemizygous or homozygous) in myeloid 
cancers correlated with reduced 5hmC levels, suggesting that its hydroxylating activity is 
impaired even upon heterozygous mutation (Ko et al., 2010). The mutant TET2 patients were 
compared to 100 AML patients with TET2 and IDH1/2 WT status.  
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Figure 2.23: Mutations in TET2 do not recapitulate mIDH-associated hypermethylation in AML.  
(A) Comparison of mutant and WT TET2 AML patients by scatterplot. Each dot shows the average 
beta value of one probe in the two groups with DMPs (P<0.05) depicted in blue. IDH mutant patients 
were removed from the analysis. (B) Average beta values of all probes in the two patient groups. (C) 
Principal component analysis of the methylomes of the two patient groups using all CpG probes left 
after quality filtering. 
 This comparison resulted in 573 significantly differentially methylated probes of which 
516 were hypermethylated (Figure 2.23A). Consistently, the median of the average beta 
values of all probes was slightly increased in patients with mutant TET2 (Figure 2.23B). 
Principal component analysis based on all CpG probes showed no clear separation of AML 
patients according to TET2 mutational status (Figure 2.23C). Taken together, these findings 
suggest limited hypermethylation upon mutation of TET2 that does not confer specific 
discriminatory methylation patterns. Since mIDH-associated hypermethylation was much 
more widespread in AML, mutations in IDH1/2 and TET2 do not phenocopy methylation 
patterns of each other. 
2.2.5 Canyon analysis in IDH mutant AML patients 
In the first part of this thesis, DNA methylation canyons were identified as key targets for 
demethylation by TET1 and TET2. Since neomorphic IDH mutations were reported to inhibit 
TET function (Figueroa et al., 2010; Turcan et al., 2012), canyon hypermethylation should be 
an inherent feature of the mIDH-associated methylome.  
To investigate canyon methylation, a publically available whole genome bisulfite 
sequencing dataset of an IDH WT AML patient was used to map canyons and the 
corresponding 450K probes. This identified 1711 canyons and 26,117 canyon-associated 
probes. Average beta values of these probes were only slightly increased in mIDH AML 
patients (Figure 2.24B). When all the canyons were size-normalized and superposed, very 
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modest hypermethylation was detected in mIDH samples. This was evenly distributed over 
the entire canyon and not enriched at canyon borders, as observed in Tet-deficient cells 
(Figure 2.24C, compare to Figure 2.8B). In conclusion, canyons are not specifically 
hypermethylated in mIDH AML, arguing against a strong inhibition of the demethylating TET 
activity in the presence of mIDH.  
 
 
Figure 2.24: TET-dependent DNA methylation canyons are not specifically hypermethylated in 
mIDH AML.  
(A) Average beta values of all canyon-associated probes in IDH WT and mIDH AML patients. (B) All 
canyons identified in whole genome bisulfite sequencing data of an IDH WT AML patient were size 
normalized, superposed and the average beta values of associated probes in mIDH and IDH WT AML 
patients were depicted. Canyon analysis was performed by Günter Raddatz.  
2.2.6 Effect of D-2-HG on the methylome of an AML cell line 
MIDH-dependent TET inhibition was suggested to function by competitive displacement of the 
essential cofactor α-ketoglutarate by D-2-hydroxyglutarate (Koivunen et al., 2012; Xu et al., 
2011a). To reliably inhibit all three TET enzymes and assess resulting DNA methylation 
changes, WT HL-60 cells were treated with high doses of synthetic D-2-HG. Intracellular D-2-
HG quantification confirmed incorporation of the compound into the cells in a concentration-
dependent manner, resulting in final concentrations of 10 to 114 pmol/µg protein (Figure 
2.25A). However, total intracellular D-2-HG concentrations upon addition of 30 mM dropped 
over time, possibly due to upregulation of the D-2-HG converting dehydrogenase (D-2HGDH) 
or cellular transporters that shuttle D-2-HG. Nevertheless, intracellular D-2-HG concentrations 
at any time point strongly exceeded those obtained by overexpression of mIDH2 in HL-60 
cells (Figure 2.25A, right panel), indicating that this is a valid experiment to model mIDH-
mediated scenarios in cells and patients. 
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Figure 2.25: D-2-HG does not provoke genomic hypermethylation in vitro.  
(A) Intracellular D-2-HG quantification in HL-60 cells cultured for 4, 11 and 18 days in medium 
supplemented with the indicated concentrations of D- or L-2-HG (left panel). On the right the 
intracellular quantification of D-2-HG in HL-60 cells transduced with empty vector (EV) or mIDH2 is 
shown. Error bars indicate standard deviations of three replicates. (B) Scatterplot comparing the 
average beta values of all CpG probes in two replicates of untreated (u.t.) and D-2-HG treated (2-HG) 
HL-60 cells (30 mM for 21 days). Each dot represents one probe. No significantly changed probes 
were identified (P<0.05). (C) Average beta values of all probes in untreated and D-2-HG treated HL-60 
cells.  
Analysis of cell proliferation showed that cells grew slower when cultured in D/L-2-HG 
supplied medium and D-2-HG conferred a bigger growth disadvantage than L-2-HG (Figure 
S5). However, cells remained viable. After 21 days of treatment with 30 mM D-2-HG genomic 
DNA was extracted and subjected to DNA methylation analysis by the Infinium chip. 
Comparison to untreated HL-60 cells demonstrated no significant change in DNA methylation 
with zero differentially methylated probes upon D-2-HG treatment (P<0.5; Figure 2.25B). 
Consistently, the distribution of the average beta values of all probes was largely unchanged 
(Figure 2.25C). Taken together, these data indicate the insufficiency of D-2-HG to induce 
global DNA methylation changes in cultured cells. 
2.2.7 Comparison of IDH mutant AML and normal hematopoietic methylomes 
Previous studies have shown that IDH mutations impair cellular differentiation in 
hematopoietic and other cell culture systems as well as in hematopoiesis in vivo (Figueroa et 
al., 2010; Losman et al., 2013; Lu et al., 2012; Sasaki et al., 2012b). DNA methylation 
patterns are dynamic during mammalian differentiation and define cellular identity (Smith and 
Meissner, 2013; Ziller et al., 2013). Analysis of FACS-purified hematopoietic cell populations 
with varying differentiation degree revealed that myeloid cells successively reduce their global 
methylation during commitment and differentiation (Bocker et al., 2011; Farlik et al., 2016; 
Hodges et al., 2011; Rönnerblad et al., 2014).  
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 To examine the differentiation state of AML cells in patients with and without IDH 
mutation, the distribution of French–American–British (FAB) classes, which were available for 
each patient and assign the maturation grade to the predominant blast type in AML based on 
morphological characteristics, were analyzed in the two patient groups. This showed a strong 
enrichment of FAB category M1 (acute myeloblastic leukemia with minimal maturation) in the 
group of patients with IDH mutations compared to IDH WT AML patients (Figure 2.26A). 
Additionally, undifferentiated acute myeloblastic leukemia (M0) was more frequently observed 
among mIDH AML patients, whereas all the remaining classes occurred more rarely. This 
indicates a skewed distribution of FAB classes among mIDH compared to IDH WT AML 
patients towards less mature cell types. When the assigned FAB category of each patient 
was marked in the previously conducted principal component analysis (Figure 2.16A), many 
mIDH patients that clustered with the IDH WT group were classified as M2 to M5. In contrast, 
mIDH patients clearly segregating from IDH WT patients were assigned with M0 or M1 
(Figure 2.26B), suggesting that poor maturation determines discriminatory methylation. 
Consistently, methylomes of blast cells that managed to mature despite carrying IDH 
mutations rather resembled IDH WT methylation profiles.  
To assess whether mIDH-associated hypermethylation in AML cells resembled 
methylation patterns of normal myeloid cells, comparison analyses between (m)IDH AML 
methylomes and 450K profiles of FACS-sorted human myeloid cell types were performed. 
Sorted common myeloid progenitors (CMP), granulocyte macrophage progenitors (GMP), 
promyelocytes (PMC) and polymorphonuclear/terminally differentiated bone marrow 
granulocytes (PMN) that were previously analyzed by 450K array (Rönnerblad et al., 2014) 
provided reference methylomes of the major myeloid differentiation stages. Principal 
component analysis segregated the CD34 positive progenitor cell types (CMP and GMP) from 
the CD34 negative differentiated cell types (PMC and PMN). When the AML profiles were 
projected on top of these, mIDH AML cases rather clustered with the progenitor cell types, 
whereas IDH WT patients resembled differentiated cell types (Figure 2.26C). Analysis of the 
10,000 most differentially methylated probes between CMP/GMP and PMC/PMN populations 
in hierarchical clustering clearly separated the two groups from each other and placed most of 
the mIDH samples in the same branch as the progenitor cells (Figure 2.26D). Next, the 
10,000 most differentially methylated probes between mIDH and IDH WT patients were 
extracted and used for hierarchical clustering of myeloid cell types. This ordered the 
reference cells according to their degree of differentiation with CD34 positive cells separated 
from CD34 negative cell types (Figure 2.26E). This indicates a pronounced overlap between 
the mIDH-associated methylation signature in AML and the myeloid differentiation-associated 
methylation program. 
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In summary, DNA methylation patterns of AML patients with mutations in IDH show 
high similarity to methylomes of myeloid progenitor cell types, identifying an early 
differentiation state as a source of mIDH-associated hypermethylation. 
 
 
Figure 2.26: MIDH-associated hypermethylation in AML resembles methylation patterns of 
myeloid progenitors.  
(A) Frequency distribution of French-American-British (FAB) AML categories in the TCGA cohort 
divided into mIDH and IDH WT patients. (B) Principal component analysis as in Figure 2.16A with 
different FAB categories of mIDH AML patients marked in orange and yellow hues. (C) Principal 
component analysis using published 450K profiles of four human myeloid cell types from Rönnerblad et 
al., 2014. AML patient profiles were projected on the cell type clusters. (D) Heatmap showing color-
coded beta values (color scale to the right) of the 10,000 most differentially methylated probes between 
the CMP/GMP and PMC/PMN population in AML patients. Each row represents one probe and each 
column one patient. IDH mutational status and reference cell types are indicated below the heatmap by 
colored boxes. Hierarchical clustering by similarity was used to obtain dendrograms. (E) Heatmap of 
the four hematopoietic reference cell types using the 10,000 most differentially methylated probes 
between mIDH and IDH WT AML patients. Each row represents one probe and each column one 
replicate of the indicated cell type. Analyses for (C) – (E) were performed by Günter Raddatz. 
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3 Discussion 
DNA methylation is dynamically changing during development and differentiation and its 
deregulation has been associated with cancer pathogenesis (Jones and Baylin, 2007). The 
interplay of DNMTs, recently identified TET enzymes and their cofactor-providing partners 
including IDH enzymes defines the cellular methylation landscape. However, the functional 
contribution of TET enzymes to the methylation profiles of differentiated normal and cancer 
cells is poorly understood. Here, these two aspects were addressed by characterizing the 
methylomes of genetically TET1/2-deficient primary mouse embryonic fibroblasts and of IDH 
mutated AML patients, in which TET enzymes are chemically inhibited. The findings 
presented in this thesis identify DNA methylation canyons as key target features of TET1/2-
demethylating activity in mouse embryonic fibroblasts and expand on the mechanistic 
understanding of IDH-associated global hypermethylation in AML. 
3.1 Role of TET enzymes in mouse development 
TET-mediated DNA demethylation has been implicated in a variety of mammalian 
developmental processes including the large-scale DNA demethylation waves during PGC 
and zygotic development and differentiation of ESCs (Wu and Zhang, 2017). A series of 
recent reports has shown functions of TET enzymes in differentiation and lineage choice of 
multipotent cells of the adult organism, for example in hematopoietic (Orlanski et al., 2016), 
neuronal (Perera et al., 2015), hepatic (Ancey et al., 2017) and myogenic (Zhong et al., 2017) 
cell types. To expand on this knowledge, the biological role of TET enzymes in an embryonic 
differentiated cell type was analyzed here. 
3.1.1 A differentiated model system with impaired DNA demethylation 
TET1/2-deficiency resulted in increased 5mC and decreased 5hmC levels in E13.5 mouse 
embryos, neonates and essentially all analyzed adult DKO tissues (Dawlaty et al., 2013). This 
indicates impaired DNA demethylation in DKO animals and thus qualifies DKO MEFs – 
typically isolated at day 13.5 from the embryonic torso – as a convenient differentiated cellular 
model to investigate epigenomic changes upon 5hmC loss.  
 TET1 and TET2 are highly expressed in mESCs, the preimplantation blastocyst and 
the early epiblast (Wu and Zhang, 2014), but they are rapidly downregulated upon in vitro 
differentiation of mESCs, while TET3 emerges (Koh et al., 2011). TET2 and TET3 are the 
major expressed TET enzymes in a variety of adult tissues (Rasmussen and Helin, 2016). 
The observed expression pattern of TET enzymes in WT MEFs is in line with these 
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observations and a previous report (Koh et al., 2011), suggesting that MEFs are in the 
transition from a stem-like state to an adult fibroblast, where TET1 is still detectable but TET2 
and TET3 are likewise expressed. Due to their redundant enzymatic activities TET enzymes 
in principle can compensate for each other, but TET3 expression was largely unchanged in 
DKO MEFs. Since global 5hmC in genomic DNA of DKO MEFs was reduced but not absent, 
TET3 activity most likely accounts for the remaining 5hmC.  
3.1.2 Hypermethylated canyons are a key feature of the DKO methylome 
To analyze the consequences of impaired DNA demethylation, whole genome bisulfite 
sequencing of DKO MEFs was performed in this study. Since this approach enables genome-
wide detection of methylated cytosines with single-base resolution and high individual CpG 
coverage, it is currently considered the gold standard of DNA methylation analysis. The 
resulting average methylation levels were moderately increased in the two DKO replicates, 
confirming the previously noted genomic hypermethylation upon loss of TET1 and TET2 that 
was detected by mass spectrometry (Dawlaty et al., 2013).  
 In order to identify functionally important genomic elements that may be TET-
dependently demethylated, it was reasoned that these would accumulate aberrant DNA 
methylation in TET1/2-deficient compared to WT MEFs. An unbiased analysis of the 
methylation of different genomic features identified enhancers, promoters, transcribed gene 
bodies, insulators and intragenic regions as most severely hypermethylated. Consistent with 
this, enhancer hypermethylation has been described in TET2-deficient (Hon et al., 2014) and 
TKO mESCs (Lu et al., 2014). Both studies also provided evidence that promoters, gene 
bodies and CTCF sites (insulators) are affected by TET-dependent hypermethylation. Another 
study mapped regions of 5hmC loss upon TET1 or TET2 depletion in mESCs and found 
5hmC reduction at TSS and exons of highly expressed genes, respectively (Huang et al., 
2014). These findings match the observations presented here and suggest that regions losing 
5hmC are overlapping with regions accumulating 5mC upon TET-deficiency, arguing for an 
active DNA demethylation process at these regions.  
 The identification of DNA methylation canyons as conserved, hypomethylated features 
of mammalian genomes whose borders are enriched with 5hmC (Jeong et al., 2013) 
prompted their analysis in this study. Here, DNA methylation canyons were found as a key 
feature of hypermethylation upon TET1/2-deficiency. While a subset of canyons was lost in 
DKO cells, remaining canyons displayed hypermethylation. Overall, two thirds of all identified 
canyons collapsed or diminished in size, strongly suggesting that TET1/2 activities are 
required to maintain canyons. In particular canyon borders were affected by hypermethylation 
as confirmed by targeted bisulfite sequencing. Data from (hydroxy)methylated DNA 
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immunoprecipitation experiments reported in Wiehle et al., 2016 corroborate these findings, 
as 5mC was increased at canyon borders, while 5hmC was reduced.  
 Conversely, a quarter of all identified canyons increased in size upon TET1/2-
deficiency. It has been reported that canyon borders also depend on the activity of DNMT3A 
and become eroded upon deletion in mouse HSCs (Jeong et al., 2013). Thus, defective 
targeting, reduced expression, activity or stability of DNMT3A upon TET1/2 loss may account 
for expanded canyons. More recently, it was also suggested that TET2 and DNMT3A, which 
are frequently co-mutated in leukemia, have context-dependent functions on DNA methylation 
in mouse HSCs, that could be synergistic or competitive (Zhang et al., 2016b). This analysis 
of TET2 and DNMT3A double deficient HSCs supports the model of opposing activities of 
DNMT3A and TET2 at the edges of canyons presented in Figure 3.1. Moreover, the authors 
identified redistribution of global DNA methylation upon double KO and TET2 KO specific 
hypermethylation in the center of canyons. Similar observations were made in the present 
study, for example in the anterior HOXA cluster (Figure 2.8A). Although no mechanistic 
explanation on how synergistic activities may be elicited is provided in that study, expanded 
canyons could represent such regions of TET and DNMT cooperation or methylation 
redistribution. Furthermore, ectopically targeted TET3 may exert compensatory demethylation 
at certain canyons. 
 The analysis of single KO MEFs indicated that combined cooperative activities of 
TET1 and TET2 protect the canyon borders from hypermethylation, but with a major 
contribution of TET2. This is in line with other reports showing that TET1 and TET2 appear 
together in different cell types and seem to have overlapping and non-redundant functions 
under certain conditions, for instance in HSCs (Zhao et al., 2015), regulatory T-cells (Yang et 
al., 2015) and during NANOG-assisted somatic cell reprogramming (Costa et al., 2013). 
Nevertheless, specific roles for TET1 and TET2 have been reported as well. For instance, in 
mESCs with TET2-deficiency a particular loss of 5hmC from gene bodies and other 
regulatory elements was reported, whereas TET1-deficiency resulted in a general 5hmC 
reduction with global 5hmC patterns reminiscent of WT ESCs (Hon et al., 2014). Another 
study showed TET1-dependent 5hmC depletion specifically from TSS (Huang et al., 2014). 
Similar to the presented findings, 5hmC loss and 5mC gain were generally greater upon 
TET2-deficiency compared to TET1 loss. Hence, TET enzymes may share their 
demethylation targets in certain cell types or developmental stages, while having specific 
roles in others. Moreover, overlapping functions might be a relict of an ancestral single TET 
gene, while individual TET enzymes may have acquired additional specific functions during 
evolution. Particularly in unstressed differentiated cells, where transcriptional and methylation 
patterns are largely established, TET enzymes might serve a broad role in the maintenance 
of normal methylation patterns rather than directed DNA demethylation of specific features.  
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The findings presented here further advance on previous publications implicating 
TET1 in fine-tuning of the physiological DNA methylation landscape. TET1 was found to bind 
specifically CpG-rich TSS, where 5hmC is also enriched in mESCs. It was thus speculated 
that TET1 might mediate DNA methylation fidelity by opposing stochastic hypermethylation at 
CpG-rich gene regulatory sequences (Williams et al., 2011). Similarly, a study that used 
HEK293T cells proposed that TET1-mediated oxidative 5mC conversion is essential at 
hypomethylated CGIs to prevent aberrant invasion of DNA methylation (Jin et al., 2014). The 
present study attributes a shared role for TET1 and TET2 in the maintenance of normal 
methylation patterns and identifies significantly larger DNA methylation canyons as TET-
dependent epigenomic features.  
3.1.3 A role for TET1/2-dependent canyon maintenance in differentiation 
Canyon hypermethylation upon TET1/2-deficiency was associated with severe differentiation 
and gene regulation defects, suggesting functional relevance for the maintenance of canyon 
integrity.  
 Firstly, in vitro adipogenesis of DKO MEFs was inhibited as evident by the failure to 
generate lipid droplets and upregulate key adipogenic transcription factors and effector 
genes. Secondly, the promoters of canyon-associated genes with reported functions in 
adipogenesis acquired even more pronounced hypermethylation during in vitro adipogenic 
differentiation of DKO MEFs compared to untreated cells. Finally, TET transcripts were 
induced during adipogenesis in WT MEFs. Together, these data suggest a functional 
requirement for TET enzymes in adipogenesis that may be related to the maintenance of 
canyons associated with adipogenic regulators and their promoters. Indeed, the newest 
literature confirms these observations showing that TET enzymes are required for 
adipogenesis (Yoo et al., 2017) and activation of essential genes, such as PPARγ (Dubois-
Chevalier et al., 2014; Yoo et al., 2017) or PRDM16 (Yang et al., 2016b). Mechanistically, 
several explanations have been reported, such as TET-mediated hydroxylation of enhancers 
directed by an interaction with CTCF (Dubois-Chevalier et al., 2014) or recruitment of TET1 to 
PPAR response elements by PARylated PPARγ (Fujiki et al., 2013). Although the findings 
presented herein cannot explain how TET enzymes may be attracted to their target regions, 
they strongly suggest that the lack of canyon demethylation by TET1 and TET2 is responsible 
for the adipogenic differentiation defects. The four canyon-associated genes, whose promoter 
methylation was assessed in this study, have reported roles in adipogenesis. PPARγ is an 
essential key adipogenic transcription factor (Rosen and MacDougald, 2006), IGF1 initiates 
IGF-signaling that is involved in staging of the differentiation process (Tang and Lane, 2012) 
and FOXC1 and 2 are transcription factors that have been associated with the maintenance 
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of the adipose tissue phenotype (Davis et al., 2004; Omatsu et al., 2014; Rosen and 
MacDougald, 2006). Especially in the absence of PPARγ adipogenesis cannot take place 
(Rosen et al., 1999), supporting the notion that defective transcriptional PPARγ activation in 
DKO MEFs may be causative for the differentiation block. 
 In this study, deficiency of TET1 and TET2 was further accompanied by broad gene 
deregulation. As 95% of canyons are associated with transcriptional start sites, canyon 
hypermethylation is likely to influence gene expression through aberrant promoter silencing. 
Hundreds of differentially expressed genes were present in DKO MEFs and there was a 
statistically significant overlap between canyon hypermethylation and deregulation of 
associated genes. This correlation suggests a requirement of canyon maintenance for proper 
gene expression. Nevertheless, only half of the genes associated with a hypermethylated 
canyon were deregulated and the majority of deregulated genes were not canyon-associated. 
These genes might either depend on smaller hypomethylated regions potentially protected by 
TET enzymes (e.g. reported insulator sites) or other described TET1/2 activities. For 
example, a study by Hon et al. showed that TET2 KO in mESCs leads to loss of 5hmC and 
concomitant gain of 5mC at enhancers. This results in decreased enhancer activity, which 
correlated with transcriptional delay of lineage-specific genes that are normally induced 
during neuronal in vitro differentiation (Hon et al., 2014). On the other hand, the canyon-
associated genes whose expression remained unchanged may be not severely affected by 
hypermethylation or protected from hypermethylation by active chromatin states. 
Developmental regulators residing in large hypomethylated domains are usually regulated by 
chromatin modifications (Jeong et al., 2013; Nakamura et al., 2014; Xie et al., 2013). Indeed, 
additional bioinformatical analyses documented in Wiehle et al., 2016 suggested that canyons 
marked by repressed or poised chromatin states are prone to become hypermethylated. In 
these canyons transcriptional regulation by chromatin states may be disrupted, whereas more 
active regions may be resistant to hypermethylation. Consistently, the genomic localizations 
of TET1 and 5hmC appear to significantly overlap with Polycomb-repressed genes (Williams 
et al., 2011; Wu et al., 2011a, 2011b).  
A substantial proportion of genes was also upregulated in DKO MEFs and thus TET-
deficiency seems to elicit context-dependent transcriptional changes. On the one hand, 
hypermethylation of transcribed gene bodies, intergenic regions and enhancers observed in 
DKO MEFs might be responsible for this effect. On the other hand, dual functions for TET1 in 
transcriptional regulation in mESCs have been reported previously and may also explain the 
opposing transcriptional effects observed in MEFs. Derepression upon TET1/2-deficiency 
could thus be due to the reported function of TET1 in facilitating PRC2 complex binding to 
DNA and repressing PRC2 target genes (Wu et al., 2011b). Moreover, TET1 is involved in the 
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recruitment of the SIN3A co-repressor complex and silencing of its target genes (Williams et 
al., 2011). 
Canyons appear to harbor TSS of many developmentally important regulators 
including genes involved in transcriptional regulation, embryonic morphogenesis and RNA 
metabolism (Jeong et al., 2013). In accordance with this, pathway analysis of deregulated 
genes in DKO MEFs revealed the enrichment of exclusively developmental categories. A 
prominent example of a hypermethylated canyon is the one at the HOXA cluster (Figure 2.8). 
Consequently, HOXA3 was significantly and strongly downregulated in DKO MEFs. HOX 
transcription factors have important roles during early embryonic development and hence 
their deregulation may account at least in part for the developmental defects observed upon 
TET DKO in vivo. Apart from that, genes with roles in mesenchymal-to-epithelial transition 
(MET) were deregulated, among them FOXC1 and FOXC2 (Bard et al., 2008; Hader et al., 
2010; Thiery et al., 2009). Since these genes are also canyon-associated, their defective 
regulation may contribute to the reported block in MET during somatic cell reprogramming of 
TET TKO MEFs (Hu et al., 2014). While the authors considered the defective demethylation 
and activation of key miRNAs of the miR-200 family responsible for this effect, a potential 
interplay of these miRNAs with canyon-associated genes that are involved in RNA 
metabolism is also conceivable.  
 In summary, the findings from this study strongly suggest that canyon-associated 
differentiation genes depend on the TET1/2-mediated protection of canyons from 
hypermethylation. The promoters of canyon-associated developmental genes rely on 
epigenetic regulation during differentiation. It is proposed that disruption of canyon integrity 
prevents proper regulation and activation of differentiation genes upon environmental cues. 
Together with the previously published data on DNMT3A activity at canyons, the balanced 
antagonizing functions of TET1/2 and DNMT3A may keep DNA methylation canyons in their 
physiological state (Figure 3.1).  
 
 
Figure 3.1: Model for the proposed actions of TET1, TET2 and DNMT3A on canyons. 
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3.1.4 A potential role of canyon hypermethylation in cancer 
TET2 and DNMT3A are among the most frequent, recurrently mutated genes in human clonal 
hematopoiesis and AML (Voigt and Reinberg, 2013; Welch et al., 2012). Canyon-associated 
genes have been observed to be significantly enriched for genes that are dysregulated in 
leukemia (Jeong et al., 2013). Hence, cancer cells with mutations in the genes responsible for 
canyon maintenance may acquire canyon hypermethylation. In turn, this could facilitate the 
induction of a cancerous gene expression signature because canyon genes appear to have 
crucial roles in transcriptional regulation. In this study, not only downregulation of HOXA3, but 
also increased expression of various genes of the HOXB and HOXC clusters was observed in 
DKO MEFs. HOX genes have an appreciated oncogenic role in leukemia (Alharbi et al., 
2013). Similarly, the TET-dependent block in MET (Hu et al., 2014) may sustain acquired 
migratory potential of cancer cells with canyon hypermethylation. In addition, differentiation as 
a rescue mechanism of aberrantly dividing pre-cancerous stem cells may be impaired by 
canyon hypermethylation. TET1 downregulation has been observed in aging (Bormann et al., 
2016) and replicative senescence (Sakaki et al., 2017). As such, canyon hypermethylation 
could contribute to the predisposition of aged cells to cancer development, whereas in 
senescent cells canyon maintenance may become dispensable. Lastly, it was shown recently 
that 5hmC marks promoters in matched normal tissue that are resistant to hypermethylation 
in colorectal cancer. These regions are also occupied by TET2 in colorectal cancer cell lines 
(Uribe-Lewis et al., 2015). Taken together, these findings suggest that TET1 and TET2 are 
important to prevent promoter hypermethylation in cancer and TET impairment may 
participate in the establishment of the cancer epigenome. Further studies will be required to 
analyze canyon deregulation in cancer.  
3.2 Role of IDH-TET axis in human disease 
The association between mutations in IDH and genomic hypermethylation has been noted 
first in glioma (Noushmehr et al., 2010) and the paradigm of the causal relationship between 
the two was established by the study of Turcan and colleagues (Turcan et al., 2012). 
Mechanistically, TET enzymes became implicated in this pathway soon after their discovery 
by the analysis of mutational and DNA methylation patterns in AML as well as biochemical 
studies (Figueroa et al., 2010; Koivunen et al., 2012; Xu et al., 2011a). However, these 
employed low coverage assays for DNA methylation analysis, indirect detection methods for 
5hmC and 5mC in complex overexpression models and partially questionable comparisons. 
Thus, the nature of mIDH-associated epigenome deregulation remains poorly understood. To 
advance its understanding, the influence of IDH mutations on TET enzymes and the 
methylome in AML was analyzed in the second part of this thesis. 
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3.2.1 Genomic hypermethylation is a key feature of AML with mutations in IDH 
Methylomes of AML patients with mIDH were characterized by a pronounced large-scale 
genomic hypermethylation. Approximately 70,000 CpG residues were significantly 
differentially methylated in mIDH carrying AML with >98% being hypermethylated. These 
findings are consistent with earlier reports that found hypermethylation in IDH-mutated AML 
(Figueroa et al., 2010), glioma (Noushmehr et al., 2010; Turcan et al., 2012), 
chondrosarcoma (Lu et al., 2013), enchondroma (Pansuriya et al., 2011) and 
cholangiocarcinoma (Wang et al., 2013b) and thus confirm the association between IDH 
mutation and hypermethylation. 
Of the differentially methylated probes, 50% had intermediate methylation ratios in 
IDH WT AML (beta values approximately 0.2 – 0.8), indicating that regions of variable 
methylation are affected by the mIDH-associated gain of methylation. This was corroborated 
by the fact that, although hypermethylation was widespread among all kinds of analyzed 
epigenomic features, the methylation gain was most pronounced in CGI shores. Consistently, 
it was reported previously that most cancer-associated methylation changes take place in 
CGI shores (Irizarry et al., 2009). 
CIMP has been defined in colorectal cancer as the coordinated cancer-specific 
acquisition of hypermethylation at specific gene-associated CGIs in a subset of cancers, 
instead of a stochastic gain in CGI methylation frequency (Toyota et al., 1999; Weisenberger 
et al., 2006). In glioblastoma, a distinct subset of the proneural tumors, which are identified by 
a specific gene expression pattern, exhibits coordinated CGI hypermethylation reminiscent of 
the changes found in colorectal cancer and thus has been associated with glioma-specific 
CIMP (G-CIMP; Noushmehr et al., 2010). The extremely high concordance between G-CIMP 
phenotype and IDH mutation has led to the assumption that mIDH is causally linked to CIMP 
establishment (Noushmehr et al., 2010; Turcan et al., 2012). However, it is not clear to which 
extent mIDH-associated hypermethylation targets exclusively CGIs, due to the use of non-
genome-wide methods to call methylation. Further, the influence of cancer type on the 
methylome upon IDH mutation remains elusive. Turcan and colleagues reported that G-
CIMP-defining CpGs were located in CGIs and shores, but on the Infinium 450K array the 
majority of CpG probes are devoted to assess CGI and shore methylation (Sandoval et al., 
2011). Other studies made use of (enhanced) reduced representation bisulfite sequencing 
and found mainly CGIs hypermethylated in the presence of mIDH (Akalin et al., 2012; Lu et 
al., 2013), however these techniques rely on restriction enzymes that cut more frequently in 
CpG-rich regions and are thus biased to CGIs as well (Meissner et al., 2005). The results 
presented here rather suggest no specific hypermethylation of CGIs even though the same 
experimental strategy (450K array) was used. Consistently, a recent report showed that 
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mIDH-associated hypermethylation favored non-CGI regions in AML using an alternative 
method. Interestingly, this study also identified an AML hypermethylation signature that was 
enriched at CGIs but independent of IDH mutations, which was termed A-CIMP (Kelly et al., 
2017). These results argue against sufficiency of mIDH to establish CIMP independently of 
tissue type. In summary, the term CIMP appears to represent a conglomerate of 
miscellaneous hypermethylation signatures. Thus, it remains to be clarified which are the 
main targets of IDH-dependent hypermethylation, preferably by using comprehensive 
genome-wide methods. Ultimately, this should allow discriminating and comparing mIDH-
dependent methylation signatures of distinct cancers.  
 To establish the causality between mIDH expression and hypermethylation, a 
leukemia cell line overexpressing mIDH2 was generated. Although these HL-60 cells 
acquired various methylation changes, the AML-specific hypermethylation pattern could not 
be faithfully recapitulated. Whereas the overall number of differentially methylated probes was 
comparable between mIDH AML patient samples and HL-60 cells, approximately one third of 
all significantly changed probes (20,905) displayed hypomethylation in the cellular model. 
Consistently, a very similar distribution of hyper- and hypomethylation was observed upon 
introduction of mIDH2 into TF-1 erythroleukemia cells and mIDH1 into primary astrocytes, 
respectively, in previous studies (Kernytsky et al., 2014; Turcan et al., 2012). 
Hypomethylation of lamina-associated domains reported to occur during repeated passaging 
of cells in vitro (Gaidatzis et al., 2014) could be excluded as a putative cause of methylation 
loss. Together, these data suggest dual effects of mIDH in cultured cells eliciting hyper- and 
hypomethylation. It is conceivable that the unique mIDH-associated hypermethylation in AML 
patients is caused by additional mechanisms such as increased activity of DNMT3A during 
AML progression, that has been recently reported to result in CGI hypermethylation (Spencer 
et al., 2017). The influence of the tumor microenvironment on cancer cells, specifically 
mesenchymal stromal cells in the case of hematological malignancy, can hardly be modeled 
in cell culture, but has been recognized in vivo (Geyh et al., 2013). Recently, D-2-HG was 
shown to affect surrounding cells in a paracrine fashion (Chaturvedi et al., 2016; Chen et al., 
2016) and may thus change the interplay between microenvironment and cancer cells 
eventually translating into epigenomic changes. 
3.2.2 MIDH-associated methylomes and their relation to TET inhibition 
The inhibition of TET activity by D-2-HG produced by the neomorphic mIDH enzymes has 
been suggested as the mechanistic basis for the observed hypermethylation. This was due to 
the observation that IDH and TET2 mutations are mutually exclusive in AML, but display 
overlapping hypermethylation signatures (Figueroa et al., 2010).  
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 In this study, large-scale mIDH-associated hypermethylation did not recapitulate DNA 
methylation changes associated with TET2 mutations in AML, nor did it affect specifically 
TET-dependent DNA methylation canyons. Furthermore, D-2-HG did not induce genome-
wide DNA methylation changes in a cell-based model. Together, these findings challenge the 
currently established paradigm of mIDH-dependent TET inhibition.  
 Several details from the literature support this notion. Firstly, clinical differences have 
been reported between TET2 and IDH mutant hematopoietic malignancy, indicating that the 
oncogenic mechanisms of each mutated enzyme may not be identical. For instance, TET2 
mutations are more frequent in premalignant MDS compared to AML, whereas this is 
reversed in the case of mIDH1 (Im et al., 2014), indicating that mIDH may be involved in the 
progression to more aggressive disease. Furthermore, the prognosis for TET2 and IDH 
mutated AML appears distinct with adverse outcomes of TET2 mutated, but favorable 
prognosis for IDH2 R140Q carrying AML patients (Patel et al., 2012). Secondly, the 
phenotypes of TET2-deficient and mIDH-expressing mice are distinct. TET2-deficiency 
resulted in pronounced expansion of the LSK cell pool, increased repopulation capacity, 
impaired or skewed differentiation and the development of myeloid malignancies (Li et al., 
2011; Moran-Crusio et al., 2011; Quivoron et al., 2011). In contrast, mIDH-expressing cells 
had an augmented pool of lineage-restricted progenitors, but reduced numbers of long-term 
HSCs (Inoue et al., 2016b) and normal repopulating activity (Sasaki et al., 2012b). Lastly, the 
consequences of TET2 mutation with regard to methylome changes in myeloid malignancies 
are controversial. Thus, it remains unclear whether reduction of TET activity (be it triggered 
genetically or chemically) indeed yields hypermethylation. While some studies identified a 
number of hypermethylated CpGs in TET2-mutated AML and CMML (Figueroa et al., 2010; 
Rasmussen et al., 2015; Yamazaki et al., 2012, 2015), others found hypomethylation upon 
TET2 mutation in CMML and a range of myeloid diseases (Ko et al., 2010; Pérez et al., 
2012). A recent study depleted erythroid cells of TET2 or TET3 but could not detect 
significant changes in global 5mC levels (Yan et al., 2017). None of these studies reported 
significant hypermethylation at tens of thousands of CpGs upon TET-deficiency in agreement 
with the presented findings, indicating that mIDH and mutated TET2 elicit distinct methylome 
changes. 
 In vitro enzymatic studies demonstrated that D-2-HG can inhibit TET enzymes 
(Koivunen et al., 2012; Xu et al., 2011a), albeit only achieving partial inhibition with a 500-fold 
excess of D-2-HG over α-ketoglutarate. Hence, D-2-HG is a weak TET inhibitor at the most. 
This would be consistent with the fact that the dotblot immunostaining in HL-60 cells 
expressing mIDH2 did not detect changes in 5hmC levels. Either this method is not sensitive 
enough to detect small changes in 5hmC or the TET inhibition under these conditions is too 
weak. Arguing for the latter, in the present study extracellularly supplied D-2-HG was not 
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sufficient to elicit DNA hypermethylation in HL-60 cells, although it penetrated the cell 
membrane and accumulated to intracellular concentrations exceeding the ones obtained with 
overexpression of mIDH2. Consistent with the observed uptake of D-2-HG into the cells, 
paracrine activity of D-2-HG was recently reported (Chaturvedi et al., 2016). Consequently, 
the incorporated D-2-HG should be able to inhibit TET enzymes. However, the absence of 
significant gains in DNA methylation upon D-2-HG-supplied cell culture contradicts D-2-HG-
mediated impairment of TET activity. Recent findings from IDH WT AML mouse models 
receiving D-2-HG are in support of this notion: Although the metabolite promoted leukemia 
onset, it was insufficient to induce myeloproliferation or leukemia on its own. Furthermore, 
mIDH exhibited stronger oncogenic potential and its overexpression changed DNA 
methylation patterns more drastically than D-2-HG administration, indicating additional D-2-
HG-independent roles of mIDH in leukemogenesis and epigenome deregulation (Chaturvedi 
et al., 2016). Interestingly, increased proliferation, cytokine independence and an in vitro 
differentiation block of TF-1 cells upon expression of mIDH1 could be mimicked by culturing 
the cells in D-2-HG, suggesting that 2-HG can confer cancer-promoting features. However, 
these effects were not elicited by L-2-HG, although it has been shown to inhibit TET enzymes 
more efficiently than D-2-HG (Koivunen et al., 2012; Losman et al., 2013; Xu et al., 2011a). 
This argues against a major contribution of TET enzymes and DNA methylation to the 
cancerous phenotype. Interestingly, recent preclinical tests evaluating small molecule 
inhibitors specific to mIDH also reported controversial results. Albeit blocking 2-HG 
production, reducing growth and promoting differentiation of cancer cells, in some studies 
these inhibitors were unable to restore normal DNA methylation levels of glioma xenografts 
and primary AML cells (Chaturvedi et al., 2017; Pusch et al., 2017; Rohle et al., 2013), 
suggesting 2-HG-independent deregulation of DNA methylation by mIDH or the irreversibility 
of the acquired changes. Nevertheless, another publication claimed the partial reversal of 
hypermethylation in mIDH-overexpressing cells that were treated with an mIDH inhibitor 
(Kernytsky et al., 2014). 
Ultimately, D-2-HG-mediated TET inhibition appears unlikely to be the sole cause of 
mIDH-associated genomic hypermethylation. Further clarification could be provided by the 
analysis of patients or models with mIDH expression but low D-2-HG secretion or different 
catalytic IDH mutations that can neither produce α-ketoglutarate nor D-2-HG. 
3.2.3 MIDH-associated methylomes in view of hematopoietic differentiation states  
Mutations in IDH have been associated with a differentiation block using in vitro and in vivo 
models. For example, expression of mIDH1 from its endogenous locus in the myeloid lineage 
of the mouse resulted in increased numbers of early hematopoietic progenitors (Sasaki et al., 
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2012b). Furthermore, in vitro differentiation of TF-1 erythroleukemia cells and 3T3-L1 cells 
was blocked by the expression of mIDH1 or mIDH2, respectively (Losman et al., 2013; Lu et 
al., 2012), and primary mouse bone marrow cells transduced with mIDH2 showed depletion 
of myeloid markers and elevation of LSK cell markers (Figueroa et al., 2010). In line with this, 
the mIDH2-expressing HL-60 cells generated here upregulated several hematopoietic stem 
cell markers and conversely reduced the expression of myeloid genes. Furthermore, the fact 
that mIDH was specifically enriched in the poorly differentiated M1 FAB category may reflect 
the inhibition of differentiation in vivo. Indeed, methylomes of mIDH carrying AML patients 
displayed high similarity to those of early myeloid progenitor cell types (CMPs and GMPs) in 
contrast to IDH WT AML. Together with the TET independency of mIDH-associated changes 
discussed in the previous chapter, this study identifies differentiation state rather than TET 
inhibition as a critical factor responsible for hypermethylation.  
 The differentiation cascade of myelopoiesis is characterized by an overall loss of 
methylation compared to hematopoietic stem cells (Figure 1.5; Bock et al., 2012; Farlik et al., 
2016; Hodges et al., 2011; Rönnerblad et al., 2014). The analysis of raw unsorted bone 
marrow aspirates of AML patients may underestimate considerable intra- and inter-individual 
heterogeneity of samples. Therefore, the comparison of mutational subgroups may in fact be 
a comparison of distinct differentiation stages. In the case of mIDH, this may result in the 
detection of hypermethylation as mIDH could arrest hematopoietic cells in an early progenitor 
state, whereas IDH WT AML cells could mature further. Indeed, the findings presented here 
suggest the undifferentiated state of the AML cells as a cause for the mIDH-associated 
hypermethylation (Figure 3.2). In agreement, normal methylation patterns of different B cell 
maturation states have been discovered in lymphoid malignancy and a vast majority of 
cancer-specific methylation events actually seem to be physiological (Kulis et al., 2012, 2015; 
Oakes et al., 2016). Interestingly, G-CIMP was found highly enriched among the so-called 
proneural subgroup of glioma (Noushmehr et al., 2010), which is characterized by a gene 
expression signature reminiscent of neural progenitors (Bertrand et al., 2002; Verhaak et al., 
2010). Thus, mIDH may likewise block differentiation in tumors of the central nervous system, 
arresting the cancer cells at the neural progenitor stage. Whether mIDH-associated G-CIMP 
indeed reflects methylation patterns corresponding to immature neural cells remains to be 
studied.  
Physiological methylation patterns associated with a certain degree of cellular 
differentiation might also explain some of the observed cancer-associated hypermethylation 
phenotypes or CIMP that cannot be related to IDH or other mutations currently (Kelly et al., 
2017; Mack et al., 2014; Toyota et al., 1999; Weisenberger et al., 2006). Likewise, 
overlapping methylation signatures in mIDH and mutant TET2 leukemia (Figueroa et al., 
2010) may be due to the differentiation block rather than similar hypermethylation targets. 
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Recently, diverging methylation patterns in DNMT3A WT and DNMT3A R882 AML have been 
reported, consistent with the data presented here. Hypermethylation was suggested to be a 
result of cancer progression, that is accompanied by increased DNMT3A activity, rather than 
a driver of aberrant gene silencing (Spencer et al., 2017). This supports the notion of 
methylomes reflecting the cellular history proposed here and challenges the concept of 
cancer-specific hypermethylation driving malignant transformation. Together with the fact that 
DNMT3A has been implicated in hematopoietic differentiation and silencing of HSC-specific 
stem cell genes (Challen et al., 2014, 2011), distinct differentiation states could also play a 
role in the observed methylation differences between mutant and WT DNMT3A AML.  
 
 
Figure 3.2: Schematic of the proposed action of mIDH in the myeloid lineage.  
Whenever IDH mutations occur, they arrest cells in their current differentiation state and “lock in” cell-
type specific methylation patterns. Since these events often take place early in the differentiation 
hierarchy, methylomes of myeloid progenitors are associated with mIDH. 
The genetic mutation model for the evolution of variable cancer phenotypes suggests 
that the mutational events taking place in any cell with proliferative potential govern its 
specific phenotype (Visvader, 2011). The hypermethylation phenotype observed in IDH 
mutated cancer could thus be considered a manifestation of this theory. However, due to the 
enhanced understanding of the distinct epigenomes of specialized cells in healthy tissues 
(Kundaje et al., 2015; Ziller et al., 2013), it becomes clearer now that many of the “cancer-
specific” epigenetic changes may instead reflect the epigenetic make-up of normal cell types. 
The cell-of-origin model proposes that phenotypically diverging tumor subtypes emerge 
depending on which cell type in a differentiation hierarchy of a tissue is afflicted by an 
oncogenic transforming event (Visvader, 2011). The findings presented here rather favor the 
second model, in which the mutation in IDH is one of the early oncogenic events arresting 
cells in an undifferentiated state and this is reflected in the associated methylation patterns. 
Remaining outliers in principal component and clustering analysis could thus reflect patients, 
in which transformation and IDH mutation happened later in the differentiation hierarchy. 
Thus, this study underlines the need to assess homogeneous, comparable cancer cell 
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populations or ideally cancers with identical cell of origin, to unequivocally detect mutation-
associated epigenetic changes.  
Although using 450K array data like others before, this study expands on previous 
analyses. Firstly, comparison between AML patients with mIDH and IDH WT status allowed 
the extraction of mIDH-dependent instead of general cancer-associated methylation changes. 
Secondly, unbiased analysis of mIDH carrying AML patients and HL-60 cells revealed distinct 
methylome changes, challenging the concordance of mIDH-associated methylation patterns 
between cancer patients and cell culture systems. Further, in an attempt to dissect mIDH- 
and TET-dependent methylation changes in AML, methylation profiles of patients with mutant 
TET2 and mIDH were compared and DNA methylation canyons as specific target features of 
TET activity were examined in patients with mIDH. This uncovered far fewer hypermethylation 
events in TET2 mutant compared to mIDH harboring patients and poor hypermethylation of 
canyons in IDH mutant samples. Together with the absence of methylation changes upon D-
2-HG treatment in HL-60 cells, these observations argue against D-2-HG-mediated TET 
inhibition as the sole cause for the mIDH-associated hypermethylation. To the best of my 
knowledge this study is the first to assess DNA methylation changes in 2-HG-treated human 
cells in order to investigate effects directly mediated by the metabolite. Finally, in contrast to 
previous reports, the various blood differentiation states potentially present in whole bone 
marrow aspirates of AML patients were taken into account here. By comparing certain 
purified hematopoietic cell types to mIDH carrying patient samples, a major contribution of 
methylation patterns characteristic of undifferentiated myeloid progenitors to the mIDH-
associated hypermethylation was identified.  
To finally understand mIDH-associated pathogenesis, it will be important to dissect its 
neomorphic and catalytic independent effects. It is currently elusive, how mIDH might exactly 
block differentiation, but one paper suggested that histone hypermethylation due to KDM4C 
inhibition may be responsible (Lu et al., 2012). In order to precisely determine TET- and 
mIDH-dependent methylation changes in the hematopoietic lineages a conditional TET triple 
KO mouse model could be compared to the established mIDH knock-in model. Furthermore, 
cancer-specific and differentiation-associated DNA methylation changes resulting from IDH 
mutation may be inferred by in-depth comparison with appropriate reference methylomes.  
3.3 Summary and Conclusions 
In this thesis a previously unknown, important epigenetic regulatory role of TET enzymes at 
DNA methylation canyons in differentiated murine cells was identified. Integrity of canyons 
was found to be essential for in vitro adipogenic differentiation and proper gene expression. It 
hence provides in vitro confirmation of the developmental requirement for TET enzymes. 
Moreover, it underscores the necessity of continuous TET activity beyond preimplantation 
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development. Future studies will be needed to understand whether and how TET enzymes 
are specifically recruited to their target features. This should also clarify whether continuous 
demethylation acts as a default process to antagonize stochastic DNA methylation in 
differentiated cells or whether TET enzymes act in a more directed way upon certain cues. 
Additionally, this study identified the differentiation state of myeloid leukemic cells as a 
major determinant of mIDH-associated hypermethylation in human AML. Conversely, 
alterations in DNA methylation upon abrogation of TET activity and expression of presumably 
TET-inhibiting mIDH were found to be poorly concordant. It thus challenges the claim of 
mIDH-mediated inhibition of TET-dependent DNA demethylation and provides an alternative 
explanation for the associated hypermethylation. More extensive studies will be required to 
understand how mIDH may disturb differentiation. Nevertheless, these findings reinforce the 
need to gain a comprehensive understanding of the oncogenic actions of mIDH, which will be 
vital to fully exploit mIDH as a therapeutic target. 
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4 Materials and Methods 
4.1 Materials 
Table 1: Chemicals, reagents and enzymes 
Name Company 
(D)-2-hydroxyglutarate dehydrogenase (HGDH) kind gift from S. Pusch, 
see Balss et al., 2012 
3-Isobutyl-1-methylxanthine Sigma-Aldrich 
Acetic acid (glacial), 100% Merck Millipore 
Agar  Fluka 
Agarose  Roth 
Ammonium acetate  Fluka 
Ammonium sulfate Roth 
Ampicillin sodium salt Sigma 
Antarctic phosphatase + buffer New England BioLabs 
Boric acid Sigma-Aldrich 
Bradford solution (Protein Assay)  Bio-Rad 
Chloroform VWR 
Complete protease inhibitor cocktail tablets Roche 
Deoxynucleotide mix (100 mM dNTPs) Agilent 
Dexamethasone Sigma-Aldrich 
Diaphorase MP Biomedicals 
Diethyl pyrocarbonate (DEPC) Roth 
Disodium hydrogen phosphate dihydrate (Na2HPO4 x 2H2O) neoLab 
Dithiothreitol (DTT)  Gerbu 
DNA ladder, O’RangeRuler 100bp+500bp Thermo Scientific 
DNA ladder HyperLadder™ 1kb Bioline 
DNA ladder HyperLadder™ 50bp  Bioline 
DNA loading dye Thermo Scientific 
DNAse-free, RNAse-free Water  Gibco 
D-α-hydroxyglutaric acid disodium salt Sigma-Aldrich 
ECL substrate PerkinElmer 
Ethanol  Sigma-Aldrich 
Ethidium bromide  Roth 
Ethylenediaminetetraacetate disodium salt, dihydrate (EDTA)  Gerbu 
Fast digest restriction enzyme buffer  Thermo Scientific 
Formaldehyde (37%) J.T.Baker 
Glycerol Sigma-Aldrich 
Glyco Blue  Ambion 
HEPES  Gerbu 
Hydrochloric acid (37% HCl) Sigma-Aldrich 
Indomethacin Sigma-Aldrich 
Insulin human recombinant zinc solution Invitrogen 
Isopropanol  Riedel-de Haën 
Kapa HiFi HotStart Uracil+ ReadyMix (2x) Kapa Biosystems 
L-α-hydroxyglutaric acid disodium salt  Sigma-Aldrich 
Methanol  Sigma-Aldrich 
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Methylene blue  New England BioLabs 
NAD+ AppliChem 
New England BioLabs restriction enzyme buffers New England BioLabs 
NP40/ Igepal CA-630  Sigma-Aldrich 
Oil Red O Sigma-Aldrich 
PBS tablets Merck Millipore 
PBS, RNAse/DNAse free , 1x/10x Gibco 
PBS-Tween tablets Merck Millipore 
Peptone from casein, tryptic digest Fluka 
PhiX Control v3 Illumina 
Phusion HF buffer (5x) New England BioLabs 
Phusion High-Fidelity DNA Polymerase New England BioLabs 
Potassium chloride (KCl)  Roth 
Potassium dihydrogen phosphate (KH2PO4)  Roth 
Powdered milk  Gerbu 
Proteinase K Ambion 
Resazurin AppliChem 
Restriction enzymes: ClaI New England BioLabs 
Restriction enzymes: EcoRI New England BioLabs 
Restriction enzymes: MscI New England BioLabs 
Restriction enzymes: NcoI Thermo Scientific 
Restriction enzymes: NotI New England BioLabs 
RNAse (DNAse free) Roche 
RNAse A Sigma-Aldrich 
RNAse H New England BioLabs 
Roti-Phenol  Roth 
Roti-Phenol/chloroform/isoamylalcohol Roth 
S.O.C. medium Invitrogen 
Sodium acetate (NaOAc)  Roth 
Sodium chloride (NaCl)  Sigma 
Sodium dodecyl sulfate (SDS)  Roth 
Sodium hydroxide (NaOH)  Riedel-de Haën 
T4 ligase + buffer New England BioLabs 
Taq polymerase FireTaq Blue + buffer Steinbrenner 
Trisodium citrate dihydrate Sigma-Aldrich 
Triton X-100  Gerbu 
Trizma® base Sigma-Aldrich 
TRIzol  Ambion 
Trypan blue dye Bio-Rad 
Tween 20  Sigma-Aldrich 
Yeast extract Gerbu/ Sigma-Aldrich 
β-Mercaptoethanol Sigma-Aldrich 
 
Table 2: Consumable material 
Name Company 
384-well plates Steinbrenner 
5 ml polystyrene round-bottom tubes filter top BD Falcon 
96-well plates black Brandtech 
Amicon filter tubes (Amicon Ultra-4, PLQK Ultracel-PL 
Membrane, 50 kDa) 
Millipore 
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Cell culture dishes (10 cm) Greiner 
Cell culture flasks (T25, T75, T150) Greiner 
Cell culture plates (12-, 24-well) Corning 
Cell culture plates (6-, 48-, 96-well) Greiner 
Cell strainer (40 µM) BD Falcon 
Centrifugal tubes (15, 50 ml)  Greiner 
Counting slides Bio-Rad 
Cryotubes Nalgene (2 ml) Thermo Scientific 
Filter tips (10, 20, 200, 1000 μl) Steinbrenner 
Filters for virus purification (Minisart® NML Syringe Filter 
16555, GUK, 0.45 µm Surfactant-free Cellulose Acetate 
Sartorius 
Filters for virus purification (Millex-HV Filter, 0,45 µm, PVDF) Millipore 
Filtropur S 0.2 sterile filters (0.2 µm) Sarstedt 
Nylon transfer membrane GE Healthcare 
Pasteur pipettes  WU Mainz 
PCR tube strips (0.2 ml) Steinbrenner 
PCR tubes (0.2 ml) Thermo Scientific 
Pipette tips (10, 20, 200, 1000 μl) Sarstedt 
Reaction safe-lock tubes (1.5 ml) Sarstedt 
Reaction safe-lock tubes (2 ml) Eppendorf 
Reaction tubes (1.5, 2 ml) Sarstedt 
Serological pipettes (5, 10, 20, 50 ml) BD Falcon/ Corning 
Syringes Braun 
X-ray film Fujifilm 
 
Table 3: Equipment and devices 
Name Company 
454 Genome Sequencer FLX Titanium Roche 
Agarose gel electrophoresis chamber  Bio-Rad  
Balance EK-200i A&D 
Bioanalyzer Instrument 2100 Agilent Technologies 
Bio-Dot® microfiltration apparatus, 96-well  Bio-Rad 
Bioruptor sonication system Diagenode 
CCD camera AxioCam ERc 5s Zeiss 
Cell culture hood HERA safe/ HERA safe KS Thermo Scientific 
Cell/Particle counter Beckman Coulter  
Cell Counter TC10 Bio-Rad 
Centrifuge 5804  Eppendorf 
Centrifuge 5804 R Eppendorf 
Centrifuge benchtop 5415 D Eppendorf 
CO2 incubator HERA cell 150 Thermo Scientific 
CO2 incubator Sanyo Sanyo 
Covaris S2 Ultrasonicator Covaris 
Cryo 1°C freezing container Nalgene/Nunc 
Developing cassette  Dr. Goos-Suprema  
Developing machine COMPACT™ 2 Protec 
Fine balance CP64 Sartorius 
FLUOstar OPTIMA plate reader BMG Labtech  
Hybridization oven PeqLab 
Illumina HiSeq 2000 system Illumina 
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Incubator & Shaker INNOVA 4200 New Brunswick Scientific 
Infinium HumanMethylation450 BeadChip Illumina 
Infinium MethylationEPIC BeadChip Illumina 
iScan array scanner Illumina 
LightCycler 480 instrument Roche 
Micropipettes Gilson 
Microscope Axiovert 25 Zeiss 
Microscope Axiovert 40 CFL Zeiss 
Microvolume spectrometer NanoDrop 2000  PeqLab  
Orbital shaker Unimax 1010 Heidolph  
pH meter  Hanna instruments 
Power supply  Consort 
Real Time PCR System, LightCycler 480  Roche 
Reflected-light microscope SZX10 Olympus 
Rocker Unimax1010 Heidolph 
Thermocycler DNA Engine Bio-Rad 
Thermomixer compact Eppendorf 
UV gel documentation, E.A.S.Y® Doc plus  Herolab  
Vortex REAX top Heidolph 
Water Bath TW12/ Julabo 12  Julabo  
Wheel REAX 2 Heidolph  
 
Table 4: Kits 
Name Company 
ABsolute qPCR SYBR green mix Thermo Scientific 
Agilent DNA 1000 Kit Agilent Technologies 
BCA Kit Pierce 
Cell Titer Glo® Promega 
Deproteinization Kit BioVision 
EpiTect Bisulfite Kit Qiagen 
EZ-96 DNA Methylation Kit Zymo Research 
GS FLX Titanium PicoTiterPlate Kit 70 x 75 Roche 
GS FLX Titanium Sequencing Kit XLR70 Roche 
GS Junior Maintenance Wash Kit V2 Roche 
GS Junior Titanium emPCR Kit (Lib-A) Roche 
HiSpeed Plasmid Midi Kit Qiagen 
Mesa green qPCR mastermix PLUS for SYBR assay (no ROX) Eurogentec 
PeqGold Extraction Kit PeqLab 
PyroMark PCR Kit Qiagen 
QIAprep Spin Miniprep Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR purification Kit Qiagen 
QuantiTect cDNA synthesis Kit Qiagen 
Quant-iTTMPicoGreen ®dsDNA Kit Invitrogen 
Qubit Assay Kit Broad Range (BR) Invitrogen 
Qubit Assay Kit High Sensitivity (HS) Invitrogen 
SuperScript® III First-Strand Synthesis System for RT-PCR  Invitrogen 
TruSeq DNA Sample Prep v2 Kit Illumina 
TruSeq RNA Library Preparation Kit v2 Illumina 
Zymo RNA Clean & Concentrator Kit Zymo Research 
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Table 5: Buffers and solutions 
Name Composition 
Dotblot blocking solution 5% w/v milk in 1x PBS 
Dotblot denaturation solution 2 mM NaOH 
50 mM EDTA 
Dotblot neutralization solution (pH 7) 2 M ammonium sulfate 
LB agar 5 g yeast extract 
10 g NaCl 
10 g peptone 
15 g agar 
Ad 1 l with ddH2O 
LB medium 5 g yeast extract 
10 g NaCl 
10 g peptone 
Ad 1 l with ddH2O 
Methylene blue staining solution (pH 5.2) 
 
Methylene blue 0.04% w/v 
500 mM sodium acetate 
NP-40 lysis buffer 150 mM NaCl 
0.1% v/v NP40 
50 mM Tris-HCl (pH 8) 
+ freshly added 1x complete protease inhibitor 
Oil Red O stock solution  0.35% w/v Oil Red O in isopropanol 
Oil Red O working solution  60% v/v Oil Red O stock solution in ddH2O 
PBS-Tween 20 (PBST)  1x PBS  
0,1% v/v Tween20  
Phosphate buffered saline (PBS), 10x, 
(pH 7.5) 
 
1,37 M NaCl 
27 mM KCl 
100 mM Na2HPO4  
18 mM KH2PO4  
Pre-lysis buffer for gDNA isolation (pH 8) 10 mM Tris-HCl pH 8 
5 mM EDTA 
100 mM NaCl 
Freshly added: 
1.1% v/v SDS 
0.1 mg/ml Proteinase K 
0.04 mg/ml RNAse A 
SSC, 20x, (pH 7) 
 
3 M NaCl  
300 mM trisodium citrate  
Tris-acetate-EDTA buffer (TAE), 50x, 
(~pH 8) 
2 M Tris 
50 mM EDTA  
0.95 M acetic acid (to adjust pH) 
Tris-borat-EDTA buffer (TBE), 10x  
 
890 mM Trizma® base 
890 mM Boric acid  
20 mM EDTA  
Tris-EDTA buffer (TE) 10 mM Tris-HCl (pH 8) 
1 mM EDTA  
 
Table 6: Antibodies 
Name Species Dilution Company 
5-hydroxymethylcytosine, #39791  rabbit 1:1000 Active Motif  
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5-methylcytosine, #39649, clone 33D3  mouse 1:1000 Active Motif  
 
HRP-coupled anti mouse IgG (115-035-
003)  
goat 1:10000 Jackson 
ImmunoResearch  
HRP-coupled anti rabbit IgG (111-035-
003) 
goat 1:10000 Jackson 
ImmunoResearch 
 
Table 7: Biological material 
Name Company/Source 
HEK293T cell line Hofmann laboratory cell collection 
HL-60 cell line Lyko laboratory cell collection 
NOMO-1 cell line DSMZ (#ACC 542) 
Primary MEFs  
Tet1+/+; Tet1-/-; Tet1/2-/- (DKO)  
Rudolf Jaenisch, Whitehead Institute for 
Biomedical research, Cambridge, US 
Primary MEFs 
Tet2+/+; Tet2-/-  
Mingjiang Xu, Herman B Wells Center for 
Pediatric Research, Indiana University Melvin 
and Bren Simon Cancer Center, Indiana 
University School of Medicine, Indianapolis, US  
Stbl3™ One Shot™ Chemically 
Competent E. coli 
Invitrogen 
 
Table 8: Cell culture reagents 
Name Composition/ Company 
ADM  1 µM Dexamethasone  
1 µg/ml Insulin 
500 µM 3-Isobutyl-1-methylxanthine 
50 µM Indomethacin  
in DMEM supplemented with 10% FCS and 
Pen/Strep  
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
DMEM (1x), 4.5 g/l D-Glucose, (+) L-
Glutamine, (-) Pyruvate 
Gibco 
FBS Gibco 
Ficoll-Paque PLUS GE Healthcare 
HEPES buffer solution 1 M PAN Biotech 
L-Glutamine 200 mM (100x) Gibco 
Lipofectamine® 2000 Invitrogen 
OptiMEM (1x) + GlutaMAX Gibco 
Penicillin Streptomycin mix, 100x Gibco 
RPMI Medium 1640 (1x) + GlutaMAX Gibco 
Sodium pyruvate 100 mM (100x) Gibco 
Trypsin- EDTA 0.25% (1x) Gibco 
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Table 9: Vectors 
Name Company/Source 
pHAGE PGK-GFP-IRES-LUC-W Addgene plasmid # 46793 (gift from Darrell 
Kotton, see Wilson et al., 2010) 
pLVX-IRES-ZsGreen1 kind gift from M. Rodríguez (Division of 
Epigenetics, Prof. F. Lyko, DKFZ; Clontech 
plasmid #632187) 
pMD2.G  kind gift from M. Rodríguez (Division of 
Epigenetics, Prof. F. Lyko, DKFZ; Addgene 
plasmid #12259; gift from Didier Trono) 
pMXs-IDH1R132C kind gift from S. Pusch (Clinical Cooperation 
Unit Neuropathology, Prof. A. von Deimling, 
DKFZ) 
pMXs-IDH1WT kind gift from S. Pusch (Clinical Cooperation 
Unit Neuropathology, Prof. A. von Deimling, 
DKFZ) 
pMXs-IDH2R140Q kind gift from S. Pusch (Clinical Cooperation 
Unit Neuropathology, Prof. A. von Deimling, 
DKFZ) 
pMXs-IDH2WT kind gift from S. Pusch (Clinical Cooperation 
Unit Neuropathology, Prof. A. von Deimling, 
DKFZ) 
psPAX2 kind gift from M. Rodríguez (Division of 
Epigenetics, Prof. F. Lyko, DKFZ; Addgene 
plasmid #12260; gift from Didier Trono) 
 
Table 10: Primers 
Application Name Sequence 
454 m_Hoxa1_up TGGTTAGGGTTAGAGTTTGTTGTTT 
 m_Hoxa1_lo AAAACCTTAAAATTTCTTATTCCCACT 
 m_Hoxa3_up AATTTTTTGAATAATTAGGGTATAGAATTT 
 m_Hoxa3_lo AAATTTTAATTTTTAAAATTACACTTCTTA 
 m_Foxc1_up TTTGGGGAATTGTAATTTTTTTAG 
 m_Foxc1_lo TAAATACCCTCTTTCTATTATCCCC 
 m_Foxc1-prom_up TTTTTAGTTTTTTTAAGTTTTGGAA 
 m_Foxc1-prom_lo ATTTACTCTCCACAAACAAATTCTC 
 m_Foxc2_up TTTGTTTGATAATTAGGATTTAAGAAGT 
 m_Foxc2_lo CCTAAAATAACACAAAAAACTCTCC 
 m_Foxc2-prom_up GGGTTGGTTGTTTTGTTTTAATTT 
 m_Foxc2-prom_lo ACACCTAAAAAACCATTAATCCTTC 
 m_Igf1_up TTAGAATTGGGGGTTATTTATAAATTGT 
 m_Igf1_lo CATAAACACAAACACAAAAACATACTCTA 
 m_Pparγ_up ATTTAGGGATAGAGTGAGGGGTTT 
 m_Pparγ_lo TCTAAAACAAAAACAACCCTATTCC 
qRT-PCR m_β-actin_up TGAACCCTAAGGCCAACCGTGAAA 
 m_β-actin_lo CAGGATGGCGTGAGGGAGAGCATAG 
 m_C/ebpα_up TGGACAAGAACAGCAACGAG 
 m_C/ebpα_lo TCACTGGTCAACTCCAGCAC 
 m_Col2a1_up AACTGGCAAACAAGGAGACAGAG 
 m_Col2a1_lo TGCCAGAGGGACCAACAGG 
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 m_Ebf3_up CTCCTTCCTGCACCAGCG 
 m_Ebf3_lo GTCTTTTGTAGCATTCAACTGTGG 
 m_Foxc1_up CGAGTGCTTCGTCAAGGTGC 
 m_Foxc1_lo GGTTCTTGGAGGTGCAGCC 
 m_Foxc2_up GCCCAAGGACCTGGTGAAG 
 m_Foxc2_lo GTCGAGCGTCCAGTAGCTGC 
 m_Foxp1_up AACGAGAGTGACAGCAGTCCAG 
 m_Foxp1_lo GTTCGTCTTCGTAATCTCTGTCATG 
 m_Gapdh_up CATGGCCTTCCGTGTTCCTA 
 m_Gapdh_lo TGCTTCACCACCTTCTTGATGT 
 m_Hoxa3_up CAATGGGTTCGCTTACAATGC 
 m_Hoxa3_lo AGGCAGGTCGATGGTACTCAAC 
 m_Hoxb6_up TTCCTATTTCGTGAACTCCACCTT 
 m_Hoxb6_lo CCGCATAGCCAGACGAGTAGA 
 m_Hoxb9_up TGTCCATTTCTGGGACGCTTA 
 m_Hoxb9_lo GAACACCGGCGCTTTGG 
 m_Hoxc5_up ACCCGTGGATGACCAAACTG 
 m_Hoxc5_lo AGGGTCTGGTAGCGCGTGTA 
 m_Hoxc8_up TCTCCCAGCCTCATGTTTCC 
 m_Hoxc8_lo GTCTGATACCGGCTGTAAGTTTGTC 
 m_Jag1_up AGAAGTCAGAGTTCAGAGGCGTC 
 m_Jag1_lo GGAGTGAGTGTGGCTGCTGG 
 m_Loxl2_up CGCATCTGGATGTACAACTGTCA 
 m_Loxl2_lo TGTCCAGAGTGGAAATCTTGTGG 
 m_Pparγ_up CATAAAGTCCTTCCCGCTGA 
 m_Pparγ_lo GAAACTGGCACCCTTGAAAA 
 m_Tet1_3-4_up GCTGGATTGAAGGAACAGGA 
 m_Tet1_3-4_lo GTCTCCATGAGCTCCCTGAC 
 m_Tet1_4-5_up GTCAGGGAGCTCATGGAGAC  
 m_Tet1_4-5_lo CCTGAGAGCTCTTCCCTTCC  
 RT-Tet2-m-1_F GTCAACAGGACATGATCCAGGAG 
 RT-Tet2-m-1_R CCTGTTCCATCAGGCTTGCT 
 RT-Tet3-m_F GGAGTTGGCTGGAGTCACCAC 
 RT-Tet3-m_R CCACCGCATTGCCACTGTAC 
 m_Zeb2_up TACCCAACGGGAGCAGCTAC 
 m_Zeb2_lo CGCAGAAGGGAACTGCTTTTC 
 human_IDH1_1_for TTGTCCAGATGGCAAGACAG  
 human_IDH1_1_rev GCTTTGCTCTGTGGGCTAAC 
 human_IDH1_2_for AGTCTGCAAGACTGGGAGGA  
 human_IDH1_2_rev CCAATTCCACGTAGGGAAAA  
 hIDH1_exo_down_for GAGACAATTGAGGCTGGCTTC 
 hIDH1_exo_down_rev CCAGAGGTTGATTAGGATCTATCG 
 human_IDH2_1_for TGGCTCAGGTCCTCAAGTCT  
 human_IDH2_1_rev CTCAGCCTCAATCGTCTTCC  
 hACTB_up AGCACAGAGCCTCGCCTTT  
 hACTB_lo GAATCCTTCTGACCCATGC 
 hGAPDH_up CGACCACTTTGTCAAGCTCA 
 hGAPDH_lo GGTGGTCCAGGGGTCTTACT 
cloning  IDH1_cloning_3_for 
(to introduce MscI site) 
AATCTGTGGCCAACCATGTCCAAAAAAATC
AGT 
 IDH1_cloning_3_rev 
(to introduce ClaI site) 
AATCTATCGATACCCTAAAGTTTGGCCTGA
GC 
 IDH2_cloning_3_for AATCTGTGGCCAACCATGGCCGGCTACCT
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(to introduce MscI site) GCGG 
 IDH2_cloning_3_rev 
(to introduce ClaI site) 
AATCTATCGATACCCTACTGCCTGCCCAGG
GC 
other hIDH1_mut_for CGGTCTTCAGAGAAGCCATT 
 hIDH1_mut_rev TTGGAAGGAACTGTGTGCAA 
 
Table 11: Software 
Name Purpose 
BiSQuID 454 data analysis 
GIMP picture manipulation 
Image J particle/pixel quantifications 
Ingenuity® Pathway Analysis calculations of biological pathway enrichments 
Inkscape figure assembly, schemes 
Microsoft Office Suite data analysis, document generation 
OPTIMA analysis software analysis of absorbance or fluorescence 
measurements (from OPTIMA plate reader) 
pDRAW32 vector visualization 
R Infinium data analysis, graphs 
SigmaPlot graphs, statistical testing 
 
4.2 Eukaryotic cells and cell culture 
All cells were grown under sterile conditions in a humidified atmosphere with 5% CO2 and at 
37°C. Cells were handled under sterile culture hoods for splitting and manipulation. Standard 
culture media were supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/ml 
penicillin and 100 µg/ml streptomycin. Complement contained in the FBS was heat-
inactivated by incubation at 56°C for 30 min and FBS was sterile-filtrated prior to use.  
4.2.1 Cell lines and primary cells 
4.2.1.1 Culture of adherent cells 
Primary MEFs were isolated as described before (Wiehle et al., 2016) and maintained in 
standard T25 or T75 cell culture flasks in DMEM standard culture medium. Cells were 
passaged every three to four days at a ratio of 1:3. For subculture cells were washed twice in 
PBS, dissociated using trypsin, pelleted (130 x g, 5 min) and resuspended in fresh medium. 
For seeding defined cell numbers MEFs were counted using a particle counter from Beckman 
Coulter. 
4.2.1.2 Culture of suspension cells 
HL-60 and NOMO-1 cells were cultured in RPMI standard culture medium in cell culture 
plates or T25/T75 suspension culture flasks. Cells were maintained at a density of 1 to 
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10 x 105 viable cells/ml and split twice per week by addition or replacement with fresh 
medium. To seed a defined viable number of cells they were mixed with Trypan blue in a 1:1 
ratio to label dead cells and live cells were counted using the TC10 automated cell counter.  
4.2.1.3 Thawing and freezing of cells 
For long-term storage 1 to 2 x 106 cells were resuspended in 1 ml of standard culture medium 
supplemented with 10 % (v/v) DMSO. The cell suspension was stored in cryotubes and 
cooled down at a rate of -1°C per minute in freezing containers that were placed at -80°C. 
Few days later the tubes were transferred to liquid nitrogen (-196°C) for long-term 
preservation. For thawing cells were placed in a water bath of 37°C and resuspended in 5 ml 
of medium once the suspension was liquid. After centrifugation at maximally 300 x g for 5 min 
the freezing medium was quickly removed to prevent cell damage due to toxic DMSO, cells 
were taken up in pre-warmed standard culture medium and plated.  
4.2.2 Generation of stable cell lines 
Stable HL-60 and NOMO-1 cell lines expressing either wildtype or mutant IDH enzymes or 
none of them (empty vector control) were generated by lentiviral transduction. For lentivirus 
production HEK293T cells grown in RPMI standard culture medium were seeded into 6-well 
plates. When cells reached 70 – 90% confluency, medium was exchanged with 3 ml of fresh 
RPMI and cells were transfected with target vector, lentiviral packaging vector (psPAX2) and 
envelope plasmid (pMD2.G) in a ratio of 5:4:1. Total transfected DNA per well was 2.5 µg. 
For each well to be transfected, 140 µl of OptiMEM mixed with 7.5 µl Lipofectamine® 2000, 
and 140 µl of OptiMEM containing the 2.5 µg of vector DNA, were prepared. The two 
solutions were mixed, vortexed for 2 seconds, incubated for 5 min at room temperature and 
added to the HEK293T cells in small droplets. Cells were transferred to the S2 laboratory and 
48 h later viral particles were harvested. To this end cell culture supernatants were collected, 
centrifuged for 5 min at 130 x g and filtered using 0.45 µm filters (Sartorius) to remove 
remaining HEK293T cells. For infections 200,000 HL-60/NOMO-1 cells were pelleted and 
resuspended in the freshly harvested and filtered virus-containing cell culture supernatant. 
Two days later medium was exchanged with standard RPMI and after another three days 
cells were removed from the S2 laboratory and examined for green fluorescence under the 
microscope. 
In an alternative protocol for infections HEK293T cells were cultured and transfected in 
DMEM supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin and 100 
µg/ml streptomycin, 2 mM L-Glutamine, 1 mM sodium pyruvate and 10 mM commercial 
HEPES solution. Virus particles were 0.45 µm filtered (Millipore) and concentrated in Amicon 
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filter tubes by several 10 minute spins at 1000 x g. After volume reduction to roughly 250 µl 
the concentrated virus was directly added to the cells kept in 2.5 ml of their appropriate 
standard medium. Remaining procedures were as described above. Lentiviral transductions 
were performed in collaboration with Florian Köhler and Bojana Kriznik. 
Cells were expanded for a few days and FACS sorted by GFP/ZsGreen1 expression to 
generate successfully transduced cell pools co-expressing the transgene. The 10% and 30% 
with the strongest fluorescence signal of the positive population were sorted to a pool of at 
least 1000 cells. Cell sorting was conducted by Dr. Langlotz at the Flow Cytometry & FACS 
Core Facility of the ZMBH in Heidelberg. 
Sorted cells were pelleted, plated in standard RPMI and expanded for a few days. Ficoll 
purification was performed after reasonable expansion to remove dead cells. To this end cells 
were washed once in PBS, resuspended in 700 µl of standard culture medium and 700 µl of 
Ficoll were overlaid with the cell suspension in Eppendorf tubes. Tubes were subjected to a 
15 seconds spin at 16,100 x g, rotated by 180 degree and spun again for 1 minute at 12,000 
x g. The viable cells located at the interface between Ficoll and medium were recovered, 
resuspended in medium, pelleted and plated in fresh standard culture medium.  
4.3 Molecular cloning 
Two different backbones were used in this study to accommodate transgenes and eventually 
generate stable cell lines expressing wildtype or mutant IDH: pLVX-IRES-ZsGreen1 and 
pHAGE PGK-GFP-IRES-LUC-W. Empty vectors were transduced as controls. The following 
scheme depicts the cloning strategy. 
 
Figure 4.1: Cloning strategy to introduce IDH genes into different lentiviral backbones. 
PMXs vectors harboring the different wildtype and mutant IDH genes were a kind gift of S. Pusch. 
Using EcoRI and NotI transgenes were excised and integrated into the pLVX backbone. For cloning 
them into the pHAGE backbone transgenes were PCR amplified from the pLVX vector using primers 
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introducing MscI or ClaI restriction sites at the ends of the transgenes that were compatible with the 
pHAGE backbone. 
For all enzymatic digestions in this study the units of restriction enzyme were adapted 
according to the definition that one unit digests one µg of template in one hour under optimal 
reaction conditions. To ensure efficient restriction extended incubation times and a volume of 
at least 1 µl (usually comprising more than the required units) were used. Furthermore 
volumes of glycerol were kept below 10% in all enzymatic reactions. 
4.3.1 pLVX-IRES-ZsGreen1 constructs 
4.3.1.1 Preparation of fragments 
PMXs vectors harboring wildtype or mutant IDH1 (R132C) or IDH2 (R140Q) coding 
sequences were restriction digested in triplicates to excise the gene of interest as follows: 
reagent amount 
vector 1 µg 
NEB buffer 3.1 (10x) 3 µl 
EcoRI 1 µl 
NotI 1 µl 
ddH2O To 30 µl 
 
The pLVX-IRES-ZsGreen1 target vector was treated in the same way to linearize it and 
generate corresponding sticky ends ensuring correct orientation of the transgene. Restriction 
was performed overnight at 37°C. To prevent religation of linearized target vector without 
incorporation of insert its ends were dephosphorylated for 1 hour at 37°C without shaking: 
reagent amount 
Antarctic phosphatase buffer (10x) 4 µ 
Antarctic phosphatase 1 µl 
ddH2O 5 µl 
µl target vector reaction (see above) 30 µl 
 
The resulting vector fragments were subjected to gel electrophoresis in a preparative 0.8% 
TAE agarose gel containing 0.25 µg/ml ethidium bromide (Figure 4.2A, B). Fragments and 
linearized target vector of the expected molecular size were excised and gel-extracted using 
a commercial gel extraction kit. To control for the presence of a single pure DNA fragment a 
0.8% agarose control gel was run with 75 – 200 ng of DNA loaded per pocket (Figure 4.2C). 
In this way the measured concentration of the purified DNA was also confirmed or re-
estimated if it strongly deviated from Nanodrop quantifications.  
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Figure 4.2: Restriction digestion of pLVX-IRES-ZsGreen1. 
Target vector pLVX-IRES-ZsGreen1 and source vectors pMXs-IDH2 WT, pMXs-IDH2 MUT (A), pMXs-
IDH1 WT and pMXs-IDH1 MUT (B) were digested using EcoRI and NotI. The weak middle band in B 
either represents supercoiled uncut vector or a contamination of the original plasmid stock with 
religated vector without insert. (C) Examples of expected fragments after gel extraction. 
4.3.1.2 Ligation 
In order to ligate the pLVX backbone with the IDH inserts a ligation reaction with thrice the 
molarity of fragment DNA compared to target vector DNA was set up. For example, in the 
case of IDH2 the insert size was 1442 bp and the linearized target vector was 8179 bp, 
resulting in the amount X of insert to be used: 
        
             
                    
                  
       
    
                 
Routinely, 25 ng of target vector were ligated with the appropriate amount of insert, in this 
case 13.3 ng. Ligations were set up as follows and incubated for 3 hours to overnight at 4°C. 
reagent amount 
target vector 25 ng 
insert X ng 
ligation buffer (10x) 1 µl 
T4 ligase 1 µl 
ddH2O To 10 µl 
 
A control ligation using only linearized vector was set up in addition to monitor religation 
frequency and background colony growth on agar plates.  
4.3.1.3 Transformation 
The ligated plasmids were introduced into Stbl3 chemocompetent E. coli by heat-shock. 
Bacteria were thawed on ice and 50 – 100 µl bacterial suspension was mixed with the entire 
ligation reaction. The mix was incubated for 5 min on ice, 2 min at 42°C and again 5 min on 
ice. Next, 900 µl of S.O.C medium without antibiotics were added and the suspension was 
incubated for 45 min at 37°C in a thermomixer with shaking at 1000 rpm. Bacteria were 
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pelleted by high speed centrifugation for 1 minute, resuspended in 100 µl LB medium and 
seeded onto agar plates containing 100 µg/ml ampicillin which were incubated overnight at 
37°C.  
4.3.1.4 Plasmid isolation and screening 
The next day colonies of different sizes were picked, propagated on a replica plate for 
potential plasmid midi preparations and expanded for plasmid mini preparations by 
inoculating one colony in 2 ml of LB with 100 µg/ml ampicillin and shaking them overnight at 
37°C. The next day bacteria were harvested by centrifugation and plasmid DNA was 
prepared following the instructions of the user manual of the Qiagen Miniprep Kit. Control 
digestions with 1 µg of plasmid DNA using EcoRI and NotI for four hours were performed as 
described above. The resulting fragments were monitored on a 0.8% agarose gel. 
 
Figure 4.3: Control restriction of pMXs-IDH vectors. 
Plasmids isolated from six different bacterial clones per construct were digested with EcoRI and NotI 
and fragments were visualized on a 0.8% agarose gel. (A) For IDH2 constructs clone #6 (IDH2 WT) 
and clone #1 (IDH2 MUT) were sent to sequencing and found to have the correct sequence. (B) For 
IDH1 constructs clones #1 were sent for sequencing and found to have the expected sequence. 
Alternatively, bacterial colonies were picked, resuspended in 20 µl of ddH2O and monitored 
for the presence of transgene by colony-PCR (see below). Only positive clones were 
expanded and plasmids were purified by mini preparation.  
In both cases promising plasmids were sequenced to confirm the presence and integrity of 
the cloned transgene. Sequencing was performed by a commercial sequencing service 
provider using their universal primers pEGFP-FP and pIRES-RP, which amplified the 
transgene. Correct clones were propagated from replica plates or bacterial suspensions in 
200 ml LB-Ampicillin overnight at 37°C and plasmid DNA was extracted following the 
instructions of the HiSpeed Plasmid Midi Kit. 
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4.3.2 pHAGE PGK-GFP-IRES-LUC-W constructs 
4.3.2.1 Preparation of fragments 
For cloning IDH transgenes into pHAGE PGK-GFP-IRES-LUC-W they were PCR-amplified 
from the previously cloned pLVX constructs with specific primers introducing restriction sites 
for MscI and ClaI. These enzymes had restriction sites in the pHAGE target vector 
surrounding the LUC gene. Therefore these nucleases could be used to linearize the target 
vector, excise the unwanted LUC gene and generate unambiguous DNA ends ensuring 
correct orientation of the inserts. The target vector was linearized in triplicates as follows: 
reagent amount 
target vector ~ 800 ng 
cutsmart buffer (10x) 3 µl 
MscI 1 µl 
ClaI 1 µl 
ddH2O To 30 µl 
 
After overnight incubation at 37°C digestions were pooled and analyzed on a 0.8% agarose 
gel (Figure 4.4A). 
 
Figure 4.4: Restriction digestion of pHAGE PGK-GFP-IRES-LUC-W and PCR of IDH inserts.  
(A) Linearized target vector fragment (7609 bp) and excised LUC fragment (1663 bp). (B) PCR 
products of IDH inserts from previously cloned pLVX constructs. (C) MscI and ClaI digested PCR 
products. The IDH2 transgene harbors an internal MscI site, which results in fragmentation of the insert 
into two fragments (1059 and 313 bp). (D) Gel extracted and purified fragments and target vector. 
The vector backbone was excised, gel-extracted into 60 µl of ddH2O (c = 17.6 ng/µl) and 
dephosphorylated by addition of 3 µl Antarctic phosphatase and incubation for 1 hour at 
37°C. The dephosphorylated vector was then purified by a commercial PCR product 
purification kit and analyzed on a 0.8% agarose gel (Figure 4.4D, right lane). 
PCR amplification of IDH transgenes was performed with primers listed in Table 10 in 
duplicates as follows: 
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reagent amount 
Vector template 100 ng 
Phusion high fidelity buffer (5x) 10 µl 
Phusion high fidelity polymerase 0.5 µl 
primer mix (10 µM forwards/ reverse each) 2.5 µl 
10mM dNTPs 1 µl 
ddH2O To 50 µl  
 
PCR conditions: 
temperature [°C] time cycles 
98 30 sec 1 
98 10 sec  
55 15 sec 30 
72 30 sec  
72 7 min 1 
4 ∞  
 
PCR products were pooled and 10 µl were loaded to a 0.8% agarose gel (Figure 4.4B). The 
remaining PCR products were precipitated by addition of 1/10 (v/v) sodium acetate and 3x 
(v/v) ethanol (100%) and incubation at -80°C for 30 min. After a 10 min centrifugation the 
pellets were washed with 70% ethanol, air-dried and resuspended in 25 µl of ddH2O. MscI, 
ClaI and cutsmart buffer were added as described above and PCR products were digested 
for 4 hours at 37°C to generate DNA ends corresponding to the target vector. The resulting 
fragments were separated on a preparative 0.8% agarose gel (Figure 4.4C), excised and gel 
extracted. Purified fragments were examined for their proper appearance by gel 
electrophoresis (Figure 4.4D). Cutting of the IDH2 transgene with MscI generated two 
fragments because this gene possesses an internal recognition site for MscI. Therefore three 
fragments had to be religated later on and checked carefully to ensure correct orientation of 
the smallest fragment. 
4.3.2.2 Ligation 
Ligations were set up as described above with 25 to 75 ng of target vector and the 
corresponding amounts of inserts (the total amount of IDH2 fragment was distributed among 
the two IDH2 subfragments proportionally to their molecular weights). Ligations were 
incubated overnight in an ice-waterbath placed at room temperature resulting in an increasing 
temperature gradient starting from 4°C.  
4.3.2.3 Transformation 
Ligation reactions were transformed into Stbl3 bacteria as described before. Bacteria were 
seeded on LB ampicillin plates and incubated overnight at 37°C.  
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4.3.2.4 Plasmid isolation and screening 
To check the presence of insert several bacterial clones were picked and analyzed by colony-
PCR: 
reagent amount 
Bacterial suspension/control vectors 1.5 µl/100 ng 
FireTaq Blue reaction buffer (10x) 2 µl 
FireTaq Blue polymerase 2 µl 
primer mix (10 µM forwards/ reverse each) 1 µl 
10 mM dNTPs 0.5 µl 
ddH2O To 20 µl  
 
PCR conditions: 
temperature [°C] time cycles 
95 5 min 1 
95 25 sec  
60 25 sec 30 
72 30 sec  
72 5 min 1 
4 ∞  
 
PCR products were analyzed on a 2.5% agarose gel (Figure 4.5A).  
 
Figure 4.5: Colony-PCR and control restrictions of ligated plasmids.  
(A) Example of a colony PCR of IDH2 conducted on a selection of bacterial clones. The expected PCR 
product has a size of 155 bp. Weak bands in the negative control and lanes other than #8, #14 and 
#15 are contaminations. (B) Exemplary control digestions with pHAGE PGK-GFP-IRES-IDH1 WT or –
IDH1 MUT and (C) pHAGE PGK-GFP-IRES-IDH2 WT using MscI and ClaI. Expected fragments were 
7609 and 1274 bp for (B) and 7609, 1058 and 313 bp for (C). (D) Exemplary control digestion of clone 
#22 and #34 from (C) with NcoI. Expected fragments for the correctly oriented inserts were 7154, 1302 
and 523 bp and for the wrong orientation 7154, 1601 and 224 bp. The insert of clone #22 was 
sequenced and found to have the correct sequence. 
Promising clones were amplified and their DNA was isolated as described above using mini 
preparations. The resulting plasmids were control digested with MscI and ClaI to assess the 
presence of insert (Figure 4.5B, C). In the case of IDH2 parallel digestions of 2 x 500 ng with 
NcoI were performed to control for the correct orientation of small fragment (Figure 4.5D): 
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reagent amount 
vector 500 ng 
Fast digest buffer (10x) 2 µl 
NcoI, fast digest 1 µl 
ddH2O To 20 µl 
 
Promising plasmids were sequenced to confirm the presence and integrity of the cloned 
transgene with the commercial service provider and pIRES-RP or pEGFP_C2-FP and 
h_IDH1_1_for/rev or h_IDH2_1_for/rev primers (listed in Table 10), respectively. Bacterial 
clones corresponding to correct plasmids were propagated and DNA was isolated as 
described above. 
4.4 Nucleic acid analyses  
4.4.1 DNA extraction 
For genomic DNA isolation freshly prepared cell pellets were washed in PBS and lysed in 
small falcons by addition of 4.5 ml of pre-lysis buffer. SDS, proteinase K and RNAse A were 
freshly added as described in  
Table 5. The tubes were incubated overnight at 37°C without shaking. The next day 2.5 ml of 
a 5 M NaCl solution were added, the mixture was shaken vigorously and centrifuged for 
15 min at maximal speed. The precipitated proteins should localize to the bottom of the tube 
in a white pellet-like phase. If a correct separation of phases was not achieved the procedure 
was repeated in 2 ml Eppendorf tubes. The clear supernatants were then pooled, transferred 
to a new falcon tube and mixed with 5.6 ml of isopropanol by gentle inversion of the tubes to 
precipitate the DNA. It was then transferred to a fresh Eppendorf tube with a pipet tip if visible 
or tubes were centrifuged at maximal speed for 10 min and the supernatant was discarded. 
The DNA pellet was washed with 70% (v/v) ethanol, collected by centrifugation and the 
ethanol was removed as completely as possible. Pellets were air-dried for a few minutes and 
resuspended in 50 to 100 µl of ddH2O. DNA concentration was determined by absorbance 
measurement using the Nanodrop device. 
4.4.2 Dot blot analyses 
For quantification of DNA modifications by dot blot genomic DNA was sonified for 8 cycles at 
maximal output level with one cycle consisting of 30 sec on and 30 sec off using the Bioruptor 
device. The DNA concentration of the sheared DNA was measured in triplicates by Qubit 
broad range assay following the instructions in the user manual. Next, 4 µg of DNA were 
transferred to an Eppendorf tube and filled up to 80 µl with fresh TE-buffer. 20 µl of 
denaturation solution ( 
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Table 5) were added and samples were incubated for 10 min at 95°C to denature the DNA. 
After incubation 100 µl of neutralization solution were added, samples were put on ice 
immediately and incubated 10 min. 2-fold serial dilutions were prepared in TE ranging from 
1000 ng to 31.25 ng. A nylon membrane of 8 x 12 cm was pre-wet in 6 x SSC for 10 min. The 
dot blot apparatus was washed with a 0.5% SDS/ 0.5 M NaOH solution prior to use to destroy 
remaining nucleic acids. It then was assembled according to instructions in the user manual 
and the membrane was vacuum-dried and equilibrated with 100 µl of clean TE. Samples were 
loaded in duplicates to stain for 5mC and 5hmC in a volume of 48 µl per well. Remaining 
wells were filled with TE and samples were immobilized on the membrane by gentle 
application of vacuum. Care was taken to avoid air bubbles in the wells during loading. 
Afterwards wells were washed with 100 µl of 2 x SSC, the apparatus was disassembled and 
the membrane was rinsed in 2 x SSC. The membrane was then baked at 80°C for 2 hours. 
To monitor equal loading the membrane was stained for 5 min with methylene blue solution 
on a shaker. After documentation the membrane was destained in ddH2O and shaken in dot 
blot blocking solution for 1 hour at room temperature. The membranes were incubated 
likewise in primary antibody solution, washed 3 x 5 min in PBS and stained with secondary 
antibody for one hour at room temperature. After six more 5 min washes in PBS the 
membrane was immersed in freshly prepared enhanced chemiluminescence solution for 1 
min and the signal was detected by applying light-sensitive X-ray films in the dark. The films 
were developed according to instructions of the developing machine.  
4.4.3 RNA extraction 
For total RNA isolation cells were washed in PBS, pelleted, resuspended in 50 µl PBS and 
mixed with 950 µl of TRIzol. Cells were vortexed until the pellet had dissolved and left at room 
temperature for 5 min to lyse nuclei. After addition of 200 µl chloroform, tubes were shaken 
vigorously for 15 sec, incubated for further 3 min at room temperature and centrifuged at 
12,000 x g and 4°C for 15 min. The aqueous phase was transferred into a fresh tube and 
500 µl of isopropanol (and 1 µl GlycoBlue if small quantities were used) were added to 
precipitate RNA. Samples were incubated at room temperature for 15 min and spun at 12,000 
x g and 4°C for 10 min. The supernatant was discarded and the pellet was washed with 
500 µl of 75% ethanol prepared in DEPC water. After vortexing the RNA was pelleted by 
centrifugation at 7000 x g and 4°C for 5 min. The supernatant was removed as completely as 
possible, the pellet was air-dried for a few minutes and dissolved in 10 – 100 µl RNAse-free 
water. The RNA was stored at -80°C.  
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4.4.4 Reverse transcription 
Reverse transcription was performed using the QuantiTect® reverse transcription kit (Qiagen) 
or the SuperScript™ III kit (Invitrogen). 
4.4.4.1 cDNA synthesis by QuantiTect® reverse transcription kit 
reagent amount incubation 
RNA 1 µg  
gDNA Wipeout Buffer (7x) 2 µl 5 min at 42°C, then on ice 
RNAse free water To 14 µl  
Quantiscript RT Buffer (5x) 4 µl 30 min at 42°C 
Random hexamer primer mix 1 µl 15 min at 95°C  
Quantiscript reverse transcriptase 1 µl ∞ at 4°C 
 
The cDNA was stored at -20°C and for qRT-PCR analysis 1 µl was used.  
4.4.4.2 cDNA synthesis by SuperScript™ III kit 
reagent amount incubation 
RNA 2 µg 
5 min at 65°C, then on ice 
for at least 1 min 
Random hexamer primer mix (50 ng/µl) 1 µl 
dNTP mix (10 mM) 1 µl 
RNAse free water To 10 µl 
 
The following master mix was prepared and 10 µl were added to the RNA: 
reagent amount incubation 
RT Buffer (5x) 4 µl 10 min at 25°C 
50 min at 50°C 
5 min at 85°C 
∞ at 4°C 
MgCl2 (25 mM) 4 µl 
DTT (0.1 M) 2 µl 
RNAseOUT (40 U/µl) 1 µl 
SuperScript™ III RT (200 U/µl) 1 µl 
 
The cDNA was treated with 0.4 µl of RNAse H for 20 min at 37°C and stored at -20°C. For 
qRT-PCR analysis the cDNA was diluted 1:50 and 2 µl were used per reaction. 
4.4.5 Quantitative real time PCR (qRT-PCR) 
QRT-PCRs were performed in 384-well plates using the ABsolute qPCR SYBR green mix 
(Thermo Scientific) and the LightCycler 480 (Roche) to monitor fluorescence. Reactions were 
set up as follows with qRT-PCR primers listed in Table 10: 
reagent amount 
cDNA template 1 – 2 µl 
ABsolute qPCR SYBR green mix (2x) 5 µl 
primer mix (10 µM forwards/ reverse each) 0.5 µl 
ddH2O To 10 µl  
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PCR conditions: 
temperature [°C] time cycles 
95 15 min 1 
95 15 sec 50 60 40 sec 
Melting: 60 – 95 (0.11°C/sec) - 1 
40 10 min 1 
 
4.4.6 High throughput sequencing 
Whole genome bisulfite sequencing and total RNA sequencing was performed by the High 
Throughput Sequencing Unit of the Genomics and Proteomics Core Facility at the DKFZ.  
4.4.6.1 Whole Genome Bisulfite Sequencing (WGBS) 
Library preparations for whole genome bisulfite sequencing were conducted using the R&D 
protocol of the Core Facility and 0.3 to 1.2 µg of genomic DNA as starting material. DNA was 
fragmented to an average size of 400 bp using the Covaris S2 and quality was assessed 
using the Agilent DNA 1000 Assay on a Bioanalyzer Instrument 2100. The TruSeq DNA 
Sample Prep v2 Kit (version 2012) was used to perform end repair with bead clean-up and A-
tailing according to the manufacturer´s instructions as well as adapter ligation with double 
bead clean-up. Quality was again monitored on the Bioanalyzer. Bisulfite treatment was 
conducted using the EpiTect Kit (Qiagen) and the converted DNA was purified following the 
Illumina protocol for whole genome bisulfite sequencing for Methylation Analysis (Part 
#15021861, Rev. B). The libraries were amplified using Kapa HiFi HotStart Uracil+ ReadyMix, 
TruSeq PCR primer cocktail and 14 PCR cycles following the above mentioned Illumina 
protocol. Libraries were cleaned-up and quality checked using the Qubit dsDNA HS Assay 
and the Bioanalyzer DNA 1000 Assay. Average library fragment sizes were around 350 bp. 
Final library concentrations applied to the flow cell were 8 to 10 pM with 1% PhiX control v3 
according to the manufacturer´s instructions. DNA was sequenced in paired-end mode on an 
Illumina HiSeq 2000 V3 system. Read lengths were 101 base pairs and the average insert 
size was 230 bp. Two biological replicates per condition were sequenced yielding a combined 
average coverage of 20 x.  
4.4.6.2 Total RNA sequencing 
Library preparation for RNA sequencing was performed from total RNA using the TruSeq 
RNA Library Preparation Kit v2 (version 09-2012; Illumina) according to the manufacturer´s 
instructions. Briefly, 1 µg of total RNA was mRNA enriched using Oligo dT beads, fragmented 
and first strand synthesis was followed by second strand synthesis and bead clean-up. Ends 
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were repaired, bead clean-up was performed and dA-tailing took place followed by adapter 
ligation and double bead clean-up. Libraries were amplified, cleaned again and quality was 
monitored using the Qubit dsDNA HS Assay Kit and the Bioanalyzer with DNA 1000 Assay. 
Average library fragment size was around 290 bp. The libraries were sequenced on an 
Illumina HiSeq 2000 V3 system in 101 bp paired-end mode with 10 pM final library 
concentration on the flow cell and 1% PhiX control v3 following Illumina´s instructions. The 
average insert size was 170 bp. Two biological replicates per condition were sequenced. 
4.4.7 454 targeted amplicon bisulfite sequencing 
For targeted amplicon bisulfite sequencing 500 ng of genomic DNA were bisulfite treated 
according to instructions of the EpiTect Bisulfite Kit from Qiagen with the following changes: 
step temperature [°C] time [min] 
denaturation 95 5 
incubation 60 25 
denaturation 95 5 
incubation 60 85 
denaturation 95 5 
incubation 60 295 
hold 20 ∞ 
 
Regions of interest were PCR amplified using sequence specific primers amplifying the 
deaminated template and containing cell-type specific barcodes and standard 454 adapters. 
Ideal annealing temperatures for primers were tested by gradient PCR using the predicted 
annealing temperature of the primers and 2°C steps of decreasing temperature. PCRs were 
performed using the PyroMark PCR Kit with the following reaction set up: 
reagent amount 
PyroMark PCR Master Mix (2x) 12.5 μl 
CoralLoad Concentrate (10x) 2.5 μl 
MgCl2 (25 mM) 1 µl 
primer mix (10 µM forwards/ reverse each) 2.5 µl 
template 1.5 µl/ 10-20 ng bisulfite converted DNA 
ddH2O 5 µl 
total volume 25 µl 
 
PCR conditions: 
temperature [°C] time cycles 
95 15 min 1 
94 30 sec 
30 - 35 gradient/ best annealing 30 sec 
72 45 sec 
72 10 min 1 
4 ∞  
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To obtain maximal yields the parameters were adapted for each primer pair varying MgCl2 
concentration (1.5 - 4.0 mM), the amounts of template and Q-solution, the number of PCR 
cycles (maximal 35), primer annealing temperatures and hotstart PCR protocol (if not using 
the PyroMark polymerase, which requires heat activation). PCR products were analyzed on 
2 - 2.5 % agarose gels, excised and gel-extracted using the PeqGold Extraction Kit (PeqLab) 
or the QIAquick Gel Extraction Kit (Qiagen). Sample concentrations were determined using 
the Quant-iTTMPicoGreen ®dsDNA Kit according to instructions and the FLUOstar OPTIMA 
plate reader. For sequencing amplicons were pooled in an equimolar mix, processed and 
sequenced according to the manufacturer’s instructions on the GS Junior 454 Genome 
Sequencer (Roche). Sequencing reads were processed, filtered, aligned and displayed in 
color-coded heatmaps using the BiSQuID tool internally available in the Division of 
Epigenetics. Furthermore the methylation state of each CpG in each read was assessed and 
the average methylation per CpG site was computed and displayed in color-coded tables by 
BiSQuID. This tool was programmed by Cassandra Falckenhayn.  
4.4.8 EPIC Methylation Array 
For methylation profiling using the Infinium MethylationEPIC BeadChip 1 µg of purified 
genomic DNA was provided. The analysis of DNA on the array was performed by the 
microarray unit of the DKFZ Genomics and Proteomics Core Facility.  
This platform is an extended version of the Infinium 450K array interrogating 93% of the 
previous and many additional probes resulting in a total of 866,895 CpG sites. Briefly, per 
experiment and condition two biological replicates, but no technical replicates, were used. 
Matched untreated or empty vector transduced cells served as controls. DNA concentrations 
were measured using the Quant-iTTMPicoGreen ®dsDNA Kit and DNA quality was assessed 
by agarose gel electrophoresis. Samples had to have an average fragment size of at least 
3 kb to pass quality control. 500 ng of DNA were bisulfite converted using the EZ-96 DNA 
Methylation Kit (Zymo Research) according to the manufacturer´s instructions. After whole 
genome amplification the DNA was fragmented enzymatically and denatured following the 
recommendations of the Infinium HD Assay Methylation Protocol Guide (Illumina). The DNA 
was applied to the BeadChip and hybridization took place for 16 to 24 hours at 48°C. During 
this process DNA molecules anneal to locus-specific DNA oligomers linked to different bead 
types. In the next step primers are single-base extended using 2,4-dinitrophenol- (DNP) or 
Biotin-labelled ddNTPs and the array is fluorescently stained and scanned (iScan array 
scanner, Illumina) to measure red and green fluorescence intensities. DNA methylation 
values are recorded for each of the 866,895 probes on the array. Methylation level is 
expressed as beta value which is the ratio of methylated signal over the sum of the 
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methylated and unmethylated signals. Thus average beta values represent the percentage of 
methylation of any given cytosine and can attain any value between 0 and 1, with 0 
corresponding to no methylation and 1 to full methylation. 
Raw IDAT files containing average beta values for each probe were analyzed using an 
analysis pipeline available in the Division of Epigenetics. This tool was programmed by Julian 
Gutekunst. Details can be found in chapter 4.6.3. 
4.5 Cellular assays 
4.5.1 Adipogenic differentiation 
Adipogenic differentiation was performed as described in Wiehle et al., 2016. Briefly, 1 x 105 
cells/well were seeded into 12-well plates and the next day treatment with adipogenic 
differentiation medium (ADM; Tuorto et al., 2012) was started. After 7, 14, and 21 days cells 
were harvested or fixated in order to stain lipid droplets. Fixation was performed for 1 hour in 
10% formalin. Wells were washed with 60% isopropanol and filtered (0.2 µm) Oil Red O 
working solution was added for 10 min. Next, the wells were washed in H2O to remove dye 
and air-dried. Five random images per well were acquired at 4 fold magnification using a 
reflected-light microscope (Olympus) and the particle number per image, representing the 
amount of lipid droplets, was quantified using ImageJ. 
4.5.2 2-HG treatment 
To supplement cell culture medium with 2-HG, 8.64 mg of D- or L-2-HG were freshly 
dissolved in 1.5 ml of RPMI standard culture medium yielding a 30 mM stock solution. 
Aliquots of powder were stored at 4°C (L-2-HG) or -20°C (D-2-HG) and protected from light 
until use. The solution was rotated for 30 min at room temperature and sterile-filtrated with 
0.2 µm filters prior to use. The solution was then further diluted in RPMI to obtain the required 
concentration of 5 mM. 600,000 cells/well were seeded into a 24-well plate in 1 ml of 2-HG 
supplemented medium. Every 3rd and 4th day the medium was exchanged with freshly 2-HG 
supplemented medium, the cell numbers were counted for proliferation analysis and reduced 
to 600,000 per well. Remaining cells were quickly washed in PBS for two times, pelleted, 
liquid was removed as completely as possible and pellets were immediately frozen at -20°C 
for storage.  
4.5.3 D-2-HG measurement 
To measure D-2-HG levels in cell culture supernatants (extracellular measurement) or cells 
(intracellular measurement) the same fluorimetric assay was used. For intracellular 
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measurements cell lysates were prepared and their protein content was assessed. To this 
end, a visible cell pellet was collected in safe-lock tubes and washed twice in PBS for less 
than 5 min. Cells were dissolved in NP-40 lysis buffer with freshly added protease inhibitors 
and freeze-thawed three times by immersing the tubes in liquid nitrogen and placing them at 
37°C until the suspension was liquid again. Vortexing was performed in between. After lysis 
tubes were spun for 5 min at 13,000 x g to pellet debris. The clear supernatant was 
transferred to fresh tubes and kept on ice until protein determination. For extracellular 
measurements 1 ml of cell culture supernatant per condition was collected and directly used 
for deproteinization or stored at -20°C until quantification. 
4.5.3.1 BCA protein assay 
In order to normalize measured intracellular D-2-HG levels to total cell numbers the protein 
concentration of the lysates was measured by BCA protein assay. To this end a 1:5 to 1:25 
dilution was prepared in H2O and several BSA standards were set up to create a standard 
curve. 25 µl of each sample or standard were mixed with 200 µl of a 1:50 dilution of BCA 
reagent B in reagent A in a 96-well plate. Pure NP-40 lysis buffer or H2O was used as blank 
and treated equally. The mixture was incubated for 30 min at 37°C and the OD at 562 nm 
was measured using the FLUOstar OPTIMA plate reader. Each sample, standard and blank 
was at least measured in duplicates. The preset 4-parameter fit function of the OPTIMA 
analysis software was used to establish a standard curve. Raw sample intensities were 
background subtracted and protein concentrations were automatically calculated by the 
analysis software. 
4.5.3.2 Deproteinization 
To remove proteins from cell lysates or cell culture medium a deproteinizing kit (BioVision) 
was used. In brief, 100 µl of sample were mixed with 25 µl of perchloric acid (PCA) in 8-strip 
PCR tubes and incubated on ice for 2 min. To prepare a standard curve 95 µl of 
corresponding cell culture medium (extracellular measurement) or NP-40 lysis buffer 
(intracellular measurement) were mixed with 5 µl of each standard and subjected to PCA 
treatment as described for samples. Standards were prepared in medium (extracellular 
measurement) or ddH2O (intracellular measurement). Tubes were centrifuged for 7 min at 
14,000 rpm and room temperature before transferring 100 µl of the supernatant to 5 µl chilled 
neutralization solution in new 8-strip tubes. The mixture was incubated for 2 min on ice and 
spun again as before to pellet precipitated proteins. 
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4.5.3.3 D-2-HG assay 
Of the supernatant 95 µl were transferred to fresh tubes and spun quickly. 25 µl were 
transferred into a black 96-well plate in triplicates and mixed with 75 µl of the following master 
mix: 
reagent µl/well µl/96-well plate 
HEPES pH 8 (1M) 10 1050 
NAD+ (10 mM) 1 105 
HGDH (0.1 µg/µl) 1 105 
Diaphorase (0.1 U/µl) 1 105 
Resazurin (125 µM) 4 420 
ddH2O 58 6090 
 
The mixture was incubated in the dark at room temperature for 15 to 60 min and fluorimetric 
detection was carried out using the FLUOstar OPTIMA plate reader with excitation of 540+/-
10 nm and emission of 610+/-10 nm. The standard values were curve fitted using the preset 
4-parameter or linear regression fit of the OPTIMA analysis software and D-2-HG values in 
pmol/25 µl sample were computed by the software. To normalize for protein content the 
obtained values [pmol/25 µl] were divided by the corresponding protein concentrations 
[µg/25 µl]. To obtain µM values the obtained concentrations were multiplied by 0.04. 
4.5.4 Proliferation assay by Cell Titer Glo 
At day 0 cells were seeded at 1000 cells/well into a 96-well plate in triplicates. At day 1, 3 and 
6 metabolic activity was assessed by the Cell Titer Glo assay: Cell culture plates were 
equilibrated to room temperature for 30 min and the Cell titer Glo solution was prepared 
following the manufacturer´s instructions. Per well 10 μl were added, the plate was shaken for 
two minutes to lyse cells and left for 10 min in the dark. Luminescence was recorded using 
the OPTIMA plate reader with a gain of 3000. Triplicates were background-corrected and 
averaged. 
4.5.5 Proliferation assay by assessment of cumulative population doubling 
Equal numbers of cells (e.g. 500,000) were seeded in triplicates at each new passage 
(number of inoculated cells = NI) and after 3 or 4 days cell numbers in each well were 
determined. The average was calculated (average number of cells harvested = NH) and used 
to compute the average population doubling level (PDL) based on the following formula: 
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To obtain the cumulative population doubling level the PDL obtained from each measurement 
was added to the previous one (or to 0 at the first measurement) and plotted against the time 
that passed between seeding and harvest. 
4.6 High throughput data analysis 
4.6.1 Whole genome bisulfite sequencing 
Quality control of sequencing reads was performed using FastQC. Reads were trimmed and 
mapped to the mouse reference genome (NCBI37/mm9) using BSMAP 2.5 (Xi and Li, 2009) 
and the Picard tool to remove duplicates (http://broadinstitute.github.io/picard). Methylation 
ratios were calculated with a Python script (methratio.py) from the BSMAP package. PMDs 
that were previously reported to harbor instable methylation in cell culture models (Gaidatzis 
et al., 2014), were removed using a sliding window of 100 kb as described before (Raddatz et 
al., 2012), the Mus musculus skin methylome as reference and a 2-state first-order hidden 
Markov model to identify regions with a strong reduction in methylation (PMDs). Publically 
available ChIP-seq datasets of different chromatin marks, CTCF and PolII in MEFs 
(Mikkelsen et al., 2007; Shen et al., 2012) were subjected to ChromHMM analysis (Ernst and 
Kellis, 2012; http://compbio.mit.edu/ChromHMM/) in order to segment the mouse genome into 
15 chromatin states, for which methylation ratios were calculated and compared. DNA 
methylation canyons were mapped as described in Jeong et al., 2013 and using MOABS 
(Sun et al., 2014). Canyon-associated genes were determined by the presence of their TSS 
within the canyon. More details are described in Wiehle et al., 2016. Günter Raddatz 
conducted the analyses. 
4.6.2 RNA sequencing 
Quality control of sequencing reads was performed using FastQC. Reads were adapter-
trimmed and terminal stretches of bases with a Phred quality score of <30 were removed 
resulting in a maximal read length of 80 bp. Reads were mapped to the NCBI37/mm9 
assembly of the mouse genome using TopHat 2.0.6 (Trapnell, Pachter, and Salzberg, 2009). 
To identify differentially expressed transcripts DESeq 1.10.1 (Anders and Huber, 2010) and 
Cuffdiff 2.0 (Trapnell et al., 2013) were applied. To avoid false positives p-values were 
subjected to multiple testing correction and transcripts with a corrected p-value (q-value) of 
<0.05 were considered to be differentially expressed. These analyses were performed by 
Günter Raddatz and are described in Wiehle et al., 2016. 
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4.6.3 Methylation array 
The raw intensity data files were normalized, quality-filtered and statistically analyzed as 
described before (Geyh et al., 2016). In brief, the minfi package (version 1.20.2; Aryee et al., 
2014) was used to load IDAT files into R (version 3.3.2). Data were normalized with the 
SWAN method (Maksimovic et al., 2012) without prior background correction. Cross-reactive 
and SNP containing probes (Chen et al., 2013b), probes on the sex chromosomes and 
probes with a low detection p-value (>0.01) were omitted. Differentially methylated probes 
were identified by a similar approach as implemented in minfi with the exception of adjusting 
p-values for false discovery rate using the Benjamini-Hochberg procedure. Probes with an 
adjusted p-value of <0.05 were considered as differentially methylated. PCA graphs were 
generated by the plotPCA() function provided by the R affycoretools package (version 1.46.5; 
MacDonald, 2008) with significantly differentially methylated probes used to compute principal 
components. Heatmaps were created by the heatmap.2() function of the R gplots package 
(version 3.0.1, Warnes et al., 2016). For clustering the euclidean distance function was used 
to compute the distance matrix and the complete linkage method to obtain hierarchical 
clustering. The RColorBrewer package (version 1.1-2) was used to create the assigned colors 
(Neuwirth, 2014). All above mentioned packages were obtained from Bioconductor. To be 
able to compare EPIC and 450K data the probes common to both chips were extracted and 
used for analysis. The bioinformatic pipeline containing all the described functions was 
programmed by Julian Gutekunst. 
4.7 Statistical analysis 
Numerical data, such as expression values or concentrations, are presented as arithmetic 
averages. Standard deviations were computed as a measure of statistical spread. The two-
tailed Student´s t-test was used to determine the significance of observed differences 
between means of gene expression of two groups. The required level of significance was 5% 
(p≤0.05). Enrichments of biological pathways among deregulated genes were calculated 
using the Ingenuity Pathway Analysis tool and figures showing the negative logarithm of the 
p-values were extracted from the software. 
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5 Appendix 
5.1 Supplemental Figures 
 
Figure S1: Whole genome bisulfite sequencing tracks of WT and DKO MEFs at selected 
hypermethylated canyons.  
Canyons associated with the genes Foxc1, Foxc2, Pparγ and Igf1 are shown. Each blue bar 
represents the detected methylation ratio at individual CpGs. Red boxes indicate the loci interrogated 
by targeted amplicon bisulfite sequencing in Figure 2.8 and Figure 2.14 and yellow boxes show the 
amplicon localization of Figure 2.13. 
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Figure S2: DNA methylation changes in DNMT3A mutated AML patients.  
(A) Scatterplot comparing 32 AML patients with mutations in DNMT3A (mDNMT3A) to 108 AML 
patients with DNMT3A WT status. Each dot indicates the beta values of one 450K probe retained after 
quality-filtering in the two groups and significantly differentially methylated probes (P<0.05) are 
depicted in blue. (B) Distribution of the average beta values of all 450K probes retained after filtering in 
the group of mDNMT3A and DNMT3A WT patients. (C) Principal component analysis as in Figure 
2.16A. Patients with a DNMT3A mutation are colored in blue. (D) Heatmap and hierarchical cluster 
dendrogram of mIDH and IDH WT patients as in Figure 2.16B. Patients with mutated DNMT3A were 
entirely removed from the dataset, resulting in comparison of 92 IDH WT to 16 mIDH patients. 
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Figure S3: Improved screening methods detect transgene expression and D-2-HG production in 
NOMO-1 cells.  
Electropherograms of the cDNA sequence harboring the IDH1 R132C mutation in NOMO-1 (A) and 
HL-60 (B) cells transduced with empty vector, IDH1 WT or IDH1 R132C. Grey boxes indicate the 
position of the base exchange in the mIDH gene. (C) QRT-PCR of total, endogenous and exogenous 
IDH1 transcripts in transduced NOMO-1 cells using discriminating primers. ACTB served as reference 
gene. Bars represent means and error bars standard deviations of three replicates. (D) Intracellular D-
2-HG measurement in transduced NOMO-1 cells. 
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Figure S4: Removal of probes located in PMDs retains mIDH2-associated hypomethylation in 
HL-60 cells. 
(A) Scatterplot comparing average beta values of non-PMD CpG probes between HL-60 cells 
transduced with mIDH2 and empty vector. Blue dots indicate significantly differentially methylated 
probes (P<0.05). (B) Boxplots showing average beta values for all significantly differentially methylated 
probes residing outside of PMDs in HL-60 cells transduced with mIDH2 and empty vector (EV; left 
panel). In the right panel all significantly differentially methylated probes are shown irrespective of their 
localization in PMDs. (C) Percentage of hyper- and hypomethylated non-PMD probes identified in 
mIDH2-expressing HL-60 cells. 
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Figure S5: Reduced proliferation of 2-HG treated HL-60 cells.  
Cumulative population doublings of HL-60 cells cultured in medium supplied with the indicated 
concentrations of D- or L-2-HG for 18 days. 
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